

# **Cancer incidence projections Australia 2002 to 2011**

The Australian Institute of Health and Welfare (AIHW) is Australia's national health and welfare statistics and information agency. The Institute's mission is *better health and wellbeing for Australians through better health and welfare statistics and information*.

The Australasian Association of Cancer Registries (AACR) is a collaborative body representing state and territory cancer registries in Australia, New Zealand and the Pacific islands. Most are members of the International Association of Cancer Registries. Contact details for members of the AACR are available on the AIHW website <[www.aihw.gov.au/cancer](http://www.aihw.gov.au/cancer)>.

The AACR was formed in November 1982 to provide a formal mechanism for promoting uniformity of collection, classification and collation of cancer data.

The purposes of the AACR are:

- to provide a continuing framework for the development of population-based cancer registration in Australia, New Zealand and the Pacific islands
- to facilitate the exchange of scientific and technical information between cancer registries and to promote standardisation in the collection and classification of cancer data
- to facilitate cancer research both nationally and internationally
- to facilitate the dissemination of cancer information.

The Australian Institute of Health and Welfare has joined with the AACR to produce national cancer statistics from the National Cancer Statistics Clearing House.

The National Cancer Strategies Group (NCSG) is a subcommittee of the National Health Priority Action Council formed in 1998 to provide expert advice to the Australian Government.

The role of the NCSG is to pursue strategies to improve the prevention, detection, treatment and management of cancer in Australia.

Please note that as with all statistical reports there is the potential for minor revisions of data in this report over its life. Please refer to the online version at <[www.aihw.gov.au](http://www.aihw.gov.au)>.

CANCER SERIES

Number 30

# **Cancer incidence projections**

## **Australia 2002 to 2011**

**Ian McDermid**

**August 2005**

Australian Institute of Health and Welfare  
Australasian Association of Cancer Registries  
National Cancer Strategies Group  
Canberra

AIHW cat. no. CAN 25

© Australian Institute of Health and Welfare 2005

This work is copyright. Apart from any use as permitted under the *Copyright Act 1968*, no part may be reproduced without prior written permission from the Australian Institute of Health and Welfare. Requests and enquiries concerning reproduction and rights should be directed to the Head, Business Promotion and Media Unit, Australian Institute of Health and Welfare, GPO Box 570, Canberra ACT 2601.

This publication is part of the Australian Institute of Health and Welfare's Cancer Series. A complete list of the Institute's publications is available from the Business Promotion and Media Unit, Australian Institute of Health and Welfare, GPO Box 570, Canberra ACT 2601, or via the Institute's website <[www.aihw.gov.au](http://www.aihw.gov.au)>.

ISSN 1039-3307

ISBN 1 74024 494 X

### **Suggested citation**

AIHW, AACR & NCSG: Ian McDermid 2005. Cancer incidence projections, Australia 2002 to 2011. Canberra: Australian Institute of Health and Welfare (AIHW), Australasian Association of Cancer Registries (AACR) and the National Cancer Strategies Group (NCSG).

### **Australian Institute of Health and Welfare**

Board Chair  
Hon. Peter Collins, QC, AM

Director  
Dr Richard Madden

Any enquiries about or comments on this publication should be directed to:

Ian McDermid  
Australian Institute of Health and Welfare  
GPO Box 570  
Canberra ACT 2601  
Phone: (02) 6244 1230

Published by Australian Institute of Health and Welfare

Printed by Elect Printing

# Contents

List of tables .....	vii
List of figures .....	x
Abbreviations and symbols.....	xiii
Acknowledgments.....	xiv
Executive summary .....	1
<b>1 Introduction.....</b>	<b>2</b>
1.1 Key assumptions.....	2
1.2 Cancer groups .....	3
1.3 Projection methods .....	4
<b>2 Results .....</b>	<b>5</b>
2.1 All cancers.....	5
2.2 Common cancers by age .....	6
2.3 Skin and lip cancers.....	7
2.4 Head and neck cancers .....	7
2.5 Cancers of the upper digestive tract .....	7
2.6 Colorectal (bowel) cancer .....	8
2.7 Cancers of the liver, gallbladder and pancreas .....	8
2.8 Lung cancer and other cancers of respiratory and thoracic organs.....	9
2.9 Cancers of bone and connective tissue .....	10
2.10 Breast cancer .....	10
2.11 Gynaecological cancers .....	11
2.12 Prostate cancer and other cancers of male genital organs .....	11
2.13 Cancers of the urinary tract.....	12
2.14 Eye cancer .....	12
2.15 Cancers of the brain and central nervous system .....	13
2.16 Cancers of thyroid and other endocrine glands.....	13
2.17 Cancers of unknown primary site.....	13
2.18 Non-Hodgkin lymphoma, leukaemia and other cancers of lymphoid and haematopoietic tissue .....	13
2.19 Cancers attributed to smoking and alcohol consumption.....	14

<b>Tables and figures .....</b>	<b>15</b>
<b>Appendix A: Data sources and issues.....</b>	<b>144</b>
<b>Appendix B: Statistical methods .....</b>	<b>147</b>
<b>References .....</b>	<b>150</b>

# List of tables

More detailed versions of these tables, including full historical data from 1982 to 2001 and associated population data, can be found on the AIHW website <[www.aihw.gov.au](http://www.aihw.gov.au)>.

Table 1:	Number of new cases of cancer by clinical group and cancer site/type, Australia 1982 to 2001, females .....	16
Table 2:	Projected number of new cases of cancer by clinical group and cancer site/type, Australia 2002 to 2011, females.....	17
Table 3:	Number of new cases of cancer by clinical group and cancer site/type, Australia 1982 to 2001, males .....	18
Table 4:	Projected number of new cases of cancer by clinical group and cancer site/type, Australia 2002 to 2011, males .....	19
Table 5:	Common cancers by age, Australia, females, 1991, 2001 and projected 2011 .....	22
Table 6:	Common cancers by age, Australia, males, 1991, 2001 and projected 2011 .....	23
Table 7:	All cancers, excluding NMSC (ICD-10 C00–C96, excl. C44), Australia, females.....	24
Table 8:	All cancers, excluding NMSC (ICD-10 C00–C96, excl. C44), Australia, males .....	26
Table 9:	Skin and lip cancers, excluding NMSC (ICD-10 C00, C43, C46), Australia, females.....	28
Table 10:	Skin and lip cancers, excluding NMSC (ICD-10 C00, C43, C46), Australia, males .....	30
Table 11:	Melanoma (ICD-10 C43), Australia, females .....	32
Table 12:	Melanoma (ICD-10 C43), Australia, males.....	34
Table 13:	Head and neck cancers (ICD-10 C01–C14, C30–C32), Australia, females .....	36
Table 14:	Head and neck cancers (ICD-10 C01–C14, C30–C32), Australia, males.....	38
Table 15:	Cancers of the upper digestive tract (ICD-10 C15–C17), Australia, females.....	40
Table 16:	Cancers of the upper digestive tract (ICD-10 C15–C17), Australia, males .....	42
Table 17:	Cancer of the oesophagus (ICD-10 C15), Australia, females.....	44
Table 18:	Cancer of the oesophagus (ICD-10 C15), Australia, males .....	46
Table 19:	Cancer of the stomach (ICD-10 C16), Australia, females .....	48
Table 20:	Cancer of the stomach (ICD-10 C16), Australia, males .....	50

Table 21:	Cancers of the colon, rectum and anus (ICD-10 C18–C21), Australia, females.....	52
Table 22:	Cancers of the colon, rectum and anus (ICD-10 C18–C21), Australia, males.....	54
Table 23:	Cancers of the liver, gallbladder and pancreas (ICD-10 C22–C25), Australia, females.....	56
Table 24:	Cancers of the liver, gallbladder and pancreas (ICD-10 C22–C25), Australia, males.....	58
Table 25:	Cancer of the liver (ICD-10 C22), Australia, females.....	60
Table 26:	Cancer of the liver (ICD-10 C22), Australia, males.....	62
Table 27:	Cancer of the pancreas (ICD-10 C25), Australia, females.....	64
Table 28:	Cancer of the pancreas (ICD-10 C25), Australia, males.....	66
Table 29:	Cancers of respiratory and thoracic organs (ICD-10 C33–C38, C45), Australia, females.....	68
Table 30:	Cancers of respiratory and thoracic organs (ICD-10 C33–C38, C45), Australia, males.....	70
Table 31:	Cancers of the trachea, bronchus and lung (ICD-10 C33–C34), Australia, females.....	72
Table 32:	Cancers of the trachea, bronchus and lung (ICD-10 C33–C34), Australia, males.....	74
Table 33:	Mesothelioma (ICD-10 C45), Australia, females.....	76
Table 34:	Mesothelioma (ICD-10 C45), Australia, males.....	78
Table 35:	Cancers of bone and connective tissue (ICD-10 C40–C41, C47–C49), Australia, females.....	80
Table 36:	Cancers of bone and connective tissue (ICD-10 C40–C41, C47–C49), Australia, males.....	82
Table 37:	Breast cancer (ICD-10 C50), Australia, females.....	84
Table 38:	Breast cancer (ICD-10 C50), Australia, males.....	86
Table 39:	Cancers of female genital organs (ICD-10 C51–C58), Australia.....	88
Table 40:	Cancer of the cervix (ICD-10 C53), Australia.....	90
Table 41:	Cancer of the uterus (ICD-10 C54–C55), Australia.....	92
Table 42:	Ovarian cancer (ICD-10 C56–C57), Australia.....	94
Table 43:	Cancers of the vulva, vagina and placenta (ICD-10 C58, C51–C52), Australia.....	96

Table 45:	Prostate cancer (ICD-10 C61), Australia .....	100
Table 46:	Cancers of other male genital organs (ICD-10 C62-C63, C60), Australia .....	102
Table 47:	Cancers of the urinary tract (ICD-10 C64-C68), Australia, females .....	104
Table 48:	Cancers of the urinary tract (ICD-10 C64-C68), Australia, males.....	106
Table 49:	Cancer of the eye (ICD-10 C69), Australia, females.....	108
Table 50:	Cancer of the eye (ICD-10 C69), Australia, males .....	110
Table 51:	Cancers of the brain and central nervous system (ICD-10 C70-C72), Australia, females .....	112
Table 52:	Cancers of the brain and central nervous system (ICD-10 C70-C72), Australia, males.....	114
Table 53:	Cancers of thyroid and other endocrine glands (ICD-10 C73-C75), Australia, females .....	116
Table 54:	Cancers of thyroid and other endocrine glands (ICD-10 C73-C75), Australia, males.....	118
Table 55:	Cancers of unknown primary site (ICD-10 C76-C80, C26, C39), Australia, females.....	120
Table 56:	Cancers of unknown primary site (ICD-10 C76-C80, C26, C39), Australia, males .....	122
Table 57:	Cancers of lymphoid and haematopoietic tissue (ICD-10 C81-C96), Australia, females .....	124
Table 58:	Cancers of lymphoid and haematopoietic tissue (ICD-10 C81-C96), Australia, males.....	126
Table 59:	Non-Hodgkin lymphoma (ICD-10 C82-C85, C96), Australia, females .....	128
Table 60:	Non-Hodgkin lymphoma (ICD-10 C82-C85, C96), Australia, males.....	130
Table 61:	Leukaemia (ICD-10 C91-C95), Australia, females .....	132
Table 62:	Leukaemia (ICD-10 C91-C95), Australia, males .....	134
Table 63:	Cancers attributed to alcohol consumption, Australia, females .....	136
Table 64:	Cancers attributed to alcohol consumption, Australia, males.....	138
Table 65:	Cancers attributed to smoking, Australia, females .....	140
Table 66:	Cancers attributed to smoking, Australia, males .....	142
Table A1:	Standard populations: Australia 2001 and WHO 2000 .....	146

# List of figures

Figure 1:	Age-standardised incidence rates (A2001) for NHPA cancers and for all cancers (excluding NMSC), Australia, females, 1982 to 2001 and projected 2002 to 2011 .....	20
Figure 2:	Number of new cases of cancer for NHPA cancers and for all cancers (excluding NMSC), Australia, females, 1982 to 2001 and projected 2002 to 2011 .....	20
Figure 3:	Age-standardised incidence rates (A2001) for NHPA cancers and for all cancers (excluding NMSC), Australia, males, 1982 to 2001 and projected 2002 to 2011 .....	21
Figure 4:	Number of new cases of cancer for NHPA cancers and for all cancers (excluding NMSC), Australia, males, 1982 to 2001 and projected 2002 to 2011 .....	21
Figure 5:	Number of new cases of cancer by age, Australia, females, 1982 to 2001 and projected 2002 to 2011.....	22
Figure 6:	Number of new cases of cancer by age, Australia, males, 1982–2001 and projected 2002 to 2011 .....	23
Figure 7:	All cancers, excluding NMSC (ICD-10 C00–C96, excl. C44), Australia, females.....	25
Figure 8:	All cancers, excluding NMSC (ICD-10 C00–C96, excl. C44), Australia, males .....	27
Figure 9:	Skin and lip cancers, excluding NMSC (ICD-10 C00, C43, C46), Australia, females.....	29
Figure 10:	Skin and lip cancers, excluding NMSC (ICD-10 C00, C43, C46), Australia, males .....	31
Figure 11:	Melanoma (ICD-10 C43), Australia, females .....	33
Figure 12:	Melanoma (ICD-10 C43), Australia, males.....	35
Figure 13:	Head and neck cancers (ICD-10 C01–C14, C30–C32), Australia, females .....	37
Figure 14:	Head and neck cancers (ICD-10 C01–C14, C30–C32), Australia, males.....	39
Figure 15:	Cancers of the upper digestive tract (ICD-10 C15–C17), Australia, females.....	41
Figure 16:	Cancers of the upper digestive tract (ICD-10 C15–C17), Australia, males .....	43
Figure 17:	Cancer of the oesophagus (ICD-10 C15), Australia, females.....	45
Figure 18:	Cancer of the oesophagus (ICD-10 C15), Australia, males .....	47
Figure 19:	Cancer of the stomach (ICD-10 C16), Australia, females .....	49

Figure 20: Cancer of the stomach (ICD-10 C16), Australia, males .....	51
Figure 21: Cancers of the colon, rectum and anus (ICD-10 C18–C21), Australia, females.....	53
Figure 22: Cancers of the colon, rectum and anus (ICD-10 C18–C21), Australia, males .....	55
Figure 23: Cancers of the liver, gallbladder and pancreas (ICD-10 C22–C25), Australia, females.....	57
Figure 24: Cancers of the liver, gallbladder and pancreas (ICD-10 C22–C25), Australia, males .....	59
Figure 25: Cancer of the liver (ICD-10 C22), Australia, females.....	61
Figure 26: Cancer of the liver (ICD-10 C22), Australia, males .....	63
Figure 27: Cancer of the pancreas (ICD-10 C25), Australia, females .....	65
Figure 28: Cancer of the pancreas (ICD-10 C25), Australia, males .....	67
Figure 29: Cancers of respiratory and thoracic organs (ICD-10 C33–C38, C45), Australia, females .....	69
Figure 30: Cancers of respiratory and thoracic organs (ICD-10 C33–C38, C45), Australia, males.....	71
Figure 31: Cancers of the trachea, bronchus and lung (ICD-10 C33–C34), Australia, females.....	73
Figure 32: Cancers of the trachea, bronchus and lung (ICD-10 C33–C34), Australia, males .....	75
Figure 33: Mesothelioma (ICD-10 C45), Australia, females .....	77
Figure 34: Mesothelioma (ICD-10 C45), Australia, males .....	79
Figure 35: Cancers of bone and connective tissue (ICD-10 C40–C41, C47–C49), Australia, females .....	81
Figure 36: Cancers of bone and connective tissue (ICD-10 C40–C41, C47–C49), Australia, males.....	83
Figure 37: Breast cancer (ICD-10 C50), Australia, females .....	85
Figure 38: Breast cancer (ICD-10 C50), Australia, males .....	87
Figure 39: Cancers of female genital organs (ICD-10 C51–C58), Australia.....	89
Figure 40: Cancer of the cervix (ICD-10 C53), Australia.....	91
Figure 41: Cancer of the uterus (ICD-10 C54–C55), Australia .....	93
Figure 42: Ovarian cancer (ICD-10 C56–C57), Australia .....	95
Figure 43: Cancers of the vulva, vagina and placenta (ICD-10 C58, C51–C52), Australia.....	97

Figure 44: Cancers of male genital organs (ICD-10 C60–C63), Australia .....	99
Figure 45: Prostate cancer (ICD-10 C61), Australia .....	101
Figure 46: Cancers of other male genital organs (ICD-10 C62–C63, C60), Australia.....	103
Figure 47: Cancers of the urinary tract (ICD-10 C64–C68), Australia, females .....	105
Figure 48: Cancers of the urinary tract (ICD-10 C64–C68), Australia, males.....	107
Figure 49: Cancer of the eye (ICD-10 C69), Australia, females.....	109
Figure 50: Cancer of the eye (ICD-10 C69), Australia, males .....	111
Figure 51: Cancers of the brain and central nervous system (ICD-10 C70–C72), Australia, females .....	113
Figure 52: Cancers of the brain and central nervous system (ICD-10 C70–C72), Australia, males.....	115
Figure 53: Cancers of thyroid and other endocrine glands (ICD-10 C73–C75), Australia, females .....	117
Figure 54: Cancers of thyroid and other endocrine glands (ICD-10 C73–C75), Australia, males.....	119
Figure 55: Cancers of unknown primary site (ICD-10 C76–C80, C26, C39), Australia, females .....	121
Figure 56: Cancers of unknown primary site (ICD-10 C76–C80, C26, C39), Australia, males.....	123
Figure 57: Cancers of lymphoid and haematopoietic tissue (ICD-10 C81–C96), Australia, females .....	125
Figure 58: Cancers of lymphoid and haematopoietic tissue (ICD-10 C81–C96), Australia, males.....	127
Figure 59: Non-Hodgkin lymphoma (ICD-10 C82–C85, C96), Australia, females .....	129
Figure 60: Non-Hodgkin lymphoma (ICD-10 C82–C85, C96), Australia, males.....	131
Figure 61: Leukaemia (ICD-10 C91–C95), Australia, females .....	133
Figure 62: Leukaemia (ICD-10 C91–C95), Australia, males .....	135
Figure 63: Cancers attributed to alcohol consumption, Australia, females .....	137
Figure 64: Cancers attributed to alcohol consumption, Australia, males.....	139
Figure 65: Cancers attributed to smoking, Australia, females .....	141
Figure 66: Cancers attributed to smoking, Australia, males .....	143

# Abbreviations and symbols

<b>AACR</b>	Australasian Association of Cancer Registries
<b>ABS</b>	Australian Bureau of Statistics
<b>AIHW</b>	Australian Institute of Health and Welfare
<b>ASR</b>	age-standardised rate (see Appendix B)
<b>ASR(A2001)</b>	age-standardised rate – standardised to the Australian Standard Population 2001 (see Appendix A)
<b>ASR(W2000)</b>	age-standardised rate – standardised to the WHO World Standard Population 2000 (see Appendix A)
<b>BCC</b>	basal cell carcinoma
<b>DoHA</b>	Australian Government Department of Health and Ageing
<b>ERP</b>	estimated resident population (see Appendix A)
<b>excl.</b>	excluding
<b>FDA</b>	functional data analysis (see Appendix B)
<b>n.p.</b>	not published
<b>HPV</b>	human papilloma virus
<b>ICD-10</b>	International statistical classification of diseases and related health problems, 10th revision (WHO 1992)
<b>ICD-O-2</b>	International classification of diseases for oncology, 2nd edition (WHO 1990)
<b>ICD-O-3</b>	International classification of diseases for oncology, 3rd edition (WHO 2000)
<b>NCCI</b>	National Cancer Control Initiative
<b>NCEPH</b>	The Australian National University National Centre for Epidemiology and Population Health
<b>NCSCH</b>	National Cancer Strategies Clearing House (see Appendix A)
<b>NCSG</b>	National Cancer Strategies Group
<b>NHDC</b>	National Health Data Committee
<b>NHL</b>	non-Hodgkin lymphoma
<b>NHPA</b>	National Health Priority Area
<b>NMSC</b>	non-melanoma skin cancers
<b>NOHSC</b>	National Occupational Health and Safety Commission
<b>PSA</b>	prostate-specific antigen
<b>PI</b>	prediction interval (see Appendix B)
<b>SCC</b>	squamous cell carcinoma
<b>WHO</b>	World Health Organization
<b>..</b>	not applicable

# Acknowledgments

This project was commissioned by the National Cancer Strategies Group (NCSG) who endorsed the assumptions underlying the statistical modelling. The work was funded by the Australian Government Department of Health and Ageing and the Australian Institute of Health and Welfare (AIHW).

The author of this report is Ian McDermid of the Health Registers and Cancer Monitoring Unit at AIHW. Other staff of the unit also contributed to the project, including Edith Christensen who assisted in the extraction and preparation of the data, Janet Markey who assisted with the editing of the report and John Harding and Dr Chris Stevenson who both provided advice and comments, as did John Goss of the Summary Measures Unit, Dr Ching Choi, Head of the Health Division and Dr Richard Madden, Director of AIHW. Ainsley Morrissey, Lauren Di Salvia and Paul Wright of the Information Services and Publishing Unit provided assistance with the production of this report.

A number of people associated with the NCSG and the Australian Association of Cancer Registries (AACR) provided valuable advice and comments on the modelling assumptions and on draft versions of this report, in particular Professor Alan Coates, Dr Michael Coory, Professor Mark Elwood, Professor Dallas English, Professor David Roder, Graeme Tucker, Dr Joanne Aitken, Dr Peter Baade, Vicky Thursfield, Dr Tim Threlfall and Elizabeth Tracey.

We thank Professor Rob Hyndman of the Department of Econometrics & Business Statistics at Monash University for his advice on the functional data analysis approach and for the use of his R computer software package for demographic forecasting (available on his website <[www-personal.buseco.monash.edu.au/~hyndman](http://www-personal.buseco.monash.edu.au/~hyndman)>).

We also thank Dr Mark Clements of the National Centre for Epidemiology and Population Health for his advice and comments and for his detailed review of the draft projections.

# Executive summary

This report presents projections of cancer incidence for Australia, excluding non-melanoma skin cancers (NMSC), to 2011.

## **Cancer incidence rates projected to remain stable**

For women, the age-standardised incidence rate for all cancers, excluding NMSC is projected to increase by 2% from 393.3 per 100,000 women in 2001 to 402.9 per 100,000 in 2011, with a 95% prediction interval from 380.5 to 428.6.

For men, the age-standardised rate is projected to decrease by 1% from 541.4 per 100,000 men in 2001 to 538.3 per 100,000 in 2011, with a 95% prediction interval from 495.0 to 588.0.

## **Number of new cases of cancer to increase**

The Australian population is ageing and cancer incidence rates are highest in the older age groups. Even with the relatively stable trends in the incidence rates, the projected increase in the Australian population, particularly the increased population in the older age groups, will lead to large increases in the total number of new cases of cancer.

For women, the number of new cases of cancer is projected to increase by 29% from 40,578 in 2001 to 52,356 in 2011, with a 95% prediction interval from 49,356 to 55,777. For men, the number of new cases of cancer is projected to increase by 32% from 47,820 in 2001 to 63,087 in 2011, with a 95% prediction interval from 58,122 to 68,752. Hence the total number of new cases of cancer is projected to increase by 31% from 88,398 in 2001 to around 115,400 in 2011.

Cancer of the cervix is the only cancer (out of the 60 cancers and groups of cancers for which projections were produced) where the number of new cases is projected to decrease; by 37% from 735 in 2001 to around 450 in 2011.

## **The most common cancers**

For women, the most common cancers in 2001 were breast cancer (29% of all new cases), colorectal (14%), melanoma (10%) and lung (7%). For men, the most common cancers in 2001 were prostate cancer (23%), colorectal (15%), lung (11%) and melanoma (11%).

By 2011, it is projected that melanoma will have overtaken lung cancer as the third most common cancer for men. For women, the most common cancers in 2011 are projected to be breast cancer (28% of all new cases), colorectal (15%), melanoma (9%) and lung (8%). For men, the most common cancers in 2011 are projected to be prostate cancer (24%), colorectal (15%), melanoma (11%) and lung (10%).

## **Smoking-related cancers**

In 1945 smoking rates in men were almost treble those in women, with almost three-quarters of men and a quarter of women smoking. Smoking rates have been declining since 1945 for men, but only since the mid-1970s for women, when almost a third of women smoked. In 2004, 22.5% of males and 18.8% of females aged over 14 years were current smokers.

Between 2001 and 2011, the incidence of smoking-related cancers is projected to decrease for men. For women, incidence of smoking-related cancers is projected to increase, but at a rate that slows towards the end of the projection period.

The age-standardised rates for women are projected to increase by 6% from 28.9 per 100,000 women in 2001 to 30.7 per 100,000 in 2011. The age-standardised rates for men are projected to decrease by 8% from 86.1 per 100,000 men in 2001 to 78.9 per 100,000 in 2011.

# 1 Introduction

This report presents projections of cancer incidence for Australia from 2002 to 2011. These projections were commissioned by the National Cancer Strategies Group (NCSG) to support planning of cancer services, and the report is a joint publication of the Australian Institute of Health and Welfare (AIHW), the NCSG and the Australasian Association of Cancer Registries (AACR). The project has been jointly funded by the Australian Government Department of Health and Ageing (DoHA) and AIHW.

This report includes national projections of cancer incidence for selected cancer groups and sites, but does not include any state or regional projections of cancer incidence, which have been produced by some state cancer registries (Tracey et al. 2005; SACR 2005; Threlfall & Thompson 2004; Tracey & Supramaniam 2002; Threlfall 1997).

The most recently available national data, published in *Cancer in Australia 2001* (AIHW & AACR 2004) are the starting point for these projections, which use cancer incidence data from 1982 to 2001, held by the AIHW in the National Cancer Statistics Clearing House (NCSCH). Refer to Appendix A for further details.

In producing the projections, it was necessary to make a number of assumptions about various cancers. These assumptions were made in consultation with the following expert advisers appointed by the NCSG Data Subcommittee and the AACR:

- NCSG Data Subcommittee: Professor Alan Coates, Professor Mark Elwood, Professor David Roder.
- AACR Statistical Advisory Committee: Dr Michael Coory, Professor Dallas English, Mr Graeme Tucker.

## 1.1 Key assumptions

The statistical methods described in Section 1.3 below and in Appendix B were used to extrapolate trends in the cancer incidence data from 1982 to 2001. These incidence data reflect changes in cancer prevention, in the detection rates of cancer and in the treatment of precancerous conditions. Where such changes have occurred gradually over time, using statistical methods to extrapolate past trends assumes that these gradual changes will continue to occur in the future at a similar rate.

The introduction of a new screening program or a new diagnostic test may cause changes in incidence trends. The expert advisers highlighted the commencement of national screening programs for female breast cancer and cancer of the cervix and the introduction of prostate-specific antigen (PSA) testing for prostate cancer as having caused major changes in incidence rates.

In particular, the introduction of PSA testing around 1990 caused a rapid, but temporary, increase in male cancer incidence rates in the early 1990s. PSA tests are designed to identify cancers before the onset of clinical symptoms. Much of the temporary increase in prostate cancer incidence has been attributed to the early detection of cancers that would not have been detected at that time except for PSA testing.

Following consultation with the experts, the projection for female breast cancer uses incidence data from 1994 to 2001, the projection for cancer of the cervix uses data from 1991 to 2001 and the projection for prostate cancer uses data from 1997 to 2001.

It is difficult to anticipate and quantify future developments that may cause rapid changes in incidence rates, such as the proposed introduction of a national bowel cancer screening program (DoHA 2005) or the advent of a vaccine for human papilloma virus (HPV), which is strongly linked to cancer of the cervix (Frazer 2004). The projections in this report do not reflect such possible future changes. Expert commentary has been sought on these issues and Chapter 2 includes comments on whether the projections for particular cancers may be too high or too low.

Similarly, these projections do not reflect any anticipated increase in the avoidance of risk factors such as smoking and alcohol consumption, increased response to continuing prevention campaigns, or improvements in detection tests and the treatment of precancerous conditions. If such underlying trends accelerate, rather than simply continue at the current rates of improvement, these projections may overstate the expected incidence of some cancers.

## 1.2 Cancer groups

For the purposes of these projections, rarer cancers were grouped together so that there were sufficient cases to ensure a stable projection. These groups were based on a set of clinical groups agreed on by the AACR in November 2004, with some minor differences to conform to the tabulation categories used in *Cancer in Australia 2001* (AIHW & AACR 2004), the starting point for these projections.

The clinical groups are designed to group cancers that are similar in terms of clinical treatment. Cancers have been grouped into 16 clinical groups for the purposes of these projections: skin and lip cancers; head and neck cancers; cancers of upper digestive tract (the oesophagus, stomach and small intestine); cancers of the colon, rectum and anus (colorectal cancer); cancers of the liver, gallbladder and pancreas; cancers of respiratory and thoracic organs; cancers of bone and connective tissue; breast cancer; cancer of female genital organs (gynaecological cancers); cancers of male genital organs; cancers of the urinary tract; eye cancer; cancers of the brain and central nervous system; cancers of the thyroid and other endocrine glands; cancers of unknown primary site; and cancers of lymphoid and haematopoietic tissue. Full details of the groups and the ICD-10 codes (WHO 1992) for each group and cancer are given in Table 2 for female cancers and in Table 4 for male cancers.

Projections have been produced separately for females and males for each of the 16 clinical groups, as well as projections for all cancers for both sexes. Separate projections were also produced for particular cancers of interest nominated by DoHA or during consultation with the experts. These include the National Health Priority Area (NHPA) cancers melanoma, lung, colorectal, breast, cervix, prostate and non-Hodgkin lymphoma; as well as a number of other major cancers and cancers of interest. Incidence from 1982 to 2001 of all the cancer groups and cancers of interest is shown in Table 1 for females and Table 3 for males.

Non-melanoma skin cancers (NMSC), which are also NHPA cancers, have not been included in these projections, nor have conditions with ICD-10 codes in the range D45–D47, as coverage of these cancers is not yet complete in the NCSCCH. For further details, see Appendix A. These cancers are also excluded from the projections for all cancers.

A summary of the results of the projections for each cancer from 2002 to 2011 is shown in Table 2 for female cancers and in Table 4 for male cancers. The expected accuracy of the projections differs considerably between cancers, due mainly to differences in the number of cases, and prediction intervals (confidence intervals for predictions, see Appendix B) have

been calculated for each projection and are shown in the more detailed tables for each projection (Tables 7 to 66).

Projections for subgroups and individual cancers within each clinical group have been constrained to add to the overall projection for the group. Prediction intervals were calculated separately for each projection and do not add to the group totals. The projections for all cancers were also constrained to equal the total of the projections for the clinical groups, though separate prediction intervals were again calculated.

For the reasons stated in Section 1.1, separate projections were produced for female breast cancer, cancer of the cervix and prostate cancer, with the results later added to the projections for the relevant clinical groups and to the projections for all cancers.

## 1.3 Projection methods

Each projection involves calculating the age-specific rates of cancer incidence for 1982 to 2001, as described in Appendix B on statistical methods, and projecting these rates to 2011. The methods chosen to project the age-specific rates are based on the functional data analysis (FDA) approach introduced by Ramsey and Silverman (1997), which can be used to generalise the Lee-Carter approach (Lee 2000, Lee & Carter 1992) to demographic forecasting.

These relatively new statistical methods have been used to produce demographic projections (Hyndman & Ullah 2005; Booth et al. 2001, 2002; Lee & Miller 2001; Lee & Carter 1992) and to forecast breast cancer mortality (Erbas et al. 2005). However, this is the first time the methods have been used to project cancer incidence rates.

Appendix B describes the FDA approach and compares these methods with other methods that have been used to project cancer incidence. Computer routines supplied by Professor Rob Hyndman of Monash University (Hyndman & Ullah 2005) were adapted to apply the FDA approach to project cancer incidence rates and to produce 95% prediction intervals.

The projected age-specific rates and prediction intervals were applied to the Australian estimated resident population (ERP) for 2002 and 2003 (ABS 2003b) and to the AIHW preferred series (series 8) of the Australian Bureau of Statistics (ABS) population projections from 2004 to 2011 (ABS 2003c) to produce estimates of the expected number of new cancer cases from 2002 to 2011.

Appropriate error margins are not given for the ABS estimates of ERP and projected ERP, so the 95% prediction intervals for the projected number of new cases reflect only the variability in the projected cancer incidence rates. The 95% prediction intervals for the projected number of new cases should be considered to be low and high scenarios, rather than true 95% prediction intervals.

The sensitivity of the projected age-specific rates to changes in the application of the techniques and to minor changes in the incidence data was examined. The separate projections for all cancers produced results very close to the total of the group projections (the separately projected numbers of new cases were within 1% of the total), suggesting the group level projections are reasonably stable.

The projections were also reviewed by Dr Mark Clements of the National Centre for Epidemiology and Population Health at the Australian National University (NCEPH) who fitted a series of alternative models to the data. For the major cancers, the alternative projection methods produced generally consistent results with a few exceptions, which are discussed in Chapter 2.

## 2 Results

In the following discussion, incidence rates and numbers of cases projected to 2011 are compared with equivalent figures in 2001, which is the most recent available national data in the NCSCH. All comparisons involving age-standardised rates refer to the rates for all ages standardised to the Australian Standard Population 2001.

There are a total of 60 projections for selected cancers and groups of cancers. For each projection there is both a table (Tables 7 to 66), showing the projected incidence rates and the expected number of cases from 2002 to 2011, and a corresponding set of graphs (Figures 7 to 66), showing past age distributions and the projected 2011 age distribution, as well as the past and projected trends in incidence rates and the number of new cases.

Projected age-standardised incidence rates for all cancers and for the NHPA cancers are shown in Figure 1 for women and in Figure 3 for men. The expected number of new cases are summarised in Table 2 and Figure 2 for women and in Table 4 and Figure 4 for men. The summary tables, Table 2 for women and Table 4 for men, also provide cross-references to the more detailed tables for each projection.

### 2.1 All cancers

For women, the projection for all cancers to 2011 shows the age-specific incidence rates continuing to rise for the older age groups (65 and over), although the rate of increase is projected to slow. The age-standardised incidence rate is projected to increase by 2% from 393.3 per 100,000 women in 2001 to 402.9 per 100,000 in 2011, with a 95% prediction interval from 380.5 to 428.6.

For men, the projection for all cancers from 2002 to 2011 shows almost no change in the age-specific incidence rates, except for a slight increase in the oldest age group (85 and over). The age-standardised rate is projected to decrease by 1% from 541.4 per 100,000 men in 2001 to 538.3 per 100,000 in 2011, with a 95% prediction interval from 495.0 to 588.0.

The Australian population is ageing. Under the AIHW preferred series of ABS population projections (series 8), the total population is expected to increase by 12% from 19,413,240 as at 30 June 2001 to 21,765,911 by 30 June 2011. In the same period, the population in the age range 65 and over is projected to increase by 30% from 2,435,534 to 3,169,188.

For most cancers, the highest incidence rates are in the older age groups, so that even with the relatively stable trends in the incidence rates, the projected increase in the Australian population (particularly the increased population in the older age groups) will lead to large increases in the total number of new cases of cancer.

For women, the number of new cases of cancer is projected to increase by 29% from 40,578 in 2001 to 52,356 in 2011, with a 95% prediction interval from 49,356 to 55,777. For men, the number of new cases is projected to increase by 32% from 47,820 in 2001 to 63,087 in 2011, with a 95% prediction interval from 58,122 to 68,752.

As shown in Figures 1 to 4, both the relatively stable trend in incidence rates and the projected increase in the number of new cases for all cancers are reflected in the trends for most of the NHPA cancers. A notable exception is cancer of the cervix, which is the only one of the 60 projections where the number of new cases of cancer is projected to decline between 2001 and 2011.

## 2.2 Common cancers by age

The trends in the numbers of new cases of cancer by broad age range are shown in Table 5 for women and Table 6 for men. In each age range the most common cancers in 2001 are indicated. The cancers listed were generally also the most common cancers in that age group in 1991 and are also projected to be the most common cancers in that age group in 2011.

A notable exception for women aged 15–44 years was cancer of the cervix, which was the third most common cancer in 1991 with 471 new cases and the fourth most common cancer in 2001 with 264 new cases, but is projected to be only the seventh most common with 170 new cases in 2011.

The most common cancers for women of all ages in 2001 were breast cancer (29% of all new cases of cancer for females), colorectal (14%), melanoma (10%) and lung (7%). The most common cancers for men of all ages in 2001 were prostate cancer (23% of all new cases of cancer for males), colorectal (15%), melanoma (11%) and lung (11%).

For men, it is projected that by 2011 melanoma (projected to be 11% of all new cases) will have overtaken lung cancer (10%) as the third most common cancer for all ages, although lung will still be the third most common cancer in the oldest age range, 65 years and over.

### Childhood and youth cancers

The projection models are least reliable for the youngest age groups, as the numbers of cases involved are relatively small.

In the youngest age range 0–14 years, the most common cancers in 2011 are projected to be leukaemia (a total of 210 new cases for males and females), cancers of the brain and central nervous system (106 new cases), cancers of bone and connective tissue (68 new cases), non-Hodgkin lymphoma (42 new cases) and cancers of the urinary tract (37 new cases of mainly kidney cancer, ICD-10 code C64). These cancers were also the most common in this age range in 2001.

Incidence rates are projected to increase slightly for most of the above cancers. The population in the age range 0–14 years is actually projected to decrease by 3% from 3,987,000 in 2001 to 3,884,000 in 2011. The numbers of new cases of cancer in this age range is projected to increase by only 7% for females, from 279 new cases in 2001 to 299 in 2011, and by only 5% for males, from 324 new cases in 2001 to 339 in 2011.

For women aged 15–44 the most common cancers in 2011 are projected to be breast (1,625 new cases), melanoma (1,120), cancers of thyroid and other endocrine glands (610), colorectal cancer (270), ovarian cancer (198) and non-Hodgkin lymphoma (172).

Cancers of thyroid and other endocrine glands have become increasingly common for women aged 15–44. This group of cancers was only the fifth most common in this age range in 1991 with 200 new cases, after colorectal cancer with 236. In 2001 it was the third most common with 411 new cases and is projected to increase by 49% to 610 new cases in 2011.

For men aged 15–44 the most common cancers in 2011 are projected to be melanoma (1,035 new cases), cancers of other male genital organs (487), colorectal cancer (327) and non-Hodgkin lymphoma (279).

In the age range 15–44, the cancers of other male genital organs are mainly testicular cancer (ICD-10 code C62). Age-specific incidence rates for this group of cancers are projected to decrease slightly in this age range and the number of new cases is projected to decrease by 2% from 496 in 2001 to 487 in 2011.

## 2.3 Skin and lip cancers

Non-melanoma skin cancers (NMSC) have not been included in these projections for the reasons detailed in Appendix A. The remainder of this group of cancers is dominated by melanoma, an NHPA cancer, for which there are also separate projections.

For women, the number of new cases of skin and lip cancers (excluding NMSC) is projected to increase by 27% from 4,131 in 2001 to 5,266 in 2011, with a 95% prediction interval from 4,885 to 5,647. For men, the number of new cases is projected to increase by 32% from 5,770 in 2001 to 7,640 in 2011, with a 95% prediction interval from 5,996 to 9,815.

This group of cancers has an age distribution that reflects past exposure to ultraviolet radiation. Male rates for these cancers have historically been much higher, reflecting higher occupational exposure in traditionally male jobs. The projections for melanoma and for the group of skin and lip cancers show rising age-standardised rates for both sexes. However, the projected rise is slower than the historical rise, particularly for younger age groups, probably due to the effects of skin cancer prevention campaigns that began at different times in different states, starting around 1959 (Giles et al. 1996).

A recent study (Coory et al. 2005) of melanoma in Queensland, the state with the highest incidence rates of all states and territories, suggests that incidence rates should start to stabilise for age groups 35 and over, though primary prevention programs are unlikely to lead to a decrease in overall incidence rates for at least another 20 years. If incidence rates do start to decline in the middle age groups before 2011, then the projections in this report may overstate the expected increase in the number of cases.

## 2.4 Head and neck cancers

The projections for this group of cancers show slowly decreasing age-standardised rates for men and considerably lower, but stable age-standardised rates for women. The number of cases of these cancers is expected to continue rising for both males and females due to the expected ageing of the Australian population.

For women, the number of new cases of head and neck cancers is projected to increase by 28% from 636 in 2001 to 813 in 2011, with a 95% prediction interval from 714 to 974. For men, the number of new cases is projected to increase by 23% from 1,795 in 2001 to 2,204 in 2011, with a 95% prediction interval from 1,942 to 2,603.

## 2.5 Cancers of the upper digestive tract

The three cancers in this group have displayed different historical trends, with the age-standardised rates for stomach cancer decreasing whereas cancer of the small intestine has been increasing in incidence, similar to colorectal cancer. Separate projections were produced for cancer of the stomach and for cancer of the oesophagus.

Cancer of the oesophagus, similar to some head and neck cancers, is partly attributed to smoking and alcohol consumption (see Section 2.19). Incidence of this cancer was increasing in the 1980s, but appears to have peaked in the 1990s and is projected to decrease.

As a group, these cancers are dominated by the decline in cancer of the stomach, the most common of the three, with age-standardised rates projected to steadily decrease for both

sexes; however, population ageing will still lead to increases in the expected number of cases.

For women, the number of new cases of cancers of the upper digestive tract is projected to increase by 22% from 1,203 in 2001 to 1,469 in 2011, with a 95% prediction interval from 1,280 to 1,698. For men, the number of new cases is projected to increase by 27% from 2,072 in 2001 to 2,634 in 2011, with a 95% prediction interval from 2,439 to 2,853.

## 2.6 Colorectal (bowel) cancer

Colorectal cancer includes cancers of the bowel or large intestine (ICD-10 code C18) and cancers of the rectum and anus (ICD-10 codes C18 to C21). Colorectal cancer is the most frequently occurring cancer in Australia (excluding NMSC) with a total of 12,844 new cases in 2001, and it is the second leading cause of cancer death after lung cancer (AIHW & AACR 2004). For a profile of colorectal cancer, see *Cancer in Australia 2000* (AIHW & AACR 2003).

Historically, incidence of this cancer has been slowly increasing for women; however, the age-standardised rate for men has remained between 76 and 80 (per 100,000 men) since 1991. The age-standardised rate for men is projected to remain at 79, and for women the projections show a continuation of the slow historical increase from 55 in 2001 to 56 in 2011. For both sexes, the expected ageing of the population is projected to cause large increases in the number of cases.

For women, the number of new cases of colorectal cancer is projected to increase by 30% from 5,883 in 2001 to 7,673 in 2011, with a 95% prediction interval from 7,034 to 8,414. For men, the number of new cases is projected to increase by 33% from 6,961 in 2001 to 9,249 in 2011, with a 95% prediction interval from 7,627 to 12,710.

The Australian Government has announced that a national screening program for bowel cancer will commence in a limited way from the middle of 2006, with people turning 55 or 65 years old invited to participate (DoHA 2005). As with the other cancers affected by screening programs or diagnostic tests (female breast cancer, cancer of the cervix and prostate cancer) this screening program, if implemented, is likely to cause a shift in the age distribution of incidence, with more cancers detected between 2006 and 2011 in the 55–59 and 65–69 age groups.

Introduction of this bowel screening program may cause an initial rise in incidence because of previously undetected cancers, but may ultimately also cause declines in incidence because of the detection and treatment of precancerous conditions. The timing and size of the expected changes in the age distribution are difficult to quantify and have not been taken into account in the projections in this report.

## 2.7 Cancers of the liver, gallbladder and pancreas

The projections for this group of cancers show stable age-standardised rates for women and higher and slightly increasing age-standardised rates for men. For women, the number of new cases of cancers of the liver, gallbladder and pancreas is projected to increase by 27% from 1,469 in 2001 to 1,863 in 2011, with a 95% prediction interval from 1,426 to 2,489. For men, the number of new cases is projected to increase by 43% from 1,836 in 2001 to 2,624 in 2011, with a 95% prediction interval from 2,233 to 3,160.

Separate projections have been produced for cancer of the liver (which is partly attributed to alcohol consumption) and for cancer of the pancreas (which is partly attributed to smoking).

In contrast to the other cancers in this group, the age-standardised rates for liver cancer are projected to increase for both men and women. See Section 2.19 for further comments on cancers attributed to smoking and alcohol consumption.

## 2.8 Lung cancer and other cancers of respiratory and thoracic organs

For women, the number of new cases of cancers of respiratory and thoracic organs is projected to increase by 41% from 3,017 in 2001 to 4,261 in 2011, with a 95% prediction interval from 4,002 to 4,521. For men, the number of new cases is projected to increase by 22% from 5,884 in 2001 to 7,163 in 2011, with a 95% prediction interval from 5,808 to 9,223.

### Lung cancer

This group of cancers is dominated by lung cancer, which includes cancers covered by ICD-10 codes C33 and C34 (cancers of the trachea, bronchus and lung). Lung cancer is the cancer that currently causes the most deaths in Australia and is attributed mainly to smoking (see Section 2.19).

In 1945, almost three-quarters of adult men and a quarter of adult women smoked (Woodward 1981). For men, the proportion of current smokers declined to less than a half by the 1970s and has since continued to decline. For women, the proportion of current smokers increased to almost a third by the mid-1970s, before starting to decline (Hill et al. 1988; White et al. 2003). In 2004, 22.5% of males and 18.8% of females aged over 14 years were current smokers (AIHW 2005a).

The incidence projections for lung cancer reflect the historical trends in smoking prevalence from the mid-1940s to the mid-1970s, with the age-standardised rates for men projected to continue decreasing, and the age-standardised rates for women projected to continue increasing but at a slower rate, with a possible peak in incidence towards the end of the projection period.

For women, the number of new cases of lung cancer is projected to increase by 38% from 2,891 in 2001 to 4,001 in 2011, with a 95% prediction interval from 3,762 to 4,241. For men, the number of new cases is projected to increase by 17% from 5,384 in 2001 to 6,301 in 2011, with a 95% prediction interval from 5,794 to 6,898.

An alternative model proposed by Clements et al. (2005) suggests that the age-standardised rates for female lung cancer have already reached a peak and will start to decrease early in the projection period.

### Mesothelioma

Separate projections have also been produced for mesothelioma, a usually fatal cancer that is typically associated with occupational exposure to asbestos that occurred around 20–30 years prior to diagnosis. For a profile of mesothelioma, see *Cancer in Australia 2001* (AIHW & AACR 2004).

Though still a relatively rare cancer, the incidence of mesothelioma has been increasing rapidly in both men and women since the first reported cases in the 1960s (NOHSC 2004), and the projections show a continuation of these trends.

For women, the number of new cases of mesothelioma is projected to increase by 98% from 107 in 2001 to 212 in 2011, with a 95% prediction interval from 141 to 286. For men, the

number of new cases is projected to increase by 69% from 460 in 2001 to 778 in 2011, with a 95% prediction interval from 435 to 1,454.

In Australia, asbestos was mined and asbestos products were produced, notably at Wittenoom in Western Australia until 1966 and in New South Wales until 1983. Phasing out of the use of some asbestos products began in 1967, but raw asbestos continued to be imported and consumption peaked in 1975. Use of asbestos products has been regulated since the late 1970s and early 1980s (NOHSC 2004).

Owing to these restrictions and the delay of 20–30 years between exposure and diagnosis, analysis by Leigh and Driscoll (2003) suggests that the number of new cases of mesothelioma is expected to peak around 2010; however, this is not reflected in the projections in this report, which are based on extrapolation of current trends.

## **2.9 Cancers of bone and connective tissue**

The projections for this group of cancers show increasing incidence rates for women, especially in the older age groups, and stable incidence rates for men.

For women, the number of new cases of cancers of bone and connective tissue is projected to increase by 50% from 427 in 2001 to 639 in 2011, with a 95% prediction interval from 512 to 767. For men, the number of new cases is projected to increase by 32% from 401 in 2001 to 529 in 2011, with a 95% prediction interval from 420 to 670.

## **2.10 Breast cancer**

In the 1980s, there was a rapid increase in the incidence of female breast cancer, and mammography screening programs were introduced in each state and territory from 1989 in Western Australia and South Australia to 1994 in the Northern Territory. Publicly funded mammography screening has been coordinated as a national program since 1991, now called BreastScreen Australia (AIHW 1998, 2005b).

The effect of the introduction of mammography screening programs appears to have been an increase in the incidence of female breast cancer in the target age range of 50–69 years, and the incidence in the oldest age groups has declined.

This changed age distribution appears to have been relatively stable from 1994 onwards, so the projection for female breast cancer is based only on data from 1994. The age-standardised rates for female breast cancer are projected to remain stable from 2002 to 2011. As breast cancer is the most common cancer for women and particularly affects older women, the ageing of the population will still lead to large increases in the expected number of new cases.

Men are not included in the target group for the BreastScreen Australia program, so male breast cancer, a rare cancer, has not been directly affected by screening. Male breast cancer incidence is projected to remain stable at low rates.

For women, the number of new cases of breast cancer is projected to increase by 26% from 11,791 in 2001 to 14,818 in 2011, with a 95% prediction interval from 13,939 to 15,829. For men, the number of new cases is projected to increase by 28% from 95 in 2001 to 122 in 2011, with a 95% prediction interval from 59 to 261.

## 2.11 Gynaecological cancers

For the purposes of these projections, cancers of the female genital organs have been divided into four subgroups: cancer of the cervix (ICD-10 code C53); cancers of other parts of the uterus (C53 and C54); cancers of the vulva, vagina and placenta (C51, C52 and C58 respectively) and ovarian cancer (cancers of the ovaries and other female genital organs – C56 and C57).

Separate projections are presented for all four subgroups as well as the overall total. The projection for ovarian cancer may be affected by coding changes in cancer registration (see Appendix A for details).

Incidence for three of the four subgroups is projected to remain stable; however, incidence of cancer of the cervix has been steadily decreasing and this decrease is projected to continue.

Incidence for gynaecological cancers as a group is projected to slowly decrease as a result of the decrease in incidence of cancer of the cervix. With the expected ageing of the population, the overall number of new cases of cancer of gynaecological cancers is projected to increase by 15% from 3,886 in 2001 to 4,488 in 2011, with a 95% prediction interval from 4,048 to 5,191.

### Cancer of the cervix

Pap smear testing for cancer of the cervix has been available on an opportunistic basis since well before 1982, the starting point for data in the NCSCH. An organised program for screening for cervical cancer was introduced in Australia in the early 1990s, covering a wide range of ages from 20 to 69 years (AIHW 1998).

The age distribution of incidence has been stable since the early 1990s, though the age-specific rates at each age have continued to fall because of the early detection and treatment of precancerous abnormalities (AIHW 2004). The projection for cancer of the cervix is based on data from 1991 onwards.

Cancer of the cervix is the only cancer for which the expected number of new cases is projected to decrease even with the expected ageing of the population. The number of new cases reported in 2001 was 735, which is projected to decrease by 37% to 461 by 2011, with a 95% prediction interval from 264 to 820 cases.

Human papilloma virus (HPV) is strongly linked to incidence of cervical cancer. In the longer term, the likely introduction of a vaccine for HPV (Frazer 2004) may greatly further reduce incidence, but there will probably be little impact on incidence numbers before 2011.

## 2.12 Prostate cancer and other cancers of male genital organs

Cancers of the male genital organs are dominated by prostate cancer, which is the most commonly occurring cancer in men, accounting for 23% of all new cases of cancer (excluding NMSC) diagnosed in men in 2001. Separate projections are presented for prostate cancer and for cancers of other male genital organs (which include cancers of the penis and testis), as well as an overall projection for the group.

Prostate cancer incidence rates were relatively stable in the 1980s, but between 1990 and 1994 there was a sharp rise in the number of new cases. This upward trend has been attributed to increased availability of prostate-specific antigen (PSA) testing, which first became available

in 1987 and which has been included in the Medical Benefits Schedule since 1989 (Coory & Armstrong 1998).

PSA tests are designed to identify cancers before the onset of clinical symptoms and the increased availability of the tests led to the early detection of prevalent cancers that would not otherwise have been detected. Incidence rates started to decline after 1994, leaving a noticeable 'hump' in the incidence rates from 1992 to 1996. This 'hump' is also obvious in the overall incidence rates for all cancers for men.

Attempts to project prostate cancer incidence using data before 1997 are noticeably affected by the 'hump' in incidence rates from 1992 to 1996. From 1997 onwards, the age distribution of prostate cancer has been stable, so projections using data from 1997 onwards have very narrow prediction intervals, even though they are based on only 5 years of data. The projection for prostate cancer is based on data from 1997, though the prediction intervals should be interpreted with caution.

Both the incidence of prostate cancer and cancers of other male genital organs are projected to remain stable. Cancers of other male genital organs often occur in younger age groups, particularly testicular cancer, so this projection is not strongly affected by the expected ageing of the population, and the number of new cases is projected to increase by only 10% from 701 in 2001 to 770 in 2011, with a 95% prediction interval from 540 to 1,129.

Prostate cancer is predominantly a cancer of older age groups, so the expected number of new cases is projected to increase by 36% from 11,191 in 2001 to 15,202 in 2011 with a 95% prediction interval from 14,542 to 15,999. This large expected increase is reflected in both the group projection and in the projection for all cancers for males. Overall, the number of new cases of cancers of male genital organs is expected to increase by 34% from 11,892 in 2001 to 15,972 in 2011 with a 95% prediction interval from 15,082 to 17,128.

## **2.13 Cancers of the urinary tract**

The incidence of this group of cancers is projected to remain stable at around current rates for both women and men. The projection for this group may be affected by coding changes in cancer registration involving cancer of the bladder (see appendix A for details).

For women, the number of new cases of cancers of the urinary tract is projected to increase by 31% from 1,640 in 2001 to 2,141 in 2011, with a 95% prediction interval from 1,785 to 2,587. For men, the number of new cases is projected to increase by 37% from 3,772 in 2001 to 5,186 in 2011, with a 95% prediction interval from 4,953 to 5,444.

## **2.14 Eye cancer**

The incidence of this relatively rare cancer is projected to remain stable at around current rates for both women and men.

For women, the number of new cases of eye cancer is projected to increase by 36% from 96 in 2001 to 131 in 2011, with a 95% prediction interval from 89 to 195. For men, the number of new cases is projected to increase by 39% from 137 in 2001 to 190 in 2011, with a 95% prediction interval from 133 to 279.

## **2.15 Cancers of the brain and central nervous system**

The incidence of this group of cancers is projected to remain stable at around current rates for both women and men. Some brain cancers affect children and are the second most common cancer in children after leukaemia. However, the cancers in this group also affect people in the oldest age groups and so the number of new cases is projected to increase with the ageing of the population.

For women, the number of new cases of cancers of the brain and central nervous system is projected to increase by 26% from 599 in 2001 to 754 in 2011, with a 95% prediction interval from 589 to 1,002. For men, the number of new cases is projected to increase by 25% from 822 in 2001 to 1,027 in 2011, with a 95% prediction interval from 883 to 1,206.

## **2.16 Cancers of thyroid and other endocrine glands**

This group of cancers is unusual as, historically, incidence has been considerably higher for women than for men. Incidence of these cancers is projected to increase for both sexes.

For women, the number of new cases of cancers of the thyroid and other endocrine glands is projected to increase by 58% from 916 in 2001 to 1,451 in 2011, with a 95% prediction interval from 1,017 to 1,886. For men, the number of new cases is projected to increase by 42% from 350 in 2001 to 498 in 2011, with a 95% prediction interval from 405 to 591.

## **2.17 Cancers of unknown primary site**

This diverse and relatively common group of cancers reflects the projections for all cancers, with the incidence projected to increase in the oldest age groups for women and to decrease slightly overall for men. Future numbers of new cases of these cancers may be affected by improvements in diagnostic testing and coding.

For women, the number of new cases of cancers of unknown primary site is projected to increase by 31% from 1,568 in 2001 to 2,052 in 2011, with a 95% prediction interval from 1,849 to 2,306. For men, the number of new cases is projected to increase by 29% from 1,736 in 2001 to 2,238 in 2011, with a 95% prediction interval from 1,992 to 2,539.

## **2.18 Non-Hodgkin lymphoma, leukaemia and other cancers of lymphoid and haematopoietic tissue**

Projections are presented for the overall group as well as separate projections for non-Hodgkin lymphoma (an NHPA cancer) and for leukaemia, which is the most commonly occurring cancer among children.

For non-Hodgkin lymphoma and for the overall group incidence is projected to remain stable for men, but to continue increasing for women. For leukaemia, incidence is projected to remain stable for both sexes. The projection for leukaemia may be affected by coding changes in cancer registration (see Appendix A for details) and may be overstated by up to 5%.

For women, the number of new cases of cancers of lymphoid and haematopoietic tissue is projected to increase by 37% from 3,316 in 2001 to 4,536 in 2011, with a 95% prediction interval from 4,156 to 4,916. For men, the number of new cases is projected to increase by 35% from 4,297 in 2001 to 5,811 in 2011, with a 95% prediction interval from 5,459 to 6,192.

## 2.19 Cancers attributed to smoking and alcohol consumption

The cancers partly attributed to smoking include some cancers of the oral cavity and pharynx (ICD-10 codes C01–C06, C09–C10 and C12–C14), cancer of the oesophagus (C15), stomach cancer (C16), cancer of the anus (C21.0 and C21.1), cancer of the pancreas (C25), cancer of the larynx (C32), lung cancer (C33–C34), cancer of the vulva (C51.9), cancer of the penis (C60), kidney cancer (C64), cancer of the renal pelvis (C65) and cancer of the bladder (C67).

The cancers attributable to excessive alcohol consumption include some cancers of the oral cavity and pharynx (ICD-10 codes C01–C06, C09–C10 and C12–C14), cancer of the oesophagus (C15), cancer of the liver (C22), cancer of the larynx (C32) and breast cancer (C50, females only).

Separate projections were produced for cancers attributable to smoking and to alcohol consumption. Attributable fractions based on cancer prevalence in 1998 (AIHW: Ridolfo & Stevenson 2001) were applied to the relevant cancers to find the number of cases and age-specific incidence rates. The rates were then projected using the same methods as for other cancers and the results were constrained to equal the total of the projections for the individual cancers.

For women, incidence of alcohol-related cancers is projected to remain stable for all ages. The number of new cases is projected to increase by 27% from 1,618 in 2001 to 2,058 in 2011, with a 95% prediction interval from 1,925 to 2,202.

For men, the incidence of alcohol-related cancers is projected to increase slightly for the oldest age groups (70 and over), but decrease or remain stable at younger ages. The number of new cases is projected to increase by 42% from 350 in 2001 to 498 in 2011, with a 95% prediction interval from 405 to 591.

The incidence of smoking-related cancers is projected to decrease for men. For women incidence of smoking-related cancers is projected to increase, but at a rate that becomes slower towards the end of the projection period, similar to the projections for lung cancer (see Section 2.8).

The age-standardised rates for women are projected to increase by 6% from 28.9 (per 100,000 women) in 2001 to 30.7 in 2011, with a 95% projection interval from 26.4 to 35.9. The age-standardised rates for men are projected to decrease by 8% from 86.1 in 2001 to 78.9 in 2011, with a 95% prediction interval from 72.1 to 87.1.

For women, the number of new cases of smoking-related cancers is projected to increase by 36% from 3,042 in 2001 to 4,126 in 2011, with a 95% prediction interval from 3,550 to 4,819. For men, the number of new cases is projected to increase by 23% from 7,550 in 2001 to 9,304 in 2011, with a 95% prediction interval from 8,436 to 10,338.

# Tables and figures

More detailed versions of these tables, including full historical data from 1982 to 2001 and associated population data, can be found on the AIHW website <[www.aihw.gov.au](http://www.aihw.gov.au)>.

**Table 1: Number of new cases of cancer by clinical group and cancer site/type, Australia 1982 to 2001, females**

Group	Cancer site/type <sup>(a)</sup>	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	% increase									% increase		
												1982-1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	1992-2001
Skin & lip, excluding NMSC		1,892	2,104	2,177	2,392	2,455	2,878	3,015	2,804	2,896	3,008	59	3,263	3,289	3,356	3,580	3,785	4,073	3,814	3,939	4,050	4,131	27
	Lip	114	126	115	114	152	203	187	199	225	234	105	293	236	247	257	318	333	305	272	259	262	-11
	Melanoma	1,774	1,972	2,059	2,275	2,299	2,669	2,821	2,600	2,662	2,765	56	2,961	3,038	3,101	3,306	3,458	3,734	3,493	3,651	3,783	3,861	30
	Kaposi sarcoma	4	6	3	3	4	6	7	5	9	9	125	9	15	8	17	9	6	16	16	8	8	-11
Head & neck		430	454	452	492	462	501	483	512	534	557	30	578	538	592	639	594	655	671	663	708	636	10
	Oral cavity & pharynx	336	361	359	395	379	406	390	406	436	445	32	487	445	488	520	494	536	567	547	591	546	12
	Nasal cavity & sinuses	30	29	46	45	26	23	29	36	39	40	33	26	39	39	45	39	51	45	38	50	36	38
	Larynx	64	64	47	52	57	72	64	70	59	72	13	65	54	65	74	61	68	59	78	67	54	-17
Upper digestive tract		874	957	939	945	933	1,022	1,025	949	992	1,056	21	1,029	1,036	1,057	1,116	1,112	1,160	1,169	1,137	1,193	1,203	17
	Oesophagus	205	229	256	272	242	299	344	261	301	309	51	319	350	340	356	354	346	375	372	357	374	17
	Stomach	633	678	639	621	643	662	623	628	624	667	5	638	626	637	675	663	730	670	663	718	700	10
	Small intestine	36	50	44	52	48	61	58	60	67	80	122	72	60	80	85	95	84	124	102	118	129	79
Colorectal		3,424	3,399	3,602	3,850	3,895	3,937	3,912	4,117	4,134	4,496	31	4,622	4,595	4,834	4,863	4,959	5,111	5,192	5,543	5,530	5,883	27
	Colon	2,333	2,339	2,505	2,675	2,752	2,763	2,722	2,868	2,843	3,128	34	3,175	3,191	3,289	3,339	3,417	3,520	3,605	3,838	3,827	4,085	29
	Rectum	1,030	998	1,029	1,087	1,064	1,104	1,106	1,162	1,188	1,281	24	1,351	1,321	1,436	1,428	1,437	1,488	1,465	1,563	1,583	1,675	24
	Anus	61	62	68	88	79	70	84	87	103	87	43	96	83	109	96	105	103	122	142	120	123	28
Liver, gallbladder & pancreas		761	813	896	873	987	977	1,039	1,016	1,044	1,126	48	1,145	1,194	1,219	1,289	1,327	1,335	1,435	1,451	1,472	1,469	28
	Liver	59	42	60	67	84	84	74	88	82	95	61	104	130	147	139	145	157	160	194	209	236	127
	Gallbladder	235	251	282	244	278	278	307	289	299	319	36	303	307	330	344	359	325	365	364	333	333	10
	Pancreas	467	520	554	562	625	615	658	639	663	712	52	738	757	742	806	823	853	910	893	930	900	22
Respiratory & thoracic organs		1,233	1,292	1,401	1,443	1,579	1,685	1,797	1,903	2,002	2,088	69	2,099	2,283	2,335	2,436	2,517	2,658	2,643	2,704	2,918	3,017	44
	Trachea, bronchus & lung	1,201	1,272	1,364	1,406	1,530	1,632	1,741	1,840	1,942	2,023	68	2,033	2,209	2,266	2,344	2,429	2,548	2,548	2,596	2,821	2,891	42
	Other thoracic organs	10	6	19	13	19	24	24	25	25	19	90	28	23	22	34	35	35	36	32	19	19	-32
	Mesothelioma	22	14	18	24	30	29	32	38	35	46	109	38	51	47	58	53	75	59	76	78	107	182
Bone & connective tissue		222	228	202	222	244	216	235	259	260	266	20	313	298	306	334	368	366	384	380	422	427	36
	Bone & articular cartilage	62	61	54	66	63	63	54	60	65	65	5	67	64	81	83	84	73	71	85	68	97	45
	Connective & soft tissue	160	167	148	156	181	153	181	199	195	201	26	246	234	225	251	284	293	313	295	354	330	34
Breast		5,244	5,322	5,670	5,898	6,081	6,688	6,732	7,160	7,412	8,043	53	8,027	8,796	9,738	10,054	9,742	10,181	10,730	10,662	11,345	11,791	47
Gynaecological		2,924	2,982	3,128	3,176	3,217	3,330	3,269	3,384	3,411	3,586	23	3,582	3,644	3,878	3,804	3,743	3,691	3,801	3,786	3,929	3,886	8
	Cervix	958	994	998	1,051	1,019	1,092	1,065	1,069	1,078	1,089	14	1,030	1,017	1,136	958	940	805	855	794	754	735	-29
	Uterus	928	917	998	1,007	1,069	1,073	1,069	1,042	1,081	1,170	26	1,237	1,242	1,353	1,357	1,307	1,383	1,397	1,434	1,580	1,537	24
	Ovary	849	884	914	924	918	955	932	1,058	1,048	1,056	24	1,081	1,138	1,130	1,222	1,232	1,201	1,274	1,279	1,320	1,295	20
	Vulva, vagina & placenta	189	187	218	194	211	210	203	215	204	271	43	234	247	259	267	264	302	275	279	275	319	36
Urinary tract		972	964	1,065	1,086	1,145	1,136	1,208	1,156	1,179	1,233	27	1,304	1,327	1,363	1,403	1,425	1,519	1,584	1,638	1,687	1,640	26
	Kidney & ureter	389	435	477	514	522	542	586	588	619	697	79	772	720	724	769	806	834	861	915	945	944	22
	Bladder	583	529	588	572	623	594	622	568	560	536	-8	532	607	639	634	619	685	723	723	742	696	31
Eye		57	73	54	56	65	72	77	79	81	104	82	104	89	97	87	91	96	105	90	74	96	-8
Brain & central nervous system		373	409	432	411	408	455	488	522	492	540	45	533	553	545	512	546	549	574	564	599	599	12
Thyroid & other endocrine glands		287	337	326	311	340	379	382	365	401	433	51	544	563	573	635	685	678	760	792	807	916	68
Unknown primary site		1,022	1,078	1,072	1,133	1,090	1,115	1,277	1,277	1,406	1,395	36	1,439	1,419	1,327	1,521	1,450	1,491	1,556	1,475	1,557	1,568	9
Lymphoid & haematopoietic tissue		1,753	1,784	1,883	1,895	1,980	2,103	2,134	2,302	2,365	2,457	40	2,603	2,572	2,764	2,925	2,972	3,011	3,120	3,258	3,308	3,316	27
	Hodgkin lymphoma	127	127	140	112	139	140	139	147	150	142	12	177	157	163	151	165	191	182	187	191	183	3
	Non-Hodgkin lymphoma	769	770	815	823	837	950	957	1,013	1,025	1,141	48	1,204	1,187	1,269	1,367	1,398	1,467	1,476	1,512	1,611	1,576	31
	Leukaemia	595	621	648	677	696	729	746	786	808	827	39	863	873	973	958	967	906	972	1,055	980	1,051	22
	Other lymphohaematopoietic	262	266	280	283	308	284	292	356	382	347	32	359	355	359	449	442	447	490	504	526	506	41
<b>All cancers, excluding NMSC</b>		<b>21,468</b>	<b>22,196</b>	<b>23,299</b>	<b>24,183</b>	<b>24,881</b>	<b>26,494</b>	<b>27,073</b>	<b>27,805</b>	<b>28,609</b>	<b>30,388</b>	<b>42</b>	<b>31,185</b>	<b>32,196</b>	<b>33,984</b>	<b>35,198</b>	<b>35,316</b>	<b>36,574</b>	<b>37,538</b>	<b>38,082</b>	<b>39,599</b>	<b>40,578</b>	<b>30</b>

(a) Refer to Table 2 on page 17 for a list of the ICD-10 codes associated with each cancer.

Source: NCSCH; AIHW & AACR 2004.

**Table 2: Projected number of new cases of cancer by clinical group and cancer site/type, Australia 2002 to 2011, females**

Group	Cancer site/type	ICD-10 codes	Table	Page	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	% increase 2002–2011
Skin & lip, excluding NMSC		C00, C43, C46	9	28	4,283	4,387	4,500	4,607	4,716	4,826	4,935	5,044	5,154	5,266	23
	Lip	C00			n.p.	..									
	Melanoma	C43	11	32	4,004	4,102	4,209	4,309	4,412	4,514	4,616	4,719	4,821	4,926	23
	Kaposi sarcoma	C46			n.p.	..									
Head & neck		C01–C14, C30–C32	13	36	659	674	690	706	723	740	758	776	794	813	23
	Oral cavity & pharynx	C01–C14			n.p.	..									
	Nasal cavity & sinuses	C30–C31			n.p.	..									
	Larynx	C32			n.p.	..									
Upper digestive tract		C15–C17	15	40	1,203	1,228	1,255	1,283	1,313	1,343	1,373	1,403	1,435	1,469	22
	Oesophagus	C15	17	44	391	398	405	413	421	429	437	445	453	461	18
	Stomach	C16	19	48	675	686	699	712	726	740	753	767	780	795	18
	Small intestine	C17			n.p.	..									
Colorectal		C18–C21	21	52	5,970	6,129	6,299	6,472	6,656	6,847	7,041	7,243	7,452	7,673	29
	Colon	C18			n.p.	..									
	Rectum	C19–C20			n.p.	..									
	Anus	C21			n.p.	..									
Liver, gallbladder & pancreas		C22–C25	23	56	1,478	1,514	1,553	1,592	1,635	1,679	1,722	1,767	1,814	1,863	26
	Liver	C22	25	60	218	232	246	261	276	292	308	325	343	361	65
	Gallbladder	C23–C24			n.p.	..									
	Pancreas	C25	27	64	892	908	925	943	962	981	1,000	1,019	1,039	1,061	19
Respiratory & thoracic organs		C33–C38, C45	29	68	3,145	3,255	3,369	3,483	3,602	3,727	3,853	3,985	4,121	4,261	35
	Trachea, bronchus & lung	C33–C34	31	72	2,999	3,098	3,201	3,304	3,411	3,523	3,636	3,755	3,876	4,001	33
	Other thoracic organs	C37–C38			n.p.	..									
	Mesothelioma	C45	33	76	108	117	127	137	148	160	172	185	198	212	97
Bone & connective tissue		C40–C41, C47–C49	35	80	453	470	490	509	529	549	571	593	616	639	41
	Bone & articular cartilage	C40–C41			n.p.	..									
	Connective & soft tissue	C47–C49			n.p.	..									
Breast		C50	37	84	12,081	12,363	12,661	12,957	13,261	13,566	13,874	14,186	14,499	14,818	23
Gynaecological		C51–C58	39	88	3,947	3,991	4,043	4,095	4,153	4,214	4,278	4,344	4,414	4,488	14
	Cervix	C53	40	90	703	670	640	610	582	556	530	506	483	461	–34
	Uterus	C54–C55	41	92	1,577	1,615	1,655	1,696	1,738	1,782	1,827	1,873	1,920	1,967	25
	Ovary	C56–C57	42	94	1,335	1,366	1,399	1,431	1,465	1,500	1,535	1,571	1,607	1,645	23
	Vulva, vagina & placenta	C58, C51–C52	43	96	332	340	349	357	367	376	385	394	404	414	25
Urinary tract		C64–C68	47	104	1,688	1,730	1,776	1,822	1,871	1,922	1,974	2,027	2,083	2,141	27
	Kidney & ureter	C64–C66, C68			n.p.	..									
	Bladder	C67			n.p.	..									
Eye		C69	49	108	110	112	114	116	119	121	123	126	128	131	20
Brain & central nervous system		C70–C72	51	112	628	640	653	666	680	694	708	723	738	754	20
Thyroid & other endocrine glands		C73–C75	53	116	950	1,000	1,055	1,109	1,164	1,219	1,276	1,333	1,392	1,451	53
Unknown primary site		C76–C80, C26, C39	55	120	1,630	1,669	1,713	1,756	1,804	1,852	1,900	1,948	1,998	2,052	26
Lymphoid & haematopoietic tissue		C81–C96	57	124	3,542	3,641	3,748	3,853	3,963	4,074	4,185	4,299	4,415	4,536	28
	Hodgkin lymphoma	C81			n.p.	..									
	Non-Hodgkin lymphoma	C82–C85, C96	59	128	1,735	1,796	1,860	1,924	1,992	2,060	2,129	2,200	2,272	2,348	35
	Leukaemia	C91–C95	61	132	1,082	1,101	1,123	1,143	1,165	1,186	1,207	1,228	1,249	1,271	17
	Other lymphohaematopoietic	C90, C88			n.p.	..									
<b>All cancers, excluding NMSC</b>		<b>C00–C96, excl. C44</b>	<b>7</b>	<b>24</b>	<b>41,766</b>	<b>42,801</b>	<b>43,920</b>	<b>45,027</b>	<b>46,188</b>	<b>47,373</b>	<b>48,571</b>	<b>49,799</b>	<b>51,052</b>	<b>52,356</b>	<b>25</b>

Note: All numbers in this table are estimates rounded to the nearest whole number and may not add exactly to the totals and subtotals. This rounding should not be taken as an indication of the accuracy of the estimates. The detailed tables indicated by table and page include 95% prediction intervals for each projection.

**Table 3: Number of new cases of cancer by clinical group and cancer site/type, Australia 1982 to 2001, males**

Group	Cancer site/type <sup>(a)</sup>	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	% increase										% increase	
		1982-1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	1992-2001										
Skin & lip, excluding NMSC		2,296	2,367	2,532	2,823	2,952	3,623	3,994	3,928	3,943	4,086	78	4,530	4,645	4,725	5,070	5,287	5,596	5,343	5,405	5,567	5,770	27
	Lip	574	566	505	583	473	653	670	674	667	746	30	809	768	746	758	831	866	835	652	666	705	-13
	Melanoma	1,717	1,789	2,009	2,207	2,412	2,870	3,186	3,100	3,118	3,170	85	3,550	3,686	3,803	4,115	4,329	4,661	4,430	4,695	4,839	5,024	42
	Kaposi sarcoma	5	12	18	33	67	100	138	154	158	170	3,300	171	191	176	197	127	69	78	58	62	41	-76
Head & neck		1,377	1,436	1,513	1,482	1,562	1,539	1,553	1,681	1,626	1,636	19	1,826	1,747	1,653	1,718	1,699	1,762	1,816	1,799	1,804	1,795	-2
	Oral cavity & pharynx	824	855	938	956	980	956	967	1,080	1,013	1,049	27	1,133	1,105	1,078	1,128	1,105	1,155	1,175	1,224	1,227	1,173	4
	Nasal cavity & sinuses	66	51	73	57	75	64	69	73	71	79	20	88	104	84	72	82	82	79	84	91	92	5
	Larynx	487	530	502	469	507	519	517	528	542	508	4	605	538	491	518	512	525	562	491	486	530	-12
Upper digestive tract		1,497	1,586	1,628	1,625	1,612	1,706	1,731	1,659	1,782	1,820	22	1,812	1,883	1,924	1,969	1,923	1,945	2,003	2,170	2,122	2,072	14
	Oesophagus	315	363	401	379	393	459	498	474	501	539	71	540	568	619	590	629	624	630	712	713	704	30
	Stomach	1,129	1,182	1,169	1,193	1,147	1,179	1,157	1,101	1,212	1,175	4	1,184	1,221	1,209	1,279	1,189	1,203	1,240	1,310	1,268	1,202	2
	Small intestine	53	41	58	53	72	68	76	84	69	106	100	88	94	96	100	105	118	133	148	141	166	89
Colorectal		3,497	3,694	3,863	4,181	4,161	4,343	4,476	4,758	4,809	5,209	49	5,202	5,392	5,563	5,800	6,067	6,150	6,127	6,334	6,873	6,961	34
	Colon	2,093	2,253	2,386	2,651	2,669	2,718	2,740	2,968	2,930	3,221	54	3,166	3,282	3,372	3,479	3,653	3,710	3,677	3,812	4,158	4,233	34
	Rectum	1,369	1,406	1,424	1,476	1,451	1,569	1,670	1,744	1,812	1,914	40	1,956	2,034	2,120	2,230	2,313	2,357	2,359	2,414	2,608	2,626	34
	Anus	35	35	53	54	41	56	66	46	67	74	111	80	76	71	91	101	83	91	108	107	102	28
Liver, gallbladder & pancreas		992	926	937	968	1,065	1,079	1,112	1,178	1,252	1,242	25	1,319	1,331	1,470	1,443	1,516	1,562	1,600	1,697	1,735	1,836	39
	Liver	159	148	158	158	201	219	225	256	264	291	83	341	367	378	378	410	455	468	500	551	617	81
	Gallbladder	165	171	163	175	181	199	198	190	248	216	31	219	193	246	274	267	268	251	267	251	261	19
	Pancreas	668	607	616	635	683	661	689	732	740	735	10	759	771	846	791	839	839	881	930	933	958	26
Respiratory & thoracic organs		4,699	4,842	5,010	4,994	5,050	5,393	5,226	5,384	5,497	5,448	16	5,510	5,482	5,834	5,607	5,751	5,854	5,898	5,841	5,836	5,884	7
	Trachea, bronchus & lung	4,544	4,681	4,837	4,780	4,819	5,184	4,946	5,112	5,202	5,144	13	5,163	5,115	5,409	5,218	5,339	5,410	5,436	5,398	5,382	5,384	4
	Other thoracic organs	21	31	24	37	35	33	37	43	37	44	110	60	49	53	57	51	53	50	46	55	40	-33
	Mesothelioma	134	130	149	177	196	176	243	229	258	260	94	287	318	372	332	361	391	412	397	399	460	60
Bone & connective tissue		270	295	310	276	313	314	328	348	353	359	33	374	347	360	401	415	408	425	396	359	401	7
	Bone & articular cartilage	76	90	88	81	79	89	94	95	90	94	24	100	87	89	101	98	111	88	85	92	84	-16
	Connective & soft tissue	194	205	222	195	234	225	234	253	263	265	37	274	260	271	300	317	297	337	311	267	317	16
Breast		63	43	49	59	53	56	59	69	77	64	2	47	64	73	56	86	70	94	78	81	95	102
Male genital organs		3,910	4,046	4,244	4,540	4,738	4,967	5,166	5,736	6,560	7,269	86	8,477	11,692	13,667	12,921	10,874	10,563	10,687	11,099	11,314	11,892	40
	Prostate	3,538	3,681	3,841	4,142	4,291	4,563	4,769	5,289	6,090	6,748	91	7,917	11,139	13,045	12,331	10,249	9,917	10,030	10,453	10,636	11,191	41
	Other male genital organs	372	365	403	398	447	404	397	447	470	521	40	560	553	622	590	625	646	657	646	678	701	25
Urinary tract		2,241	2,253	2,348	2,464	2,378	2,380	2,470	2,506	2,582	2,656	19	2,752	2,860	3,073	3,185	3,150	3,216	3,433	3,556	3,648	3,772	37
	Kidney & ureter	650	681	715	704	784	794	811	873	949	1,057	63	1,046	1,074	1,128	1,195	1,229	1,243	1,365	1,485	1,489	1,514	45
	Bladder	1,591	1,572	1,633	1,760	1,594	1,586	1,659	1,633	1,633	1,599	1	1,706	1,786	1,945	1,990	1,921	1,973	2,068	2,071	2,159	2,258	32
Eye		78	85	80	85	81	91	88	107	88	118	51	112	142	141	114	148	151	151	132	140	137	22
Brain & central nervous system		515	520	534	552	603	608	617	593	624	660	28	706	649	709	740	739	732	728	778	797	822	16
Thyroid & other endocrine glands		145	125	147	162	152	142	168	188	199	203	40	224	196	247	240	287	271	304	299	315	350	56
Unknown primary site		1,116	1,099	1,188	1,341	1,247	1,283	1,420	1,445	1,494	1,594	43	1,538	1,547	1,561	1,489	1,635	1,677	1,609	1,563	1,579	1,736	13
Lymphoid & haematopoietic tissue		2,176	2,164	2,320	2,421	2,438	2,661	2,822	2,904	3,134	3,169	46	3,349	3,398	3,471	3,418	3,738	3,753	3,915	4,098	4,234	4,297	28
	Hodgkin lymphoma	204	205	186	176	183	179	208	189	217	171	-16	193	194	201	185	222	207	217	234	232	218	13
	Non-Hodgkin lymphoma	841	843	906	982	1,002	1,132	1,150	1,207	1,325	1,391	65	1,490	1,537	1,486	1,520	1,691	1,708	1,720	1,799	1,900	1,923	29
	Leukaemia	816	831	919	952	939	974	1,090	1,084	1,166	1,181	45	1,219	1,177	1,268	1,215	1,303	1,282	1,324	1,422	1,466	1,465	20
	Other lymphohaematopoietic	315	285	309	311	314	376	374	424	426	426	35	447	490	516	498	522	556	654	643	636	691	55
<b>All cancers, excluding NMSC</b>		<b>24,872</b>	<b>25,481</b>	<b>26,703</b>	<b>27,973</b>	<b>28,405</b>	<b>30,185</b>	<b>31,230</b>	<b>32,484</b>	<b>34,020</b>	<b>35,533</b>	<b>43</b>	<b>37,778</b>	<b>41,375</b>	<b>44,471</b>	<b>44,171</b>	<b>43,315</b>	<b>43,710</b>	<b>44,133</b>	<b>45,245</b>	<b>46,404</b>	<b>47,820</b>	<b>27</b>



(a) Refer to Table 4 on page 19 for a list of the ICD-10 codes associated with each cancer.

Source: NCSCH; AIHW & AACR 2004.

**Table 4: Projected number of new cases of cancer by clinical group and cancer site/type, Australia 2002 to 2011, males**

Group	Cancer site/type	ICD-10 codes	Table	Page	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	% increase 2002–2011
Skin & lip, excluding NMSC		C00, C43, C46	10	30	6,037	6,203	6,371	6,542	6,719	6,900	7,081	7,264	7,449	7,640	27
	Lip	C00			n.p.	..									
	Melanoma	C43	12	34	5,238	5,392	5,547	5,705	5,869	6,037	6,205	6,376	6,548	6,727	28
	Kaposi sarcoma	C46			n.p.	..									
Head & neck		C01–C14, C30–C32	14	38	1,809	1,848	1,887	1,927	1,970	2,016	2,061	2,108	2,155	2,204	22
	Oral cavity & pharynx	C01–C14			n.p.	..									
	Nasal cavity & sinuses	C30–C31			n.p.	..									
	Larynx	C32			n.p.	..									
Upper digestive tract		C15–C17	16	42	2,140	2,188	2,236	2,287	2,341	2,399	2,455	2,513	2,572	2,634	23
	Oesophagus	C15	18	46	716	735	755	776	797	819	841	863	885	909	27
	Stomach	C16	20	50	1,265	1,286	1,307	1,330	1,354	1,381	1,407	1,434	1,462	1,492	18
	Small intestine	C17			n.p.	..									
Colorectal		C18–C21	22	54	7,165	7,358	7,557	7,765	7,987	8,228	8,467	8,718	8,976	9,249	29
	Colon	C18			n.p.	..									
	Rectum	C19–C20			n.p.	..									
	Anus	C21			n.p.	..									
Liver, gallbladder & pancreas		C22–C25	24	58	1,831	1,903	1,979	2,058	2,143	2,233	2,325	2,420	2,519	2,624	43
	Liver	C22	26	62	607	642	679	718	759	803	848	895	945	997	64
	Gallbladder	C23–C24			n.p.	..									
	Pancreas	C25	28	66	954	983	1,013	1,045	1,079	1,114	1,150	1,188	1,226	1,266	33
Respiratory & thoracic organs		C33–C38, C45	30	70	5,989	6,092	6,200	6,312	6,436	6,574	6,709	6,854	7,003	7,163	20
	Trachea, bronchus & lung	C33–C34	32	74	5,453	5,529	5,606	5,687	5,776	5,878	5,975	6,080	6,186	6,301	16
	Other thoracic organs	C37–C38			n.p.	..									
	Mesothelioma	C45	34	78	471	497	525	555	587	622	658	696	736	778	65
Bone & connective tissue		C40–C41, C47–C49	36	82	434	444	453	463	473	484	495	506	517	529	22
	Bone & articular cartilage	C40–C41			n.p.	..									
	Connective & soft tissue	C47–C49			n.p.	..									
Breast		C50	38	86	94	97	100	102	106	109	112	115	118	122	30
Male genital organs		C60–C63	44	98	12,137	12,490	12,857	13,242	13,652	14,097	14,540	15,001	15,475	15,972	32
	Prostate	C61	45	100	11,454	11,797	12,154	12,529	12,929	13,365	13,799	14,250	14,714	15,202	33
	Other male genital organs	C62–C63, C60	46	102	683	693	703	713	722	732	741	751	761	770	13
Urinary tract		C64–C68	48	106	3,960	4,075	4,195	4,319	4,452	4,593	4,733	4,879	5,028	5,186	31
	Kidney & ureter	C64–C66, C68			n.p.	..									
	Bladder	C67			n.p.	..									
Eye		C69	50	110	154	158	161	165	169	173	177	182	186	190	24
Brain & central nervous system		C70–C72	52	114	840	859	879	898	919	940	962	983	1,005	1,027	22
Thyroid & other endocrine glands		C73–C75	54	118	353	368	383	398	414	430	446	463	480	498	41
Unknown primary site		C76–C80, C26, C39	56	122	1,786	1,828	1,872	1,918	1,968	2,020	2,071	2,125	2,179	2,238	25
Lymphoid & haematopoietic tissue		C81–C96	58	126	4,488	4,621	4,756	4,895	5,040	5,190	5,339	5,493	5,648	5,811	29
	Hodgkin lymphoma	C81			n.p.	..									
	Non-Hodgkin lymphoma	C82–C85, C96	60	130	1,999	2,055	2,110	2,167	2,225	2,285	2,343	2,403	2,462	2,523	26
	Leukaemia	C91–C95	62	134	1,535	1,576	1,617	1,659	1,704	1,750	1,796	1,842	1,889	1,939	26
	Other lymphohaematopoietic	C90, C88			n.p.	..									
<b>All cancers, excluding NMSC</b>		<b>C00–C96, excl. C44</b>	<b>8</b>	<b>26</b>	<b>49,218</b>	<b>50,531</b>	<b>51,885</b>	<b>53,292</b>	<b>54,788</b>	<b>56,385</b>	<b>57,973</b>	<b>59,623</b>	<b>61,312</b>	<b>63,087</b>	<b>28</b>

Note: All numbers in this table are estimates rounded to the nearest whole number and may not add exactly to the totals and subtotals. This rounding should not be taken as an indication of the accuracy of the estimates. The detailed tables indicated by table and page include 95% prediction intervals for each projection.









Table 5: Common cancers by age, Australia, females, 1991, 2001 and projected 2011

Age group	Cancer	ICD-10 codes	1991		1991–2001		2001		2001–2011		2011	
			Number of new cases	Proportion of all cancers in age group (%)	Increase in number of new cases (%)	Number of new cases	Proportion of all cancers in age group (%)	Projected increase in number of new cases (%)	Projected number of new cases	Proportion of all cancers in age group (%)		
0–14 years, all cancers		C00–C96, excl. C44	243	100	15		279	100	7		299	100
	Leukaemia	C91–C95	79	33	30		103	37	–7		96	32
	Brain & central nervous system	C70–C72	59	24	–19		48	17	4		50	17
	Bone & connective tissue	C40–C41, C47–C49	19	8	74		33	12	10		36	12
15–44 years, all cancers		C00–C96, excl. C44	4,353	100	14		4,976	100	7		5,340	100
	Breast	C50	1,365	31	17		1,591	32	2		1,625	30
	Melanoma	C43	985	23	12		1,102	22	2		1,120	21
	Thyroid & other endocrine glands	C73–C75	200	5	106		411	8	49		610	11
45–64 years, all cancers		C00–C96, excl. C44	9,899	100	46		14,451	100	33		19,261	100
	Breast	C50	3,405	34	64		5,580	39	37		7,659	40
	Colorectal	C18–C21	1,242	13	23		1,522	11	37		2,078	11
	Melanoma	C43	899	9	56		1,404	10	39		1,951	10
65 years and over, all cancers		C00–C96, excl. C44	15,893	100	31		20,872	100	32		27,457	100
	Breast	C50	3,273	21	33		4,350	21	27		5,534	20
	Colorectal	C18–C21	3,042	19	36		4,124	20	29		5,320	19
	Trachea, bronchus & lung	C33–C34	1,305	8	49		1,939	9	41		2,729	10
<b>All ages, all cancers</b>		<b>C00–C96, excl. C44</b>	<b>30,388</b>	<b>100</b>	<b>34</b>		<b>40,578</b>	<b>100</b>	<b>29</b>		<b>52,356</b>	<b>100</b>
	Breast	C50	8,043	26	47		11,791	29	26		14,818	28
	Colorectal	C18–C21	4,496	15	31		5,883	14	30		7,673	15
	Melanoma	C43	2,765	9	40		3,861	10	28		4,926	9
	Trachea, bronchus & lung	C33–C34	2,023	7	43		2,891	7	38		4,001	8



**Table 6: Common cancers by age, Australia, males, 1991, 2001 and projected 2011**

Age group	Cancer	ICD-10 codes	1991		1991–2001		2001		2001–2011		2011	
			Number of new cases	Proportion of all cancers in age group (%)	Increase in number of new cases (%)	Number of new cases	Proportion of all cancers in age group (%)	Projected increase in number of new cases (%)	Projected number of new cases	Proportion of all cancers in age group (%)		
0–14 years, all cancers		C00–C96, excl. C44	288	100	13	324	100	5	339	100		
	Leukaemia	C91–C95	114	40	7	122	38	–6	115	34		
	Brain & central nervous system	C70–C72	42	15	62	68	21	–18	56	16		
	Non-Hodgkin lymphoma	C82–C85, C96	26	9	12	29	9	–3	28	8		
15–44 years, all cancers		C00–C96, excl. C44	3,138	100	8	3,375	100	13	3,808	100		
	Melanoma	C43	857	27	6	908	27	14	1,035	27		
	Other male genital organs	C62–C63, C60	370	12	34	496	15	–2	487	13		
	Non-Hodgkin lymphoma	C82–C85, C96	268	9	–5	255	8	9	279	7		
45–64 years, all cancers		C00–C96, excl. C44	10,584	100	36	14,391	100	28	18,366	100		
	Prostate	C61	973	9	211	3,026	21	35	4,090	22		
	Colorectal	C18–C21	1,845	17	16	2,142	15	19	2,549	14		
	Melanoma	C43	1,126	11	68	1,894	13	35	2,557	14		
65 years and over, all cancers		C00–C96, excl. C44	21,523	100	38	29,730	100	36	40,573	100		
	Prostate	C61	5,768	27	41	8,140	27	36	11,089	27		
	Colorectal	C18–C21	3,168	15	45	4,589	15	39	6,371	16		
	Trachea, bronchus & lung	C33–C34	3,295	15	17	3,870	13	24	4,802	12		
<b>All ages, all cancers</b>		<b>C00–C96, excl. C44</b>	<b>35,533</b>	<b>100</b>	<b>35</b>	<b>47,820</b>	<b>100</b>	<b>32</b>	<b>63,087</b>	<b>100</b>		
	Prostate	C61	6,748	19	66	11,191	23	36	15,202	24		
	Colorectal	C18–C21	5,209	15	34	6,961	15	33	9,249	15		
	Trachea, bronchus & lung	C33–C34	5,144	14	5	5,384	11	17	6,301	10		
	Melanoma	C43	3,170	9	58	5,024	11	34	6,727	11		



**Table 7: All cancers, excluding NMSC (ICD-10 C00–C96, excl. C44), Australia, females**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	20.5	20.1	20.2	20.3	20.3	20.4	20.5	20.6	20.7	20.8	20.9
5–9	10.9	10.8	10.8	10.8	10.8	10.8	10.8	10.8	10.8	10.8	10.8
10–14	12.0	14.7	14.8	14.9	15.1	15.2	15.4	15.5	15.6	15.8	15.9
15–19	19.9	24.0	24.3	24.5	24.8	25.0	25.3	25.5	25.8	26.1	26.3
20–24	39.4	38.5	38.8	39.2	39.5	39.8	40.1	40.5	40.8	41.1	41.4
25–29	64.7	62.9	63.1	63.4	63.7	64.0	64.3	64.6	64.9	65.2	65.5
30–34	102.5	104.9	105.1	105.2	105.4	105.5	105.7	106.0	106.2	106.4	106.7
35–39	169.7	174.2	174.1	174.2	174.2	174.3	174.4	174.5	174.7	174.9	175.1
40–44	282.2	278.6	278.5	278.4	278.4	278.4	278.4	278.5	278.7	278.8	279.0
45–49	406.4	417.8	417.7	417.7	417.6	417.6	417.7	417.7	417.8	418.0	418.1
50–54	584.8	583.3	583.3	583.4	583.5	583.6	583.7	583.8	584.0	584.1	584.3
55–59	776.1	767.8	768.3	768.7	769.1	769.5	769.9	770.3	770.7	771.1	771.5
60–64	988.4	974.0	975.4	976.7	977.9	979.2	980.4	981.6	982.8	984.0	985.1
65–69	1,179.8	1,203.5	1,206.7	1,209.8	1,212.8	1,215.7	1,218.6	1,221.4	1,224.1	1,226.8	1,229.5
70–74	1,418.6	1,437.6	1,443.2	1,448.6	1,453.9	1,459.0	1,464.0	1,468.9	1,473.7	1,478.3	1,482.9
75–79	1,641.4	1,642.4	1,649.7	1,656.8	1,663.7	1,670.4	1,676.9	1,683.1	1,689.2	1,695.2	1,701.0
80–84	1,802.3	1,813.6	1,821.3	1,828.8	1,835.9	1,842.8	1,849.4	1,855.8	1,862.0	1,868.0	1,873.8
85+	1,963.3	1,992.5	1,999.9	2,006.9	2,013.6	2,020.0	2,026.1	2,032.0	2,037.6	2,042.9	2,048.1
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	414.8	422.4	428.0	432.5	438.3	444.6	451.0	457.4	464.0	470.8	477.8
Lower 95% PI	..	397.3	403.3	407.0	412.9	419.2	425.1	431.2	437.1	444.0	450.5
Upper 95% PI	..	452.0	457.0	462.5	468.1	474.1	480.9	487.6	494.9	501.4	509.1
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	393.3	395.5	396.4	397.2	398.1	398.9	399.7	400.5	401.3	402.1	402.9
Lower 95% PI	..	372.4	373.9	374.2	375.4	376.6	377.3	378.2	378.7	379.9	380.5
Upper 95% PI	..	422.8	422.8	424.4	424.7	425.0	425.8	426.5	427.5	427.8	428.6
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	300.3	302.0	302.6	303.2	303.8	304.4	305.0	305.6	306.1	306.7	307.3
Lower 95% PI	..	284.5	285.6	285.8	286.7	287.5	288.0	288.7	289.1	290.0	290.4
Upper 95% PI	..	323.1	323.0	324.1	324.2	324.4	324.9	325.4	326.1	326.3	326.9

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	128	124	124	124	124	123	124	124	124	124	124
5–9	72	71	70	70	70	70	69	69	69	68	68
10–14	79	98	100	101	103	103	104	104	105	106	106
15–19	132	160	162	166	168	171	175	178	181	184	185
20–24	253	251	259	272	279	283	286	288	291	294	299
25–29	457	432	428	433	438	448	459	472	482	491	496
30–34	758	794	805	812	809	793	779	772	771	778	792
35–39	1,274	1,292	1,280	1,288	1,302	1,340	1,376	1,397	1,402	1,397	1,369
40–44	2,102	2,118	2,145	2,158	2,156	2,139	2,120	2,106	2,114	2,137	2,198
45–49	2,778	2,896	2,950	3,017	3,078	3,141	3,207	3,250	3,272	3,270	3,246
50–54	3,791	3,792	3,835	3,887	3,940	3,997	4,055	4,134	4,229	4,315	4,405
55–59	3,849	4,112	4,385	4,595	4,792	4,976	4,998	5,062	5,129	5,203	5,280
60–64	4,033	4,089	4,202	4,384	4,598	4,826	5,220	5,572	5,838	6,092	6,330
65–69	4,093	4,277	4,413	4,570	4,728	4,860	5,016	5,167	5,398	5,668	5,956
70–74	4,750	4,786	4,759	4,720	4,748	4,807	4,946	5,116	5,317	5,510	5,674
75–79	4,793	4,840	4,924	4,997	5,012	5,058	5,055	5,033	5,023	5,064	5,140
80–84	3,637	3,836	4,031	4,227	4,380	4,472	4,544	4,636	4,728	4,756	4,815
85+	3,599	3,798	3,930	4,099	4,302	4,581	4,842	5,091	5,327	5,595	5,871
<b>Total</b>	<b>40,578</b>	<b>41,766</b>	<b>42,801</b>	<b>43,920</b>	<b>45,027</b>	<b>46,188</b>	<b>47,373</b>	<b>48,571</b>	<b>49,799</b>	<b>51,052</b>	<b>52,356</b>
Lower 95% PI	..	39,287	40,328	41,324	42,411	43,545	44,653	45,789	46,911	48,150	49,356
Upper 95% PI	..	44,692	45,697	46,964	48,079	49,256	50,515	51,775	53,110	54,379	55,777







Figure 7: All cancers, excluding NMSC (ICD-10 C00-C96, excl. C44), Australia, females

**Table 8: All cancers, excluding NMSC (ICD-10 C00–C96, excl. C44), Australia, males**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	23.7	22.9	22.9	22.9	22.9	23.0	23.0	23.0	23.1	23.1	23.2
5–9	12.8	11.1	11.1	11.1	11.1	11.1	11.1	11.1	11.1	11.1	11.1
10–14	11.4	16.5	16.6	16.7	16.7	16.8	16.9	16.9	17.0	17.0	17.0
15–19	26.9	26.8	26.9	27.1	27.2	27.3	27.5	27.6	27.7	27.8	28.0
20–24	42.4	41.7	41.9	42.2	42.5	42.8	43.0	43.3	43.7	44.0	44.4
25–29	63.2	59.8	60.3	60.7	61.2	61.6	62.1	62.6	63.2	63.7	64.3
30–34	75.9	81.4	82.0	82.5	83.1	83.6	84.2	84.7	85.3	85.9	86.5
35–39	107.9	111.3	111.7	112.2	112.6	113.0	113.4	113.8	114.1	114.5	114.9
40–44	151.7	161.3	161.3	161.2	161.1	161.0	160.9	160.8	160.7	160.6	160.5
45–49	267.5	258.2	257.0	255.9	254.8	253.7	252.6	251.5	250.4	249.4	248.3
50–54	459.6	453.7	450.8	447.9	445.1	442.4	439.7	437.0	434.4	431.9	429.4
55–59	827.7	806.6	802.0	797.4	792.9	788.4	784.1	779.7	775.5	771.3	767.3
60–64	1,290.2	1,328.8	1,323.7	1,318.7	1,313.6	1,308.5	1,303.5	1,298.5	1,293.5	1,288.6	1,283.8
65–69	1,976.2	1,960.7	1,957.0	1,953.3	1,949.5	1,945.6	1,941.7	1,937.7	1,933.8	1,929.8	1,925.8
70–74	2,629.8	2,600.8	2,600.0	2,599.0	2,597.9	2,596.6	2,595.3	2,593.9	2,592.4	2,590.8	2,589.2
75–79	3,217.4	3,159.8	3,162.7	3,165.4	3,167.9	3,170.1	3,172.3	3,174.3	3,176.1	3,177.9	3,179.6
80–84	3,641.3	3,623.3	3,630.5	3,637.4	3,644.0	3,650.4	3,656.6	3,662.6	3,668.4	3,674.2	3,679.8
85+	3,820.7	4,059.1	4,070.9	4,082.2	4,093.2	4,104.0	4,114.5	4,124.8	4,135.0	4,145.0	4,155.0
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	496.5	504.6	511.8	518.8	526.6	535.2	544.6	553.8	563.4	573.2	583.6
Lower 95% PI	..	482.9	486.7	490.4	495.5	501.5	508.3	514.9	521.6	529.1	537.7
Upper 95% PI	..	529.0	540.1	550.6	561.5	573.1	585.6	597.8	611.0	623.6	636.1
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	541.4	542.1	541.7	541.3	540.9	540.5	540.0	539.6	539.2	538.7	538.3
Lower 95% PI	..	518.7	515.0	511.5	508.7	506.0	503.5	501.1	498.5	496.4	495.0
Upper 95% PI	..	568.3	571.8	574.8	577.1	579.3	581.4	583.3	585.8	587.3	588.0
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	387.6	387.7	387.3	386.8	386.4	386.0	385.5	385.1	384.6	384.2	383.8
Lower 95% PI	..	370.5	367.8	365.3	363.2	361.3	359.4	357.6	355.6	354.1	353.0
Upper 95% PI	..	407.4	409.7	411.5	413.0	414.3	415.6	416.8	418.6	419.5	419.7

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	156	149	149	148	147	146	146	146	146	146	146
5–9	89	77	76	76	76	76	75	75	74	74	73
10–14	79	116	118	119	120	120	121	120	120	120	120
15–19	186	187	188	191	193	196	199	202	205	207	208
20–24	280	282	292	301	308	312	315	317	320	325	331
25–29	443	412	412	416	423	434	447	460	472	483	490
30–34	552	606	618	624	626	618	612	611	615	624	640
35–39	800	816	812	818	830	856	879	894	900	900	886
40–44	1,114	1,212	1,232	1,238	1,238	1,227	1,216	1,207	1,209	1,222	1,254
45–49	1,806	1,767	1,789	1,820	1,850	1,881	1,915	1,938	1,944	1,936	1,914
50–54	2,999	2,953	2,948	2,950	2,962	2,985	3,005	3,038	3,093	3,139	3,188
55–59	4,245	4,438	4,684	4,844	4,977	5,090	5,051	5,051	5,066	5,093	5,139
60–64	5,341	5,680	5,819	6,035	6,289	6,561	7,017	7,426	7,698	7,928	8,126
65–69	6,632	6,757	6,961	7,198	7,474	7,686	7,935	8,162	8,496	8,878	9,287
70–74	7,983	7,915	7,868	7,797	7,790	7,905	8,145	8,438	8,775	9,144	9,436
75–79	7,315	7,380	7,611	7,801	7,939	8,055	8,106	8,097	8,114	8,153	8,324
80–84	4,670	4,968	5,292	5,644	5,911	6,152	6,362	6,603	6,843	7,016	7,175
85+	3,130	3,502	3,663	3,864	4,138	4,488	4,840	5,186	5,533	5,924	6,352
<b>Total</b>	<b>47,820</b>	<b>49,218</b>	<b>50,531</b>	<b>51,885</b>	<b>53,292</b>	<b>54,788</b>	<b>56,385</b>	<b>57,973</b>	<b>59,623</b>	<b>61,312</b>	<b>63,087</b>
Lower 95% PI	..	47,100	48,054	49,051	50,146	51,338	52,629	53,903	55,205	56,596	58,122
Upper 95% PI	..	51,591	53,322	55,065	56,823	58,672	60,631	62,581	64,664	66,701	68,752







Figure 8: All cancers, excluding NMSC (ICD-10 C00-C96, excl. C44), Australia, males

**Table 9: Skin and lip cancers, excluding NMSC (ICD-10 C00, C43, C46), Australia, females**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
5-9	0.9	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8
10-14	0.9	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7
15-19	5.9	6.1	6.1	6.2	6.2	6.2	6.2	6.2	6.2	6.2	6.2
20-24	12.9	11.7	11.7	11.7	11.7	11.7	11.7	11.8	11.8	11.8	11.8
25-29	20.5	19.4	19.4	19.4	19.4	19.4	19.4	19.4	19.4	19.4	19.4
30-34	29.7	28.4	28.4	28.4	28.5	28.5	28.5	28.5	28.5	28.5	28.5
35-39	37.7	37.7	37.7	37.8	37.8	37.8	37.9	37.9	37.9	37.9	37.9
40-44	49.9	46.7	46.8	46.9	47.0	47.1	47.1	47.2	47.2	47.3	47.3
45-49	52.5	55.8	56.0	56.1	56.3	56.4	56.5	56.6	56.7	56.8	56.9
50-54	68.2	65.4	65.7	65.9	66.1	66.3	66.5	66.6	66.7	66.9	67.0
55-59	70.0	75.7	76.1	76.4	76.7	76.9	77.2	77.4	77.5	77.7	77.8
60-64	81.9	86.6	87.1	87.5	87.8	88.1	88.4	88.7	88.9	89.1	89.3
65-69	93.1	97.5	98.0	98.5	99.0	99.4	99.7	100.1	100.3	100.6	100.8
70-74	110.5	107.8	108.5	109.1	109.7	110.1	110.6	111.0	111.3	111.6	111.9
75-79	117.5	117.4	118.2	119.0	119.6	120.2	120.7	121.2	121.6	121.9	122.3
80-84	119.9	126.4	127.4	128.2	129.0	129.7	130.3	130.8	131.3	131.7	132.1
85+	117.8	135.3	136.3	137.3	138.2	139.0	139.7	140.3	140.9	141.4	141.8
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	42.2	43.3	43.9	44.3	44.9	45.4	45.9	46.5	47.0	47.5	48.1
Lower 95% PI	..	40.0	40.5	41.1	41.6	41.9	42.6	43.1	43.5	44.0	44.6
Upper 95% PI	..	46.6	47.2	47.5	48.1	48.9	49.3	49.8	50.5	51.0	51.5
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	40.9	41.5	41.7	41.8	42.0	42.1	42.2	42.3	42.4	42.5	42.5
Lower 95% PI	..	38.3	38.5	38.7	38.8	38.8	39.0	39.2	39.2	39.3	39.4
Upper 95% PI	..	44.7	44.8	44.9	45.1	45.4	45.4	45.4	45.6	45.7	45.7
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	33.5	33.9	34.0	34.1	34.2	34.3	34.4	34.5	34.5	34.6	34.6
Lower 95% PI	..	31.2	31.3	31.5	31.6	31.5	31.7	31.9	31.8	31.9	32.0
Upper 95% PI	..	36.6	36.7	36.7	36.9	37.1	37.1	37.1	37.2	37.3	37.3

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	1	1	1	1	1	1	1	1	1	1	1
5-9	6	5	5	5	5	5	5	5	5	5	5
10-14	6	18	18	18	18	18	18	18	18	18	18
15-19	39	41	41	42	42	42	43	43	44	44	44
20-24	83	76	78	81	83	83	84	84	84	84	85
25-29	145	133	132	133	134	136	139	142	144	146	147
30-34	220	215	218	219	218	214	210	207	207	208	211
35-39	283	280	277	279	283	291	299	303	304	303	296
40-44	372	355	361	364	364	362	359	357	358	362	373
45-49	359	387	395	406	415	424	434	440	444	444	441
50-54	442	425	432	439	446	454	462	472	483	494	505
55-59	347	406	434	457	478	498	501	508	516	524	533
60-64	334	364	375	393	413	434	471	503	528	552	574
65-69	323	346	359	372	386	397	411	423	442	465	488
70-74	370	359	358	355	358	363	374	386	402	416	428
75-79	343	346	353	359	360	364	364	362	361	364	370
80-84	242	267	282	296	308	315	320	327	333	335	340
85+	216	258	268	280	295	315	334	352	368	387	407
<b>Total</b>	<b>4,131</b>	<b>4,283</b>	<b>4,387</b>	<b>4,500</b>	<b>4,607</b>	<b>4,716</b>	<b>4,826</b>	<b>4,935</b>	<b>5,044</b>	<b>5,154</b>	<b>5,266</b>
Lower 95% PI	..	3,955	4,054	4,172	4,269	4,350	4,470	4,581	4,673	4,774	4,885
Upper 95% PI	..	4,611	4,719	4,828	4,946	5,083	5,182	5,288	5,415	5,534	5,647







Figure 9: Skin and lip cancers, excluding NMSC (ICD-10 C00, C43, C46), Australia, females

**Table 10: Skin and lip cancers, excluding NMSC (ICD-10 C00, C43, C46), Australia, males**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
5-9	0.0	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
10-14	0.9	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
15-19	5.5	5.0	5.0	5.0	5.0	5.0	5.0	5.0	5.0	5.0	5.0
20-24	9.4	10.9	10.9	10.9	10.9	10.9	10.9	10.9	11.0	11.0	11.0
25-29	21.1	19.0	19.1	19.1	19.1	19.1	19.1	19.2	19.2	19.2	19.2
30-34	26.4	29.1	29.1	29.2	29.2	29.2	29.2	29.3	29.3	29.3	29.3
35-39	39.5	40.3	40.4	40.4	40.5	40.6	40.6	40.6	40.7	40.7	40.7
40-44	47.2	52.8	52.9	53.0	53.1	53.2	53.3	53.3	53.4	53.4	53.4
45-49	68.6	67.9	68.1	68.2	68.4	68.5	68.6	68.6	68.7	68.7	68.8
50-54	90.3	87.6	87.8	88.0	88.2	88.3	88.4	88.5	88.6	88.7	88.7
55-59	110.6	113.4	113.7	114.0	114.2	114.4	114.6	114.7	114.8	114.9	115.0
60-64	132.1	145.7	146.1	146.5	146.8	147.0	147.2	147.4	147.6	147.7	147.8
65-69	178.2	182.6	183.2	183.7	184.1	184.5	184.8	185.1	185.3	185.5	185.7
70-74	225.7	221.1	221.9	222.7	223.3	223.8	224.2	224.6	225.0	225.2	225.5
75-79	271.8	258.5	259.7	260.7	261.5	262.3	262.9	263.4	263.8	264.2	264.5
80-84	293.2	294.5	296.0	297.3	298.4	299.3	300.2	300.8	301.4	301.9	302.4
85+	294.2	330.6	332.5	334.2	335.6	336.8	337.9	338.7	339.5	340.1	340.7
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	59.9	61.9	62.8	63.7	64.6	65.6	66.6	67.6	68.6	69.6	70.7
Lower 95% PI	..	48.9	49.7	50.6	50.9	51.6	52.6	53.1	54.0	54.7	55.5
Upper 95% PI	..	79.0	80.1	80.8	82.7	84.2	85.1	86.9	88.0	89.4	90.8
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	63.4	64.7	64.9	65.1	65.3	65.4	65.5	65.6	65.7	65.8	65.8
Lower 95% PI	..	50.7	51.0	51.3	51.1	51.1	51.5	51.3	51.5	51.5	51.6
Upper 95% PI	..	83.3	83.4	83.2	84.0	84.4	84.1	84.7	84.5	84.7	84.8
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	48.8	49.9	50.0	50.2	50.3	50.4	50.5	50.5	50.6	50.6	50.7
Lower 95% PI	..	39.7	39.9	40.2	40.0	40.0	40.3	40.1	40.3	40.2	40.3
Upper 95% PI	..	63.3	63.3	63.2	63.8	64.1	63.8	64.3	64.2	64.3	64.3

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	0	0	0	0	0	0	0	0	0	0	0
5-9	0	1	1	1	1	1	1	1	1	1	1
10-14	6	10	10	10	10	10	10	10	10	10	10
15-19	38	35	35	35	36	36	36	37	37	37	37
20-24	62	74	76	78	79	80	80	80	80	81	82
25-29	148	131	130	131	132	135	138	141	143	145	146
30-34	192	216	219	221	220	216	213	211	211	213	217
35-39	293	296	293	295	299	307	315	319	321	320	314
40-44	347	397	404	407	408	405	403	400	401	406	417
45-49	463	465	474	485	496	508	520	529	533	534	530
50-54	589	570	574	580	587	596	604	615	631	645	659
55-59	567	624	664	692	717	739	738	743	750	759	770
60-64	547	623	642	670	703	737	793	843	878	909	936
65-69	598	629	652	677	706	729	755	780	814	854	895
70-74	685	673	672	668	669	681	704	731	761	795	822
75-79	618	604	625	642	655	666	672	672	674	678	693
80-84	376	404	431	461	484	504	522	542	562	577	590
85+	241	285	299	316	339	368	397	426	454	486	521
<b>Total</b>	<b>5,770</b>	<b>6,037</b>	<b>6,203</b>	<b>6,371</b>	<b>6,542</b>	<b>6,719</b>	<b>6,900</b>	<b>7,081</b>	<b>7,264</b>	<b>7,449</b>	<b>7,640</b>
Lower 95% PI	..	4,769	4,907	5,058	5,156	5,282	5,449	5,556	5,713	5,847	5,996
Upper 95% PI	..	7,703	7,904	8,086	8,368	8,618	8,809	9,099	9,311	9,568	9,815







Figure 10: Skin and lip cancers, excluding NMSC (ICD-10 C00, C43, C46), Australia, males

**Table 11: Melanoma (ICD-10 C43), Australia, females**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
5-9	0.9	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8
10-14	0.9	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6
15-19	5.9	5.9	5.9	6.0	6.0	6.0	6.0	6.0	6.0	6.0	6.0
20-24	12.8	11.4	11.4	11.4	11.4	11.4	11.4	11.4	11.4	11.4	11.4
25-29	20.0	18.9	18.9	18.9	18.9	18.9	18.9	18.9	18.9	18.9	18.9
30-34	29.1	27.6	27.6	27.6	27.6	27.6	27.6	27.6	27.6	27.6	27.6
35-39	36.6	36.5	36.5	36.6	36.6	36.6	36.6	36.7	36.7	36.7	36.7
40-44	47.0	45.0	45.1	45.2	45.3	45.4	45.4	45.5	45.5	45.6	45.6
45-49	50.3	53.5	53.7	53.8	54.0	54.1	54.2	54.3	54.4	54.5	54.6
50-54	64.0	62.3	62.6	62.8	63.0	63.2	63.4	63.6	63.7	63.8	63.9
55-59	67.4	71.7	72.0	72.4	72.6	72.9	73.1	73.3	73.5	73.7	73.8
60-64	76.2	81.3	81.7	82.1	82.5	82.8	83.1	83.4	83.6	83.8	84.0
65-69	87.6	90.4	91.0	91.5	92.0	92.4	92.7	93.1	93.4	93.6	93.9
70-74	101.2	98.6	99.3	99.9	100.4	100.9	101.4	101.8	102.1	102.5	102.8
75-79	104.1	105.4	106.2	106.9	107.6	108.2	108.7	109.2	109.6	110.0	110.4
80-84	105.1	110.8	111.8	112.7	113.5	114.2	114.8	115.4	115.9	116.3	116.7
85+	99.8	115.4	116.5	117.5	118.4	119.2	119.9	120.6	121.2	121.7	122.2
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	39.5	40.5	41.0	41.4	42.0	42.5	43.0	43.5	44.0	44.5	45.0
Lower 95% PI	..	38.5	39.0	39.4	39.9	40.4	40.9	41.4	41.9	42.3	42.8
Upper 95% PI	..	42.5	43.0	43.5	44.0	44.5	45.0	45.5	46.0	46.6	47.1
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	38.3	38.9	39.1	39.2	39.4	39.5	39.6	39.7	39.8	39.9	40.0
Lower 95% PI	..	36.9	37.1	37.3	37.4	37.6	37.7	37.8	37.9	37.9	38.0
Upper 95% PI	..	40.8	41.0	41.2	41.3	41.5	41.6	41.7	41.7	41.9	41.9
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	31.6	32.0	32.1	32.2	32.3	32.4	32.5	32.6	32.6	32.7	32.8
Lower 95% PI	..	30.3	30.4	30.5	30.6	30.7	30.8	30.9	31.0	31.0	31.1
Upper 95% PI	..	33.6	33.8	33.9	34.0	34.1	34.2	34.3	34.3	34.4	34.5

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	1	1	1	1	1	1	1	1	1	1	1
5-9	6	5	5	5	5	5	5	5	5	5	5
10-14	6	17	17	17	18	18	18	18	18	18	18
15-19	39	39	40	40	40	41	41	42	42	43	42
20-24	82	74	76	79	81	81	81	81	82	82	83
25-29	141	130	128	129	130	132	135	138	140	142	143
30-34	215	209	212	213	212	207	203	201	201	202	205
35-39	275	271	268	270	273	282	289	294	294	293	287
40-44	350	342	348	351	351	349	346	344	345	349	360
45-49	344	371	379	389	398	407	416	423	426	426	424
50-54	415	405	412	419	426	433	440	450	461	471	482
55-59	334	384	411	433	453	471	475	482	489	497	505
60-64	311	341	352	369	388	408	442	473	497	519	540
65-69	304	321	333	346	358	369	382	394	412	433	455
70-74	339	328	327	325	328	333	343	355	369	382	393
75-79	304	310	317	322	324	328	328	327	326	329	334
80-84	212	234	247	260	271	277	282	288	294	296	300
85+	183	220	229	240	253	270	287	302	317	333	350
<b>Total</b>	<b>3,861</b>	<b>4,004</b>	<b>4,102</b>	<b>4,209</b>	<b>4,309</b>	<b>4,412</b>	<b>4,514</b>	<b>4,616</b>	<b>4,719</b>	<b>4,821</b>	<b>4,926</b>
Lower 95% PI	..	3,805	3,902	4,002	4,098	4,198	4,296	4,397	4,498	4,586	4,693
Upper 95% PI	..	4,203	4,302	4,415	4,521	4,626	4,732	4,836	4,940	5,056	5,159







Figure 11: Melanoma (ICD-10 C43), Australia, females

**Table 12: Melanoma (ICD-10 C43), Australia, males**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
5-9	0.0	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
10-14	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9
15-19	5.5	3.7	3.7	3.8	3.8	3.8	3.8	3.8	3.8	3.8	3.8
20-24	8.5	8.8	8.8	8.8	8.8	8.8	8.8	8.9	8.9	8.9	8.9
25-29	18.1	16.0	16.0	16.1	16.1	16.1	16.1	16.2	16.2	16.2	16.2
30-34	22.0	24.8	24.8	24.9	25.0	25.0	25.1	25.2	25.2	25.3	25.3
35-39	30.8	34.4	34.5	34.6	34.7	34.8	34.8	34.9	35.0	35.0	35.1
40-44	40.7	45.1	45.3	45.4	45.5	45.6	45.7	45.8	45.9	45.9	46.0
45-49	59.0	58.3	58.5	58.7	58.9	59.0	59.1	59.2	59.4	59.5	59.6
50-54	77.7	75.8	76.1	76.4	76.6	76.8	77.1	77.2	77.4	77.6	77.7
55-59	100.8	99.0	99.4	99.9	100.2	100.6	100.9	101.2	101.5	101.7	102.0
60-64	114.0	127.9	128.6	129.2	129.8	130.3	130.7	131.2	131.6	132.0	132.4
65-69	159.4	160.8	161.7	162.6	163.3	164.0	164.7	165.3	165.8	166.3	166.8
70-74	195.7	194.6	195.8	196.8	197.8	198.6	199.4	200.2	200.8	201.5	202.0
75-79	243.2	226.8	228.1	229.4	230.5	231.5	232.4	233.2	233.9	234.5	235.2
80-84	251.9	256.8	258.4	259.8	261.0	262.0	263.0	263.8	264.6	265.2	265.8
85+	257.6	286.4	288.2	289.7	291.0	292.2	293.1	294.0	294.7	295.4	295.9
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	52.2	53.7	54.6	55.5	56.4	57.3	58.3	59.3	60.2	61.2	62.2
Lower 95% PI	..	50.8	51.6	52.3	52.9	53.5	54.0	54.5	54.7	54.9	55.2
Upper 95% PI	..	56.7	57.6	58.7	59.9	61.1	62.6	64.1	65.8	67.5	69.3
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	55.2	56.2	56.4	56.7	56.9	57.1	57.3	57.4	57.6	57.7	57.9
Lower 95% PI	..	53.1	53.3	53.4	53.4	53.3	53.1	52.8	52.3	51.8	51.3
Upper 95% PI	..	59.2	59.5	60.0	60.4	60.9	61.5	62.1	62.9	63.7	64.4
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	42.4	43.2	43.4	43.6	43.8	43.9	44.0	44.2	44.3	44.4	44.5
Lower 95% PI	..	40.8	41.0	41.0	41.0	41.0	40.8	40.6	40.3	39.9	39.6
Upper 95% PI	..	45.6	45.8	46.1	46.5	46.8	47.3	47.7	48.3	48.8	49.4

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	0	0	0	0	0	0	0	0	0	0	0
5-9	0	1	1	1	1	1	1	1	1	1	1
10-14	6	6	7	7	7	7	7	7	7	7	7
15-19	38	26	26	26	27	27	27	28	28	28	28
20-24	56	60	61	63	64	65	65	65	65	66	66
25-29	127	110	110	110	111	114	116	119	121	123	124
30-34	160	184	187	189	188	185	182	181	182	184	187
35-39	228	252	251	252	256	264	270	275	276	275	271
40-44	299	339	346	349	349	347	345	343	345	349	359
45-49	398	399	407	417	427	438	448	457	461	462	459
50-54	507	493	498	503	510	519	527	537	551	564	577
55-59	517	545	581	607	629	649	650	656	663	672	683
60-64	472	547	565	591	621	653	704	750	783	812	838
65-69	535	554	575	599	626	648	673	696	729	765	805
70-74	594	592	592	590	593	605	626	651	680	711	736
75-79	553	530	549	565	578	588	594	595	598	602	616
80-84	323	352	377	403	423	442	458	476	493	506	518
85+	211	247	259	274	294	319	345	370	394	422	452
<b>Total</b>	<b>5,024</b>	<b>5,238</b>	<b>5,392</b>	<b>5,547</b>	<b>5,705</b>	<b>5,869</b>	<b>6,037</b>	<b>6,205</b>	<b>6,376</b>	<b>6,548</b>	<b>6,727</b>
Lower 95% PI	..	4,951	5,095	5,227	5,352	5,479	5,594	5,703	5,790	5,871	5,963
Upper 95% PI	..	5,526	5,689	5,867	6,059	6,259	6,480	6,707	6,962	7,225	7,491







Figure 12: Melanoma (ICD-10 C43), Australia, males

**Table 13: Head and neck cancers (ICD-10 C01–C14, C30–C32), Australia, females**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
5–9	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
10–14	0.2	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3
15–19	0.2	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5
20–24	1.2	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7
25–29	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
30–34	2.0	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7
35–39	1.3	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6
40–44	3.9	3.9	3.9	3.9	3.9	3.9	3.9	3.9	3.9	3.9	3.9
45–49	5.7	6.0	6.0	6.0	6.0	6.0	6.0	6.0	6.0	6.0	6.0
50–54	9.1	8.7	8.7	8.7	8.7	8.7	8.7	8.7	8.7	8.7	8.7
55–59	14.5	12.0	12.0	12.0	12.0	12.0	12.0	12.0	12.0	12.0	12.0
60–64	15.9	15.7	15.7	15.7	15.7	15.7	15.7	15.7	15.7	15.7	15.7
65–69	17.6	19.5	19.5	19.5	19.5	19.5	19.5	19.5	19.5	19.5	19.5
70–74	23.3	23.2	23.2	23.2	23.2	23.2	23.2	23.2	23.2	23.2	23.2
75–79	24.0	26.6	26.6	26.6	26.6	26.6	26.6	26.6	26.6	26.6	26.6
80–84	32.7	29.9	29.9	29.9	29.9	29.9	29.9	29.9	29.9	29.9	29.9
85+	30.0	33.3	33.3	33.3	33.3	33.3	33.3	33.3	33.3	33.3	33.3
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	6.5	6.7	6.7	6.8	6.9	7.0	7.0	7.1	7.2	7.3	7.4
Lower 95% PI	..	5.9	6.0	6.0	6.1	6.1	6.2	6.3	6.4	6.4	6.5
Upper 95% PI	..	7.9	8.0	8.1	8.2	8.3	8.4	8.5	8.6	8.8	8.9
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	6.2	6.2	6.2	6.2	6.2	6.2	6.2	6.2	6.2	6.2	6.2
Lower 95% PI	..	5.5	5.5	5.5	5.5	5.5	5.5	5.4	5.5	5.4	5.4
Upper 95% PI	..	7.4	7.5	7.5	7.5	7.5	7.6	7.6	7.6	7.7	7.6
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	4.7	4.7	4.7	4.7	4.7	4.7	4.7	4.7	4.7	4.7	4.7
Lower 95% PI	..	4.1	4.1	4.1	4.1	4.1	4.1	4.1	4.1	4.1	4.1
Upper 95% PI	..	5.9	5.9	6.0	6.0	6.0	6.1	6.0	6.0	6.1	6.1

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	0	0	0	0	0	0	0	0	0	0	0
5–9	0	1	1	1	1	1	1	1	1	1	1
10–14	1	2	2	2	2	2	2	2	2	2	2
15–19	1	3	3	3	3	3	3	3	3	3	3
20–24	8	5	5	5	5	5	5	5	5	5	5
25–29	7	7	7	7	7	8	8	8	8	8	8
30–34	15	13	13	13	13	12	12	12	12	12	12
35–39	10	19	19	19	19	20	20	20	21	20	20
40–44	29	30	30	31	31	30	30	30	30	30	31
45–49	39	41	42	43	44	45	46	46	47	47	46
50–54	59	56	57	58	59	59	60	61	63	64	65
55–59	72	64	68	72	75	78	78	79	80	81	82
60–64	65	66	68	71	74	77	84	89	93	97	101
65–69	61	69	71	74	76	78	80	83	86	90	94
70–74	78	77	76	75	76	76	78	81	84	86	89
75–79	70	78	79	80	80	81	80	80	79	80	80
80–84	66	63	66	69	71	73	74	75	76	76	77
85+	55	64	65	68	71	76	80	83	87	91	96
<b>Total</b>	<b>636</b>	<b>659</b>	<b>674</b>	<b>690</b>	<b>706</b>	<b>723</b>	<b>740</b>	<b>758</b>	<b>776</b>	<b>794</b>	<b>813</b>
Lower 95% PI	..	584	597	611	624	638	652	667	684	697	714
Upper 95% PI	..	783	801	824	840	862	887	907	925	956	974







Figure 13: Head and neck cancers (ICD-10 C01-C14, C30-C32), Australia, females

**Table 14: Head and neck cancers (ICD-10 C01–C14, C30–C32), Australia, males**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
5–9	0.0	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
10–14	0.1	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3
15–19	0.4	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.6	0.6	0.6
20–24	0.9	0.8	0.9	0.9	0.9	1.0	1.0	1.0	1.1	1.1	1.2
25–29	2.0	1.5	1.5	1.6	1.6	1.7	1.8	1.8	1.9	2.0	2.0
30–34	1.5	2.6	2.7	2.7	2.8	2.9	3.0	3.0	3.1	3.2	3.3
35–39	3.2	4.7	4.8	4.8	4.9	4.9	5.0	5.0	5.1	5.1	5.2
40–44	8.9	8.8	8.7	8.7	8.6	8.6	8.5	8.5	8.4	8.4	8.3
45–49	18.4	15.9	15.7	15.4	15.2	15.0	14.8	14.5	14.3	14.1	13.9
50–54	26.1	27.3	26.8	26.3	25.8	25.4	24.9	24.5	24.1	23.6	23.2
55–59	44.8	42.6	41.9	41.2	40.6	40.0	39.4	38.7	38.1	37.5	37.0
60–64	67.6	59.3	58.6	58.0	57.4	56.8	56.2	55.6	55.0	54.4	53.8
65–69	79.6	73.5	73.1	72.7	72.3	72.0	71.6	71.2	70.8	70.4	70.0
70–74	75.1	82.4	82.3	82.3	82.2	82.2	82.1	82.0	82.0	81.9	81.8
75–79	90.6	85.7	85.9	86.2	86.4	86.6	86.9	87.1	87.3	87.5	87.8
80–84	85.8	85.3	85.7	86.2	86.6	87.0	87.5	87.9	88.4	88.8	89.3
85+	68.4	83.4	84.0	84.6	85.2	85.8	86.4	87.0	87.6	88.2	88.8
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	18.6	18.6	18.7	18.9	19.0	19.2	19.5	19.7	19.9	20.1	20.4
Lower 95% PI	..	16.4	16.5	16.6	16.8	17.0	17.2	17.3	17.6	17.8	18.0
Upper 95% PI	..	22.0	22.4	22.3	22.7	22.5	23.0	23.4	23.5	23.7	24.1
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	19.6	19.3	19.2	19.1	19.0	18.9	18.9	18.8	18.7	18.6	18.5
Lower 95% PI	..	17.1	16.9	16.9	16.8	16.8	16.7	16.6	16.5	16.5	16.4
Upper 95% PI	..	22.7	22.9	22.5	22.6	22.2	22.3	22.3	22.2	22.0	22.0
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	14.9	14.5	14.5	14.4	14.3	14.2	14.1	14.1	14.0	13.9	13.9
Lower 95% PI	..	12.8	12.6	12.6	12.5	12.5	12.4	12.3	12.3	12.2	12.1
Upper 95% PI	..	17.8	18.0	17.6	17.8	17.2	17.4	17.5	17.3	17.1	17.2

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	0	0	0	0	0	0	0	0	0	0	0
5–9	0	1	1	1	1	1	1	1	1	1	1
10–14	1	2	2	2	2	2	2	2	2	2	2
15–19	3	3	3	4	4	4	4	4	4	4	4
20–24	6	6	6	6	7	7	7	8	8	8	9
25–29	14	10	10	11	11	12	13	13	14	15	16
30–34	11	19	20	21	21	21	21	22	22	23	24
35–39	24	35	35	35	36	37	39	39	40	40	40
40–44	65	66	67	67	66	65	64	64	63	64	65
45–49	124	109	109	110	110	111	112	112	111	110	107
50–54	170	177	175	173	172	171	170	170	171	172	172
55–59	230	234	245	251	255	258	253	251	249	248	248
60–64	280	253	258	266	275	285	302	318	327	335	340
65–69	267	253	260	268	277	284	292	300	311	324	338
70–74	228	251	249	247	247	250	258	267	277	289	298
75–79	206	200	207	212	216	220	222	222	223	225	230
80–84	110	117	125	134	140	147	152	159	165	170	174
85+	56	72	76	80	86	94	102	109	117	126	136
<b>Total</b>	<b>1,795</b>	<b>1,809</b>	<b>1,848</b>	<b>1,887</b>	<b>1,927</b>	<b>1,970</b>	<b>2,016</b>	<b>2,061</b>	<b>2,108</b>	<b>2,155</b>	<b>2,204</b>
Lower 95% PI	..	1,597	1,626	1,665	1,696	1,743	1,778	1,814	1,858	1,903	1,942
Upper 95% PI	..	2,142	2,209	2,232	2,296	2,308	2,380	2,445	2,489	2,532	2,603







Figure 14: Head and neck cancers (ICD-10 C01-C14, C30-C32), Australia, males

**Table 15: Cancers of the upper digestive tract (ICD-10 C15–C17), Australia, females**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
5–9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
10–14	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
15–19	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
20–24	0.3	0.3	0.3	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.2
25–29	0.4	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5
30–34	0.8	1.1	1.1	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
35–39	2.9	1.9	1.9	1.9	1.9	1.9	1.9	1.8	1.8	1.8	1.8
40–44	3.2	3.4	3.4	3.4	3.4	3.3	3.3	3.3	3.3	3.2	3.2
45–49	5.6	5.9	5.9	5.8	5.8	5.7	5.7	5.7	5.6	5.6	5.5
50–54	9.4	9.8	9.7	9.7	9.6	9.6	9.5	9.5	9.4	9.4	9.3
55–59	15.1	15.5	15.4	15.4	15.4	15.3	15.3	15.2	15.2	15.1	15.1
60–64	26.5	23.6	23.5	23.5	23.4	23.4	23.3	23.3	23.2	23.2	23.2
65–69	38.9	34.2	34.2	34.1	34.1	34.0	34.0	33.9	33.9	33.9	33.8
70–74	53.8	47.8	47.7	47.6	47.5	47.5	47.4	47.3	47.2	47.2	47.1
75–79	55.5	64.5	64.4	64.2	64.1	63.9	63.7	63.6	63.4	63.3	63.1
80–84	81.3	85.1	84.8	84.5	84.2	83.9	83.6	83.3	83.0	82.7	82.4
85+	121.6	110.7	110.1	109.6	109.0	108.5	108.0	107.4	106.9	106.4	105.9
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	12.3	12.2	12.3	12.4	12.5	12.6	12.8	12.9	13.1	13.2	13.4
Lower 95% PI	..	10.6	10.7	10.7	10.8	11.0	11.1	11.3	11.4	11.5	11.7
Upper 95% PI	..	14.1	14.2	14.4	14.5	14.7	14.8	14.9	15.1	15.3	15.5
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	11.2	10.9	10.9	10.8	10.8	10.7	10.7	10.7	10.6	10.6	10.6
Lower 95% PI	..	9.5	9.5	9.4	9.4	9.4	9.3	9.3	9.3	9.2	9.2
Upper 95% PI	..	12.6	12.5	12.6	12.5	12.5	12.4	12.3	12.3	12.3	12.2
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	7.7	7.5	7.5	7.5	7.4	7.4	7.4	7.4	7.3	7.3	7.3
Lower 95% PI	..	6.5	6.5	6.5	6.5	6.4	6.4	6.4	6.4	6.3	6.3
Upper 95% PI	..	8.7	8.7	8.7	8.7	8.6	8.6	8.5	8.5	8.5	8.5

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	0	0	0	0	0	0	0	0	0	0	0
5–9	0	0	0	0	0	0	0	0	0	0	0
10–14	0	0	0	0	0	0	0	0	0	0	0
15–19	0	1	1	1	1	1	1	1	1	1	1
20–24	2	2	2	2	2	2	2	2	2	2	2
25–29	3	4	4	4	4	4	4	4	4	4	4
30–34	6	8	8	8	8	8	7	7	7	7	7
35–39	22	14	14	14	14	14	15	15	15	15	14
40–44	24	26	26	26	26	26	25	25	25	25	25
45–49	38	41	41	42	43	43	44	44	44	44	43
50–54	61	63	64	64	65	65	66	67	68	69	70
55–59	75	83	88	92	96	99	99	100	101	102	103
60–64	108	99	101	105	110	115	124	132	138	144	149
65–69	135	122	125	129	133	136	140	144	149	156	164
70–74	180	159	157	155	155	156	160	165	170	176	180
75–79	162	190	192	194	193	193	192	190	189	189	191
80–84	164	180	188	195	201	204	205	208	211	211	212
85+	223	211	216	224	233	246	258	269	280	291	303
<b>Total</b>	<b>1,203</b>	<b>1,203</b>	<b>1,228</b>	<b>1,255</b>	<b>1,283</b>	<b>1,313</b>	<b>1,343</b>	<b>1,373</b>	<b>1,403</b>	<b>1,435</b>	<b>1,469</b>
Lower 95% PI	..	1,047	1,071	1,090	1,115	1,141	1,169	1,199	1,222	1,247	1,280
Upper 95% PI	..	1,393	1,420	1,458	1,489	1,523	1,555	1,584	1,625	1,665	1,698







Figure 15: Cancers of the upper digestive tract (ICD-10 C15-C17), Australia, females

**Table 16: Cancers of the upper digestive tract (ICD-10 C15–C17), Australia, males**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
5–9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
10–14	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
15–19	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
20–24	0.0	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3
25–29	1.3	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7
30–34	1.7	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
35–39	3.1	3.2	3.2	3.2	3.1	3.1	3.1	3.1	3.0	3.0	3.0
40–44	6.3	6.2	6.1	6.1	6.0	5.9	5.9	5.8	5.7	5.6	5.6
45–49	13.9	11.6	11.5	11.4	11.2	11.1	10.9	10.8	10.6	10.5	10.4
50–54	21.6	21.1	20.8	20.6	20.4	20.1	19.9	19.7	19.5	19.2	19.0
55–59	32.6	36.1	35.8	35.5	35.2	34.9	34.6	34.3	34.0	33.7	33.4
60–64	56.0	57.4	57.1	56.7	56.4	56.0	55.7	55.4	55.0	54.7	54.4
65–69	78.1	83.9	83.5	83.2	82.8	82.4	82.1	81.7	81.3	81.0	80.6
70–74	123.2	113.3	112.8	112.3	111.9	111.4	110.9	110.5	110.0	109.6	109.1
75–79	142.5	143.6	142.9	142.1	141.4	140.7	139.9	139.2	138.5	137.8	137.0
80–84	177.8	174.8	173.5	172.3	171.1	169.9	168.7	167.5	166.3	165.2	164.0
85+	192.9	208.3	206.4	204.5	202.6	200.8	198.9	197.1	195.3	193.5	191.7
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	21.5	21.9	22.2	22.4	22.6	22.9	23.2	23.4	23.7	24.0	24.4
Lower 95% PI	..	20.3	20.5	20.7	20.9	21.2	21.5	21.7	22.0	22.3	22.6
Upper 95% PI	..	23.8	24.0	24.2	24.5	24.8	25.1	25.4	25.7	26.0	26.4
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	23.7	23.8	23.6	23.5	23.3	23.2	23.0	22.9	22.7	22.5	22.4
Lower 95% PI	..	22.1	21.9	21.7	21.6	21.4	21.3	21.2	21.0	20.9	20.7
Upper 95% PI	..	25.8	25.6	25.4	25.3	25.1	24.9	24.7	24.6	24.4	24.3
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	16.5	16.5	16.4	16.3	16.2	16.1	16.0	15.9	15.8	15.7	15.6
Lower 95% PI	..	15.3	15.2	15.1	15.0	14.9	14.8	14.7	14.6	14.5	14.4
Upper 95% PI	..	18.0	17.9	17.7	17.6	17.5	17.4	17.3	17.2	17.1	17.0

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	1	1	1	1	1	1	1	1	1	1	1
5–9	0	0	0	0	0	0	0	0	0	0	0
10–14	0	0	0	0	0	0	0	0	0	0	0
15–19	1	1	1	1	1	1	1	1	1	1	1
20–24	0	2	2	2	2	2	2	2	2	2	2
25–29	9	5	5	5	5	5	5	5	5	5	6
30–34	12	12	12	12	12	12	11	11	11	11	12
35–39	23	24	23	23	23	24	24	24	24	24	23
40–44	46	47	47	47	46	45	44	43	43	43	44
45–49	94	80	80	81	81	82	83	83	83	82	80
50–54	141	137	136	136	136	136	136	137	139	140	141
55–59	167	199	209	216	221	225	223	222	222	222	224
60–64	232	245	251	260	270	281	300	317	328	337	344
65–69	262	289	297	306	317	326	335	344	357	373	389
70–74	374	345	341	337	335	339	348	359	372	387	398
75–79	324	335	344	350	354	357	358	355	354	353	359
80–84	228	240	253	267	278	286	294	302	310	315	320
85+	158	180	186	194	205	220	234	248	261	277	293
<b>Total</b>	<b>2,072</b>	<b>2,140</b>	<b>2,188</b>	<b>2,236</b>	<b>2,287</b>	<b>2,341</b>	<b>2,399</b>	<b>2,455</b>	<b>2,513</b>	<b>2,572</b>	<b>2,634</b>
Lower 95% PI	..	1,983	2,024	2,071	2,118	2,166	2,222	2,274	2,328	2,382	2,439
Upper 95% PI	..	2,317	2,372	2,422	2,477	2,538	2,597	2,658	2,721	2,785	2,853







Figure 16: Cancers of the upper digestive tract (ICD-10 C15-C17), Australia, males

**Table 17: Cancer of the oesophagus (ICD-10 C15), Australia, females**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
5-9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
10-14	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
15-19	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
20-24	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
25-29	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
30-34	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
35-39	0.5	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3
40-44	0.4	0.7	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6
45-49	0.4	1.3	1.3	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
50-54	2.5	2.4	2.3	2.3	2.3	2.3	2.2	2.2	2.2	2.2	2.1
55-59	4.0	4.1	4.1	4.0	4.0	4.0	3.9	3.9	3.8	3.8	3.8
60-64	7.4	6.8	6.8	6.7	6.7	6.6	6.5	6.5	6.4	6.3	6.3
65-69	13.5	10.7	10.6	10.5	10.5	10.4	10.3	10.2	10.1	10.0	9.9
70-74	18.5	16.0	15.9	15.7	15.6	15.5	15.4	15.3	15.2	15.1	14.9
75-79	16.1	22.8	22.7	22.5	22.4	22.2	22.1	21.9	21.8	21.6	21.5
80-84	25.8	31.7	31.4	31.2	31.0	30.8	30.6	30.4	30.2	29.9	29.7
85+	48.6	42.9	42.6	42.3	42.0	41.7	41.4	41.1	40.8	40.5	40.1
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	3.8	4.0	4.0	4.0	4.0	4.1	4.1	4.1	4.1	4.2	4.2
Lower 95% PI	..	3.7	3.7	3.7	3.8	3.8	3.8	3.8	3.9	3.9	3.9
Upper 95% PI	..	4.3	4.3	4.3	4.3	4.4	4.4	4.4	4.5	4.5	4.5
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	3.4	3.5	3.5	3.4	3.4	3.4	3.3	3.3	3.3	3.3	3.2
Lower 95% PI	..	3.3	3.2	3.2	3.2	3.2	3.1	3.1	3.1	3.1	3.0
Upper 95% PI	..	3.8	3.7	3.7	3.7	3.6	3.6	3.6	3.6	3.5	3.5
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	2.3	2.3	2.3	2.3	2.3	2.2	2.2	2.2	2.2	2.2	2.1
Lower 95% PI	..	2.2	2.1	2.1	2.1	2.1	2.1	2.1	2.0	2.0	2.0
Upper 95% PI	..	2.5	2.5	2.5	2.4	2.4	2.4	2.4	2.4	2.3	2.3

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	0	0	0	0	0	0	0	0	0	0	0
5-9	0	0	0	0	0	0	0	0	0	0	0
10-14	0	0	0	0	0	0	0	0	0	0	0
15-19	0	0	0	0	0	0	0	0	0	0	0
20-24	0	0	0	0	0	0	0	0	0	0	0
25-29	0	0	0	0	0	0	0	0	0	0	0
30-34	1	1	1	1	1	1	1	1	1	1	1
35-39	4	2	2	2	2	2	2	2	2	2	2
40-44	3	5	5	5	5	5	5	5	5	5	5
45-49	3	9	9	9	9	9	9	9	9	9	9
50-54	16	15	15	15	15	15	16	16	16	16	16
55-59	20	22	23	24	25	26	26	26	26	26	26
60-64	30	29	29	30	31	32	35	37	38	39	40
65-69	47	38	39	40	41	41	42	43	45	46	48
70-74	62	53	52	51	51	51	52	53	55	56	57
75-79	47	67	68	68	67	67	67	66	65	65	65
80-84	52	67	70	72	74	75	75	76	77	76	76
85+	89	82	84	86	90	95	99	103	107	111	115
<b>Total</b>	<b>374</b>	<b>391</b>	<b>398</b>	<b>405</b>	<b>413</b>	<b>421</b>	<b>429</b>	<b>437</b>	<b>445</b>	<b>453</b>	<b>461</b>
Lower 95% PI	..	366	372	379	386	395	402	409	417	424	432
Upper 95% PI	..	422	429	437	445	453	462	470	478	487	496







Figure 17: Cancer of the oesophagus (ICD-10 C15), Australia, females

**Table 18: Cancer of the oesophagus (ICD-10 C15), Australia, males**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
5-9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
10-14	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
15-19	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
20-24	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
25-29	0.4	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
30-34	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3
35-39	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.7	0.7	0.7
40-44	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.7	1.7	1.7	1.7
45-49	5.0	3.9	3.9	3.9	3.8	3.8	3.8	3.7	3.7	3.6	3.6
50-54	7.8	7.6	7.5	7.5	7.4	7.4	7.3	7.2	7.2	7.1	7.0
55-59	12.3	13.1	13.1	13.0	13.0	12.9	12.8	12.7	12.7	12.6	12.5
60-64	23.2	20.5	20.5	20.4	20.4	20.3	20.3	20.2	20.1	20.0	19.9
65-69	26.2	29.1	29.1	29.1	29.0	29.0	28.9	28.9	28.8	28.7	28.7
70-74	40.2	38.0	38.0	38.0	38.0	38.0	37.9	37.8	37.8	37.7	37.6
75-79	44.9	46.8	46.8	46.8	46.7	46.7	46.6	46.5	46.4	46.2	46.1
80-84	59.3	55.5	55.4	55.4	55.3	55.2	55.0	54.8	54.6	54.4	54.2
85+	58.6	64.6	64.5	64.4	64.2	64.0	63.8	63.5	63.1	62.8	62.4
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	7.3	7.3	7.4	7.6	7.7	7.8	7.9	8.0	8.2	8.3	8.4
Lower 95% PI	..	6.6	6.7	6.8	6.9	7.0	7.1	7.2	7.3	7.4	7.5
Upper 95% PI	..	8.3	8.4	8.5	8.6	8.7	8.9	9.0	9.2	9.3	9.5
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	8.0	7.9	7.9	7.9	7.9	7.8	7.8	7.8	7.8	7.7	7.7
Lower 95% PI	..	7.0	7.0	7.0	7.0	7.0	7.0	6.9	6.9	6.9	6.8
Upper 95% PI	..	9.0	9.0	8.9	8.9	8.9	8.8	8.8	8.8	8.8	8.7
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	5.6	5.5	5.5	5.5	5.5	5.5	5.5	5.4	5.4	5.4	5.4
Lower 95% PI	..	5.0	5.0	5.0	4.9	4.9	4.9	4.9	4.9	4.8	4.8
Upper 95% PI	..	6.2	6.2	6.2	6.2	6.1	6.1	6.1	6.1	6.1	6.0

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	0	0	0	0	0	0	0	0	0	0	0
5-9	0	0	0	0	0	0	0	0	0	0	0
10-14	0	0	0	0	0	0	0	0	0	0	0
15-19	0	0	0	0	0	0	0	0	0	0	0
20-24	0	0	0	0	0	0	0	0	0	0	0
25-29	3	1	1	1	1	1	1	1	1	1	1
30-34	2	2	2	2	2	2	2	2	2	2	2
35-39	6	6	6	6	6	6	6	6	6	6	6
40-44	13	14	14	14	14	14	13	13	13	13	13
45-49	34	27	27	27	28	28	28	29	29	28	28
50-54	51	49	49	49	49	50	50	50	51	52	52
55-59	63	72	76	79	81	83	83	82	83	83	84
60-64	96	88	90	94	98	102	109	115	120	123	126
65-69	88	100	103	107	111	115	118	122	127	132	138
70-74	122	116	115	114	114	116	119	123	128	133	137
75-79	102	109	113	115	117	119	119	119	118	119	121
80-84	76	76	81	86	90	93	96	99	102	104	106
85+	48	56	58	61	65	70	75	80	84	90	95
<b>Total</b>	<b>704</b>	<b>716</b>	<b>735</b>	<b>755</b>	<b>776</b>	<b>797</b>	<b>819</b>	<b>841</b>	<b>863</b>	<b>885</b>	<b>909</b>
Lower 95% PI	..	641	659	677	696	716	736	755	775	793	814
Upper 95% PI	..	807	828	850	872	895	920	946	971	998	1,024







Figure 18: Cancer of the oesophagus (ICD-10 C15), Australia, males

**Table 19: Cancer of the stomach (ICD-10 C16), Australia, females**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
5-9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
10-14	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
15-19	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
20-24	0.0	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
25-29	0.3	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4
30-34	0.3	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7
35-39	2.1	1.3	1.3	1.3	1.3	1.3	1.2	1.2	1.2	1.2	1.2
40-44	2.1	2.2	2.2	2.2	2.1	2.1	2.1	2.1	2.1	2.0	2.0
45-49	4.2	3.6	3.6	3.6	3.5	3.5	3.4	3.4	3.4	3.3	3.3
50-54	5.6	5.7	5.7	5.6	5.6	5.5	5.5	5.4	5.4	5.3	5.3
55-59	9.5	8.8	8.7	8.7	8.6	8.5	8.4	8.4	8.3	8.2	8.1
60-64	14.0	13.1	13.0	12.9	12.8	12.7	12.6	12.5	12.4	12.3	12.2
65-69	20.8	18.8	18.7	18.6	18.5	18.3	18.2	18.1	17.9	17.8	17.6
70-74	30.2	26.2	26.1	25.9	25.8	25.6	25.4	25.3	25.1	24.9	24.8
75-79	34.6	35.4	35.3	35.1	34.9	34.7	34.5	34.3	34.1	33.9	33.7
80-84	51.0	46.8	46.6	46.3	46.1	45.8	45.5	45.3	45.0	44.8	44.5
85+	64.4	60.8	60.4	60.0	59.7	59.3	59.0	58.6	58.3	57.9	57.6
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	7.2	6.8	6.9	6.9	6.9	7.0	7.0	7.1	7.1	7.2	7.3
Lower 95% PI	..	5.7	5.7	5.6	5.6	5.6	5.4	5.3	5.2	5.0	4.8
Upper 95% PI	..	8.2	8.3	8.4	8.6	8.8	9.1	9.5	9.9	10.4	10.9
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	6.5	6.1	6.1	6.0	6.0	6.0	5.9	5.9	5.8	5.8	5.7
Lower 95% PI	..	5.1	5.1	5.0	4.9	4.8	4.6	4.4	4.3	4.1	3.9
Upper 95% PI	..	7.3	7.3	7.4	7.4	7.5	7.6	7.8	8.0	8.3	8.6
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	4.5	4.2	4.2	4.2	4.2	4.1	4.1	4.1	4.0	4.0	4.0
Lower 95% PI	..	3.6	3.5	3.5	3.4	3.3	3.2	3.1	3.0	2.8	2.7
Upper 95% PI	..	5.1	5.1	5.1	5.1	5.2	5.3	5.4	5.5	5.7	5.9

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	0	0	0	0	0	0	0	0	0	0	0
5-9	0	0	0	0	0	0	0	0	0	0	0
10-14	0	0	0	0	0	0	0	0	0	0	0
15-19	0	0	0	0	0	0	0	0	0	0	0
20-24	0	1	1	1	1	1	1	1	1	1	1
25-29	2	3	3	3	3	3	3	3	3	3	3
30-34	2	6	6	6	5	5	5	5	5	5	5
35-39	16	10	10	9	9	10	10	10	10	10	9
40-44	16	17	17	17	17	16	16	16	16	16	16
45-49	29	25	25	26	26	26	26	27	26	26	26
50-54	36	37	37	38	38	38	38	38	39	39	40
55-59	47	47	50	52	54	55	55	55	55	55	56
60-64	57	55	56	58	60	63	67	71	74	76	78
65-69	72	67	68	70	72	73	75	76	79	82	85
70-74	101	87	86	84	84	84	86	88	91	93	95
75-79	101	104	105	106	105	105	104	103	101	101	102
80-84	103	99	103	107	110	111	112	113	114	114	114
85+	118	116	119	123	128	135	141	147	152	159	165
<b>Total</b>	<b>700</b>	<b>675</b>	<b>686</b>	<b>699</b>	<b>712</b>	<b>726</b>	<b>740</b>	<b>753</b>	<b>767</b>	<b>780</b>	<b>795</b>
Lower 95% PI	..	564	571	573	577	578	572	563	556	543	530
Upper 95% PI	..	809	828	855	880	914	959	1,011	1,060	1,125	1,199







Figure 19: Cancer of the stomach (ICD-10 C16), Australia, females

**Table 20: Cancer of the stomach (ICD-10 C16), Australia, males**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
5-9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
10-14	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
15-19	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
20-24	0.0	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
25-29	0.6	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4
30-34	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	0.9	0.9	0.9
35-39	1.9	2.0	1.9	1.9	1.9	1.8	1.8	1.8	1.7	1.7	1.7
40-44	3.5	3.6	3.5	3.4	3.3	3.3	3.2	3.1	3.1	3.0	3.0
45-49	7.4	6.4	6.3	6.2	6.0	5.9	5.8	5.7	5.5	5.4	5.3
50-54	12.0	11.5	11.3	11.1	10.9	10.7	10.5	10.3	10.1	10.0	9.8
55-59	18.3	20.0	19.7	19.4	19.1	18.9	18.6	18.4	18.1	17.9	17.6
60-64	28.7	32.6	32.3	31.9	31.6	31.3	30.9	30.6	30.3	30.0	29.8
65-69	46.8	49.1	48.7	48.2	47.8	47.4	47.0	46.7	46.3	45.9	45.6
70-74	73.5	67.9	67.3	66.8	66.2	65.6	65.1	64.6	64.1	63.6	63.1
75-79	86.2	87.8	86.9	86.0	85.1	84.3	83.4	82.6	81.9	81.1	80.4
80-84	104.5	108.3	106.9	105.5	104.1	102.8	101.6	100.3	99.2	98.0	96.9
85+	120.8	130.6	128.5	126.4	124.4	122.4	120.6	118.8	117.0	115.3	113.6
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	12.5	13.0	13.0	13.1	13.1	13.2	13.3	13.4	13.6	13.7	13.8
Lower 95% PI	..	11.5	11.6	11.6	11.7	11.8	11.9	12.0	12.1	12.2	12.3
Upper 95% PI	..	14.6	14.7	14.7	14.8	14.9	15.0	15.1	15.2	15.4	15.5
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	13.8	14.1	14.0	13.8	13.6	13.5	13.3	13.1	13.0	12.9	12.7
Lower 95% PI	..	12.6	12.4	12.3	12.1	12.0	11.8	11.7	11.6	11.4	11.3
Upper 95% PI	..	15.9	15.7	15.5	15.3	15.2	15.0	14.8	14.6	14.5	14.3
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	9.5	9.7	9.6	9.5	9.4	9.3	9.2	9.1	9.0	8.9	8.8
Lower 95% PI	..	8.7	8.6	8.4	8.4	8.2	8.1	8.1	8.0	7.9	7.8
Upper 95% PI	..	11.0	10.9	10.7	10.6	10.5	10.4	10.2	10.1	10.0	9.9

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	1	1	1	1	1	1	1	1	1	1	1
5-9	0	0	0	0	0	0	0	0	0	0	0
10-14	0	0	0	0	0	0	0	0	0	0	0
15-19	0	0	0	0	0	0	0	0	0	0	0
20-24	0	1	1	1	1	1	1	1	1	1	1
25-29	4	3	3	3	3	3	3	3	3	3	3
30-34	7	8	8	8	7	7	7	7	7	7	7
35-39	14	14	14	14	14	14	14	14	14	13	13
40-44	26	27	27	26	26	25	24	24	23	23	23
45-49	50	44	44	44	44	44	44	44	43	42	41
50-54	78	75	74	73	72	72	72	72	72	72	73
55-59	94	110	115	118	120	122	120	119	118	118	118
60-64	119	140	142	146	151	157	167	175	181	185	188
65-69	157	169	173	178	183	187	192	197	203	211	220
70-74	223	207	204	200	198	200	204	210	217	225	230
75-79	196	205	209	212	213	214	213	211	209	208	210
80-84	134	149	156	164	169	173	177	181	185	187	189
85+	99	113	116	120	126	134	142	149	157	165	174
<b>Total</b>	<b>1,202</b>	<b>1,265</b>	<b>1,286</b>	<b>1,307</b>	<b>1,330</b>	<b>1,354</b>	<b>1,381</b>	<b>1,407</b>	<b>1,434</b>	<b>1,462</b>	<b>1,492</b>
Lower 95% PI	..	1,126	1,146	1,163	1,186	1,206	1,230	1,253	1,279	1,300	1,329
Upper 95% PI	..	1,426	1,447	1,473	1,495	1,525	1,555	1,584	1,612	1,649	1,678







Figure 20: Cancer of the stomach (ICD-10 C16), Australia, males

**Table 21: Cancers of the colon, rectum and anus (ICD-10 C18–C21), Australia, females**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
5–9	0.2	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
10–14	0.0	0.3	0.3	0.4	0.4	0.4	0.5	0.5	0.6	0.6	0.7
15–19	1.1	0.6	0.6	0.7	0.7	0.8	0.8	0.9	0.9	1.0	1.0
20–24	1.1	1.0	1.0	1.0	1.1	1.1	1.1	1.2	1.2	1.3	1.3
25–29	1.7	1.9	1.9	2.0	2.0	2.0	2.1	2.1	2.1	2.2	2.2
30–34	4.1	4.3	4.3	4.3	4.3	4.4	4.4	4.4	4.4	4.4	4.5
35–39	8.5	9.4	9.3	9.3	9.2	9.2	9.2	9.1	9.1	9.0	9.0
40–44	15.6	18.3	18.2	18.0	17.8	17.7	17.5	17.4	17.2	17.0	16.9
45–49	33.1	32.5	32.2	31.9	31.6	31.3	31.0	30.7	30.4	30.1	29.8
50–54	48.4	54.2	53.9	53.5	53.1	52.8	52.4	52.0	51.7	51.3	51.0
55–59	82.9	87.1	86.9	86.7	86.5	86.3	86.1	85.9	85.7	85.5	85.3
60–64	139.9	134.0	134.3	134.6	134.9	135.2	135.5	135.8	136.1	136.5	136.8
65–69	199.5	193.5	194.6	195.7	196.8	197.9	199.0	200.1	201.3	202.4	203.6
70–74	262.8	258.3	260.2	262.0	263.9	265.8	267.6	269.6	271.5	273.4	275.4
75–79	346.6	319.9	322.0	324.1	326.3	328.4	330.6	332.8	335.0	337.2	339.4
80–84	375.6	374.7	376.5	378.3	380.1	381.9	383.7	385.5	387.3	389.2	391.0
85+	426.6	426.8	427.8	428.8	429.8	430.8	431.8	432.8	433.8	434.8	435.8
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	60.1	60.4	61.3	62.0	63.0	64.1	65.2	66.3	67.5	68.7	70.0
Lower 95% PI	..	55.5	56.2	57.0	57.8	58.7	59.8	60.7	62.0	63.0	64.2
Upper 95% PI	..	66.0	67.1	67.8	68.9	70.3	71.3	72.8	73.9	75.3	76.8
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	55.4	54.9	55.0	55.2	55.3	55.5	55.6	55.8	56.0	56.1	56.3
Lower 95% PI	..	50.3	50.3	50.5	50.6	50.6	50.8	50.8	51.1	51.2	51.3
Upper 95% PI	..	60.1	60.4	60.5	60.8	61.1	61.2	61.6	61.7	62.0	62.3
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	38.9	38.7	38.8	38.9	39.0	39.1	39.2	39.3	39.4	39.5	39.6
Lower 95% PI	..	35.4	35.4	35.5	35.6	35.6	35.7	35.7	35.9	35.9	36.0
Upper 95% PI	..	42.6	42.8	42.9	43.0	43.3	43.4	43.7	43.7	43.9	44.1

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	0	0	0	0	0	0	0	0	0	0	0
5–9	1	0	0	0	0	1	1	1	1	1	1
10–14	0	2	2	2	3	3	3	4	4	4	5
15–19	7	4	4	5	5	5	6	6	6	7	7
20–24	7	6	7	7	8	8	8	8	9	9	10
25–29	12	13	13	13	14	14	15	15	16	16	17
30–34	30	32	33	33	33	33	32	32	32	32	33
35–39	64	70	69	69	69	71	72	73	73	72	70
40–44	116	139	140	140	138	136	133	131	130	131	133
45–49	226	225	227	230	233	235	238	239	238	235	231
50–54	314	353	354	356	359	361	364	368	374	379	384
55–59	411	467	496	518	539	558	559	564	570	577	584
60–64	571	563	579	604	634	667	722	771	809	845	879
65–69	692	687	712	739	767	791	819	847	888	935	986
70–74	880	860	858	854	862	875	904	939	979	1,019	1,054
75–79	1,012	943	961	978	983	994	997	995	996	1,007	1,026
80–84	758	792	833	874	907	927	943	963	984	991	1,005
85+	782	813	841	876	918	977	1,032	1,084	1,134	1,191	1,249
<b>Total</b>	<b>5,883</b>	<b>5,970</b>	<b>6,129</b>	<b>6,299</b>	<b>6,472</b>	<b>6,656</b>	<b>6,847</b>	<b>7,041</b>	<b>7,243</b>	<b>7,452</b>	<b>7,673</b>
Lower 95% PI	..	5,483	5,618	5,786	5,941	6,097	6,284	6,448	6,650	6,834	7,034
Upper 95% PI	..	6,523	6,711	6,884	7,078	7,298	7,493	7,726	7,926	8,166	8,414







Figure 21: Cancers of the colon, rectum and anus (ICD-10 C18-C21), Australia, females

**Table 22: Cancers of the colon, rectum and anus (ICD-10 C18–C21), Australia, males**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
5–9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
10–14	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2
15–19	0.3	0.4	0.5	0.5	0.5	0.6	0.6	0.7	0.7	0.8	0.8
20–24	1.1	1.1	1.2	1.3	1.5	1.6	1.8	1.9	2.1	2.3	2.6
25–29	2.0	2.4	2.6	2.8	3.1	3.3	3.6	3.9	4.3	4.6	5.0
30–34	4.4	4.7	5.0	5.2	5.5	5.8	6.1	6.4	6.7	7.1	7.5
35–39	9.2	8.8	9.0	9.2	9.4	9.6	9.8	9.9	10.1	10.3	10.5
40–44	14.4	16.8	16.7	16.7	16.6	16.5	16.5	16.4	16.3	16.3	16.2
45–49	34.5	32.7	32.2	31.7	31.2	30.7	30.2	29.8	29.3	28.9	28.4
50–54	63.1	63.9	62.8	61.7	60.6	59.6	58.6	57.6	56.6	55.6	54.6
55–59	131.4	119.7	118.1	116.6	115.0	113.5	112.0	110.5	109.0	107.6	106.2
60–64	198.8	204.9	203.4	201.9	200.4	198.9	197.5	196.0	194.6	193.1	191.7
65–69	306.6	309.9	309.3	308.7	308.1	307.5	306.9	306.2	305.6	305.0	304.3
70–74	416.4	412.3	413.0	413.7	414.4	415.0	415.7	416.3	417.0	417.6	418.3
75–79	497.0	492.7	494.4	496.2	497.9	499.6	501.3	503.0	504.7	506.4	508.1
80–84	559.1	548.9	551.1	553.3	555.6	557.8	560.0	562.3	564.5	566.8	569.1
85+	548.1	592.5	594.9	597.3	599.7	602.1	604.6	607.1	609.6	612.1	614.6
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	72.3	73.5	74.5	75.6	76.7	78.0	79.5	80.9	82.4	83.9	85.6
Lower 95% PI	..	67.0	67.9	68.4	69.1	69.6	70.0	70.1	70.4	70.8	70.6
Upper 95% PI	..	81.4	82.7	84.5	86.6	89.2	92.9	97.4	102.2	107.8	117.6
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	79.0	79.1	79.0	79.0	78.9	78.8	78.8	78.7	78.7	78.6	78.6
Lower 95% PI	..	72.4	72.2	71.8	71.3	70.6	69.6	68.4	67.5	66.5	64.9
Upper 95% PI	..	87.3	87.4	88.0	88.7	89.8	91.8	94.6	97.6	101.4	109.1
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	55.4	55.4	55.3	55.2	55.1	55.0	54.9	54.9	54.8	54.8	54.7
Lower 95% PI	..	50.2	50.1	49.7	49.2	48.7	47.9	47.0	46.2	45.4	44.2
Upper 95% PI	..	61.9	62.0	62.5	63.1	64.1	65.9	68.4	71.3	75.0	82.8

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	0	0	0	0	0	0	0	0	0	0	0
5–9	0	0	0	0	0	0	0	0	0	0	0
10–14	1	1	1	1	1	1	1	1	1	1	1
15–19	2	3	3	3	4	4	5	5	5	6	6
20–24	7	7	8	9	11	12	13	14	16	17	19
25–29	14	16	18	19	21	23	26	29	32	35	38
30–34	32	35	37	39	41	43	44	46	49	52	55
35–39	68	65	66	67	69	72	76	78	80	81	81
40–44	106	126	128	128	127	126	124	123	123	124	127
45–49	233	224	224	225	226	228	229	229	228	224	219
50–54	412	416	411	406	403	402	400	400	403	404	406
55–59	674	659	690	708	722	733	721	716	712	710	711
60–64	823	876	894	924	960	997	1,063	1,121	1,158	1,188	1,213
65–69	1,029	1,068	1,100	1,138	1,181	1,215	1,254	1,290	1,343	1,403	1,468
70–74	1,264	1,255	1,250	1,241	1,243	1,263	1,305	1,354	1,411	1,474	1,524
75–79	1,130	1,151	1,190	1,223	1,248	1,269	1,281	1,283	1,289	1,299	1,330
80–84	717	753	803	859	901	940	974	1,014	1,053	1,082	1,110
85+	449	511	535	565	606	658	711	763	816	875	940
<b>Total</b>	<b>6,961</b>	<b>7,165</b>	<b>7,358</b>	<b>7,557</b>	<b>7,765</b>	<b>7,987</b>	<b>8,228</b>	<b>8,467</b>	<b>8,718</b>	<b>8,976</b>	<b>9,249</b>
Lower 95% PI	..	6,534	6,702	6,845	6,992	7,129	7,244	7,336	7,451	7,570	7,627
Upper 95% PI	..	7,940	8,168	8,454	8,763	9,136	9,623	10,198	10,812	11,528	12,710







Figure 22: Cancers of the colon, rectum and anus (ICD-10 C18-C21), Australia, males

**Table 23: Cancers of the liver, gallbladder and pancreas (ICD-10 C22-C25), Australia, females**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	0.8	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6
5-9	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
10-14	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
15-19	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
20-24	0.0	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3
25-29	0.4	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5
30-34	0.7	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9
35-39	2.1	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
40-44	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0
45-49	5.1	5.6	5.6	5.6	5.6	5.6	5.6	5.6	5.6	5.6	5.6
50-54	9.3	10.2	10.2	10.2	10.2	10.2	10.2	10.2	10.2	10.2	10.2
55-59	20.0	17.5	17.5	17.5	17.5	17.5	17.5	17.5	17.5	17.5	17.5
60-64	27.7	28.5	28.5	28.5	28.5	28.5	28.5	28.5	28.5	28.5	28.5
65-69	44.7	43.2	43.2	43.2	43.2	43.2	43.2	43.2	43.2	43.2	43.2
70-74	57.6	61.6	61.6	61.6	61.6	61.6	61.6	61.6	61.6	61.6	61.6
75-79	90.8	83.7	83.7	83.7	83.7	83.7	83.7	83.7	83.7	83.7	83.7
80-84	112.5	109.8	109.8	109.9	109.9	109.9	109.9	109.9	109.9	109.9	109.9
85+	147.3	141.5	141.5	141.5	141.5	141.5	141.5	141.5	141.6	141.6	141.6
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	15.0	14.9	15.1	15.3	15.5	15.7	16.0	16.2	16.5	16.7	17.0
Lower 95% PI	..	12.2	12.2	12.2	12.3	12.4	12.5	12.7	12.7	12.9	13.0
Upper 95% PI	..	18.7	19.0	19.5	19.9	20.4	20.8	21.2	21.7	22.1	22.7
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	13.5	13.3	13.3	13.3	13.3	13.3	13.3	13.3	13.3	13.3	13.3
Lower 95% PI	..	10.9	10.9	10.7	10.7	10.6	10.5	10.5	10.4	10.4	10.3
Upper 95% PI	..	16.5	16.6	16.9	16.9	17.1	17.2	17.3	17.4	17.5	17.7
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	9.2	9.1	9.1	9.1	9.1	9.1	9.1	9.1	9.1	9.1	9.1
Lower 95% PI	..	7.5	7.5	7.4	7.4	7.3	7.3	7.3	7.2	7.2	7.1
Upper 95% PI	..	11.2	11.2	11.4	11.4	11.6	11.6	11.7	11.8	11.8	11.9

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	5	4	4	4	4	4	4	4	4	4	4
5-9	1	0	0	0	0	0	0	0	0	0	0
10-14	0	0	0	0	0	0	0	0	0	0	0
15-19	0	1	1	1	1	1	1	1	1	1	1
20-24	0	2	2	2	2	2	2	2	2	2	2
25-29	3	3	3	3	3	3	3	3	4	4	4
30-34	5	7	7	7	7	7	6	6	6	6	7
35-39	16	12	12	12	12	13	13	13	13	13	13
40-44	22	23	23	24	24	23	23	23	23	23	24
45-49	35	39	40	41	41	42	43	44	44	44	44
50-54	60	66	67	68	69	70	71	72	74	75	77
55-59	99	94	100	105	109	113	114	115	117	118	120
60-64	113	119	123	128	134	140	151	162	169	176	183
65-69	155	153	158	163	168	173	178	183	190	200	209
70-74	193	205	203	201	201	203	208	215	222	230	236
75-79	265	247	250	252	252	253	252	250	249	250	253
80-84	227	232	243	254	262	267	270	274	279	280	282
85+	270	270	278	289	302	321	338	355	370	388	406
<b>Total</b>	<b>1,469</b>	<b>1,478</b>	<b>1,514</b>	<b>1,553</b>	<b>1,592</b>	<b>1,635</b>	<b>1,679</b>	<b>1,722</b>	<b>1,767</b>	<b>1,814</b>	<b>1,863</b>
Lower 95% PI	..	1,202	1,225	1,238	1,266	1,287	1,314	1,344	1,368	1,399	1,426
Upper 95% PI	..	1,846	1,901	1,984	2,039	2,118	2,186	2,250	2,330	2,402	2,489







Figure 23: Cancers of the liver, gallbladder and pancreas (ICD-10 C22-C25), Australia, females

**Table 24: Cancers of the liver, gallbladder and pancreas (ICD-10 C22-C25), Australia, males**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	1.1	0.8	0.8	0.9	0.9	1.0	1.0	1.1	1.2	1.2	1.3
5-9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
10-14	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
15-19	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
20-24	0.2	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3
25-29	0.4	0.6	0.6	0.6	0.7	0.7	0.7	0.7	0.7	0.7	0.7
30-34	1.4	1.3	1.3	1.3	1.4	1.4	1.4	1.5	1.5	1.5	1.6
35-39	2.7	2.6	2.7	2.7	2.8	2.9	2.9	3.0	3.1	3.1	3.2
40-44	4.5	5.3	5.4	5.5	5.6	5.7	5.8	5.9	6.0	6.1	6.2
45-49	11.7	10.2	10.4	10.5	10.7	10.9	11.0	11.2	11.4	11.5	11.7
50-54	21.5	18.8	19.0	19.2	19.4	19.6	19.8	20.1	20.3	20.5	20.7
55-59	32.0	31.9	32.2	32.4	32.7	33.0	33.3	33.5	33.8	34.1	34.4
60-64	45.2	49.7	50.1	50.4	50.8	51.1	51.5	51.8	52.2	52.6	52.9
65-69	73.9	71.3	71.8	72.3	72.8	73.3	73.8	74.3	74.8	75.4	75.9
70-74	99.8	95.2	95.9	96.7	97.5	98.3	99.1	99.9	100.7	101.5	102.3
75-79	139.9	120.3	121.5	122.7	123.9	125.2	126.4	127.7	129.0	130.3	131.6
80-84	142.7	146.8	148.6	150.5	152.4	154.3	156.2	158.2	160.2	162.2	164.2
85+	169.7	176.0	178.6	181.3	184.1	186.9	189.7	192.6	195.5	198.5	201.5
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	19.1	18.8	19.3	19.8	20.3	20.9	21.6	22.2	22.9	23.6	24.3
Lower 95% PI	..	16.1	16.5	17.0	17.4	17.9	18.4	18.9	19.5	20.0	20.7
Upper 95% PI	..	22.4	23.1	23.5	24.3	25.1	25.8	26.7	27.4	28.4	29.2
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	21.0	20.3	20.5	20.8	21.0	21.2	21.4	21.6	21.9	22.1	22.4
Lower 95% PI	..	17.4	17.5	17.8	17.9	18.1	18.3	18.4	18.7	18.8	19.0
Upper 95% PI	..	24.3	24.6	24.7	25.1	25.4	25.7	26.1	26.3	26.8	27.1
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	14.6	14.2	14.3	14.5	14.6	14.8	15.0	15.1	15.3	15.4	15.6
Lower 95% PI	..	12.1	12.2	12.4	12.5	12.6	12.7	12.8	13.0	13.1	13.2
Upper 95% PI	..	17.3	17.5	17.6	17.9	18.2	18.4	18.7	18.9	19.2	19.5

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	7	5	5	6	6	6	7	7	7	8	8
5-9	0	0	0	0	0	0	0	0	0	0	0
10-14	0	0	0	0	0	0	0	0	0	0	0
15-19	1	1	1	1	1	1	1	1	1	1	1
20-24	1	2	2	2	2	2	2	2	2	2	2
25-29	3	4	4	4	5	5	5	5	5	6	6
30-34	10	9	10	10	10	10	10	11	11	11	12
35-39	20	19	19	20	21	22	23	23	24	25	25
40-44	33	40	41	42	43	43	44	44	45	47	49
45-49	79	70	72	75	78	81	84	86	88	90	90
50-54	140	122	124	126	129	132	136	140	144	149	154
55-59	164	176	188	197	205	213	214	217	221	225	230
60-64	187	213	220	231	243	256	277	296	311	323	335
65-69	248	246	255	266	279	290	302	313	329	347	366
70-74	303	290	290	290	292	299	311	325	341	358	373
75-79	318	281	292	302	311	318	323	326	330	334	345
80-84	183	201	217	233	247	260	272	285	299	310	320
85+	139	152	161	172	186	204	223	242	262	284	308
<b>Total</b>	<b>1,836</b>	<b>1,831</b>	<b>1,903</b>	<b>1,979</b>	<b>2,058</b>	<b>2,143</b>	<b>2,233</b>	<b>2,325</b>	<b>2,420</b>	<b>2,519</b>	<b>2,624</b>
Lower 95% PI	..	1,567	1,627	1,701	1,762	1,831	1,910	1,980	2,066	2,144	2,233
Upper 95% PI	..	2,188	2,280	2,353	2,460	2,568	2,671	2,797	2,902	3,034	3,160







Figure 24: Cancers of the liver, gallbladder and pancreas (ICD-10 C22-C25), Australia, males

**Table 25: Cancer of the liver (ICD-10 C22), Australia, females**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	0.6	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5
5-9	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
10-14	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
15-19	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
20-24	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0
25-29	0.1	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
30-34	0.5	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.4	0.4	0.4
35-39	0.7	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.6	0.6
40-44	0.9	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.8	0.8	0.8
45-49	0.9	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1
50-54	1.7	1.6	1.7	1.7	1.7	1.8	1.8	1.8	1.9	1.9	1.9
55-59	3.8	2.8	2.9	3.0	3.1	3.1	3.2	3.3	3.4	3.4	3.5
60-64	4.9	4.7	4.9	5.1	5.2	5.4	5.5	5.7	5.8	6.0	6.1
65-69	6.1	7.2	7.5	7.8	8.0	8.3	8.6	8.8	9.1	9.3	9.6
70-74	10.5	9.7	10.1	10.5	10.9	11.3	11.7	12.1	12.5	12.9	13.2
75-79	13.7	11.7	12.3	12.8	13.4	13.9	14.4	14.9	15.4	15.9	16.4
80-84	14.9	13.3	13.9	14.6	15.3	15.9	16.5	17.2	17.8	18.4	19.0
85+	17.5	14.7	15.4	16.2	16.9	17.6	18.4	19.1	19.8	20.5	21.2
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	2.4	2.2	2.3	2.4	2.5	2.7	2.8	2.9	3.0	3.2	3.3
Lower 95% PI	..	1.8	1.9	2.0	2.1	2.2	2.3	2.4	2.5	2.6	2.7
Upper 95% PI	..	2.6	2.8	2.9	3.0	3.1	3.3	3.4	3.5	3.7	3.9
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	2.2	2.0	2.1	2.2	2.2	2.3	2.4	2.5	2.5	2.6	2.7
Lower 95% PI	..	1.6	1.7	1.8	1.9	1.9	2.0	2.0	2.1	2.1	2.2
Upper 95% PI	..	2.4	2.5	2.6	2.6	2.7	2.8	2.9	2.9	3.0	3.1
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	1.6	1.5	1.5	1.6	1.6	1.7	1.7	1.7	1.8	1.8	1.9
Lower 95% PI	..	1.2	1.2	1.3	1.3	1.4	1.4	1.5	1.5	1.5	1.5
Upper 95% PI	..	1.7	1.8	1.8	1.9	1.9	2.0	2.0	2.1	2.2	2.2

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	4	3	3	3	3	3	3	3	3	3	3
5-9	1	0	0	0	0	0	0	0	0	0	0
10-14	0	0	0	0	0	0	0	0	0	0	0
15-19	0	0	0	0	0	0	0	0	0	0	0
20-24	0	0	0	0	0	0	0	0	0	0	0
25-29	1	1	1	1	1	1	1	1	1	1	1
30-34	4	3	3	3	3	3	3	3	3	3	3
35-39	5	4	4	4	4	4	4	4	4	4	4
40-44	7	5	5	6	6	6	6	6	6	6	6
45-49	6	7	7	7	8	8	8	8	9	9	9
50-54	11	11	11	11	12	12	12	13	14	14	15
55-59	19	15	16	18	19	20	21	22	22	23	24
60-64	20	20	21	23	25	27	29	32	35	37	39
65-69	21	26	27	29	31	33	35	37	40	43	46
70-74	35	32	33	34	36	37	40	42	45	48	51
75-79	40	35	37	39	40	42	43	45	46	48	50
80-84	30	28	31	34	36	39	41	43	45	47	49
85+	32	28	30	33	36	40	44	48	52	56	61
<b>Total</b>	<b>236</b>	<b>218</b>	<b>232</b>	<b>246</b>	<b>261</b>	<b>276</b>	<b>292</b>	<b>308</b>	<b>325</b>	<b>343</b>	<b>361</b>
Lower 95% PI	..	176	188	201	215	227	241	256	270	281	295
Upper 95% PI	..	261	276	292	307	325	343	361	381	404	427







Figure 25: Cancer of the liver (ICD-10 C22), Australia, females

**Table 26: Cancer of the liver (ICD-10 C22), Australia, males**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	0.9	0.7	0.7	0.8	0.8	0.9	0.9	1.0	1.0	1.1	1.2
5-9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
10-14	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
15-19	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
20-24	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
25-29	0.1	0.3	0.3	0.3	0.4	0.4	0.4	0.4	0.4	0.4	0.4
30-34	1.0	0.6	0.6	0.7	0.7	0.7	0.7	0.7	0.8	0.8	0.8
35-39	1.2	1.3	1.3	1.4	1.4	1.5	1.5	1.6	1.6	1.7	1.7
40-44	2.3	2.5	2.6	2.7	2.8	2.9	2.9	3.0	3.1	3.2	3.3
45-49	5.5	4.4	4.5	4.7	4.8	4.9	5.1	5.2	5.3	5.5	5.6
50-54	8.6	7.0	7.2	7.4	7.6	7.8	8.0	8.2	8.3	8.5	8.7
55-59	9.2	11.0	11.3	11.6	11.9	12.2	12.4	12.7	13.0	13.3	13.5
60-64	15.5	17.3	17.7	18.1	18.6	19.0	19.4	19.9	20.3	20.7	21.2
65-69	23.8	25.2	25.9	26.6	27.3	28.0	28.7	29.3	30.0	30.7	31.4
70-74	34.9	32.7	33.7	34.8	35.8	36.8	37.8	38.8	39.8	40.7	41.7
75-79	44.9	37.1	38.4	39.8	41.1	42.4	43.7	45.0	46.3	47.6	49.0
80-84	40.5	37.3	38.8	40.3	41.8	43.3	44.8	46.4	47.9	49.5	51.1
85+	37.8	34.7	36.2	37.7	39.2	40.8	42.4	44.1	45.7	47.4	49.1
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	6.4	6.2	6.5	6.8	7.1	7.4	7.8	8.1	8.5	8.8	9.2
Lower 95% PI	..	5.4	5.7	5.9	6.2	6.5	6.8	7.2	7.5	7.8	8.2
Upper 95% PI	..	7.0	7.3	7.7	8.0	8.3	8.7	9.0	9.4	9.8	10.3
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	6.9	6.6	6.8	7.0	7.2	7.4	7.6	7.8	8.0	8.3	8.5
Lower 95% PI	..	5.7	5.9	6.1	6.3	6.5	6.7	6.9	7.1	7.3	7.5
Upper 95% PI	..	7.5	7.7	7.9	8.1	8.3	8.5	8.7	8.9	9.2	9.4
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	5.0	4.8	4.9	5.1	5.2	5.4	5.5	5.7	5.8	6.0	6.1
Lower 95% PI	..	4.2	4.3	4.4	4.6	4.7	4.9	5.0	5.2	5.3	5.5
Upper 95% PI	..	5.4	5.6	5.7	5.9	6.0	6.2	6.3	6.5	6.6	6.8

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	6	4	5	5	5	5	6	6	7	7	7
5-9	0	0	0	0	0	0	0	0	0	0	0
10-14	0	0	0	0	0	0	0	0	0	0	0
15-19	1	1	1	1	1	1	1	1	1	1	1
20-24	1	1	1	1	1	1	1	1	2	2	2
25-29	1	2	2	2	2	3	3	3	3	3	3
30-34	7	5	5	5	5	5	5	5	5	6	6
35-39	9	9	10	10	10	11	12	12	13	13	13
40-44	17	19	20	21	21	22	22	23	23	24	26
45-49	37	30	31	33	35	36	38	40	41	42	43
50-54	56	46	47	49	50	52	54	57	59	62	65
55-59	47	61	66	70	75	78	80	82	85	88	91
60-64	64	74	78	83	89	95	105	114	121	128	134
65-69	80	87	92	98	105	110	117	124	132	141	151
70-74	106	100	102	104	107	112	119	126	135	144	152
75-79	102	87	93	98	103	108	112	115	118	122	128
80-84	52	51	57	63	68	73	78	84	89	95	100
85+	31	30	33	36	40	45	50	55	61	68	75
<b>Total</b>	<b>617</b>	<b>607</b>	<b>642</b>	<b>679</b>	<b>718</b>	<b>759</b>	<b>803</b>	<b>848</b>	<b>895</b>	<b>945</b>	<b>997</b>
Lower 95% PI	..	527	559	593	631	666	708	751	795	839	886
Upper 95% PI	..	687	725	765	805	851	898	944	996	1,051	1,108







Figure 26: Cancer of the liver (ICD-10 C22), Australia, males

**Table 27: Cancer of the pancreas (ICD-10 C25), Australia, females**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
5-9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
10-14	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
15-19	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
20-24	0.0	0.1	0.1	0.1	0.2	0.2	0.2	0.2	0.2	0.2	0.2
25-29	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
30-34	0.1	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4
35-39	1.3	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8
40-44	1.9	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
45-49	2.6	3.1	3.1	3.1	3.1	3.1	3.1	3.0	3.0	3.0	3.0
50-54	5.9	5.6	5.6	5.6	5.5	5.5	5.4	5.4	5.4	5.3	5.3
55-59	10.1	9.6	9.5	9.4	9.3	9.3	9.2	9.1	9.1	9.0	8.9
60-64	17.4	15.5	15.3	15.2	15.1	14.9	14.8	14.7	14.6	14.5	14.3
65-69	26.2	23.9	23.7	23.5	23.3	23.1	22.9	22.7	22.5	22.3	22.1
70-74	30.8	35.7	35.4	35.1	34.8	34.5	34.2	33.9	33.6	33.4	33.1
75-79	58.2	51.4	50.9	50.6	50.2	49.8	49.4	49.0	48.7	48.3	48.0
80-84	71.9	71.7	71.2	70.7	70.2	69.8	69.3	68.8	68.4	67.9	67.5
85+	101.5	97.5	97.0	96.4	95.9	95.3	94.8	94.3	93.8	93.2	92.7
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	9.2	9.0	9.1	9.1	9.2	9.3	9.3	9.4	9.5	9.6	9.7
Lower 95% PI	..	8.0	8.0	8.1	8.1	8.2	8.3	8.3	8.4	8.5	8.6
Upper 95% PI	..	10.3	10.4	10.5	10.5	10.6	10.7	10.8	10.9	11.0	11.2
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	8.2	7.9	7.9	7.8	7.8	7.7	7.7	7.6	7.6	7.5	7.5
Lower 95% PI	..	7.0	6.9	6.9	6.9	6.8	6.7	6.7	6.7	6.6	6.5
Upper 95% PI	..	9.2	9.1	9.1	9.0	8.9	8.9	8.9	8.8	8.7	8.7
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	5.5	5.3	5.2	5.2	5.2	5.1	5.1	5.1	5.0	5.0	5.0
Lower 95% PI	..	4.6	4.6	4.5	4.5	4.5	4.4	4.4	4.4	4.3	4.3
Upper 95% PI	..	6.3	6.2	6.2	6.2	6.1	6.1	6.1	6.0	6.0	6.0

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	1	1	1	1	1	1	1	1	1	1	1
5-9	0	0	0	0	0	0	0	0	0	0	0
10-14	0	0	0	0	0	0	0	0	0	0	0
15-19	0	0	0	1	1	1	1	1	1	1	1
20-24	0	1	1	1	1	1	1	1	1	1	1
25-29	2	2	2	2	2	2	2	2	2	2	2
30-34	1	3	3	3	3	3	3	3	3	3	3
35-39	10	6	6	6	6	6	6	6	6	6	6
40-44	14	12	13	13	13	12	12	12	12	12	12
45-49	18	22	22	22	23	23	23	24	24	24	23
50-54	38	37	37	37	37	38	38	38	39	39	40
55-59	50	51	54	56	58	60	60	60	60	61	61
60-64	71	65	66	68	71	74	79	83	87	89	92
65-69	91	85	87	89	91	92	94	96	99	103	107
70-74	103	119	117	114	113	114	115	118	121	124	127
75-79	170	151	152	152	151	151	149	147	145	144	145
80-84	145	152	158	163	168	169	170	172	174	173	173
85+	186	186	191	197	205	216	227	236	245	255	266
<b>Total</b>	<b>900</b>	<b>892</b>	<b>908</b>	<b>925</b>	<b>943</b>	<b>962</b>	<b>981</b>	<b>1,000</b>	<b>1,019</b>	<b>1,039</b>	<b>1,061</b>
Lower 95% PI	..	792	804	820	835	853	869	884	902	923	937
Upper 95% PI	..	1,022	1,043	1,062	1,082	1,103	1,128	1,152	1,173	1,190	1,223







Figure 27: Cancer of the pancreas (ICD-10 C25), Australia, females

**Table 28: Cancer of the pancreas (ICD-10 C25), Australia, males**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
5-9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
10-14	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
15-19	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
20-24	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
25-29	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
30-34	0.3	0.4	0.4	0.4	0.4	0.5	0.5	0.5	0.5	0.5	0.5
35-39	1.1	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0
40-44	1.5	2.0	2.0	2.0	2.1	2.1	2.1	2.1	2.1	2.2	2.2
45-49	5.2	4.5	4.5	4.5	4.5	4.6	4.6	4.6	4.6	4.7	4.7
50-54	9.8	9.3	9.3	9.3	9.3	9.3	9.4	9.4	9.4	9.4	9.5
55-59	19.5	16.7	16.7	16.7	16.7	16.6	16.6	16.6	16.6	16.6	16.6
60-64	23.7	26.1	26.0	25.9	25.8	25.8	25.7	25.6	25.6	25.5	25.5
65-69	41.1	36.8	36.7	36.5	36.4	36.2	36.1	35.9	35.8	35.7	35.6
70-74	48.1	49.3	49.1	48.9	48.7	48.6	48.4	48.3	48.1	48.0	47.8
75-79	73.5	64.6	64.5	64.5	64.4	64.4	64.3	64.3	64.3	64.3	64.3
80-84	79.5	83.5	83.8	84.1	84.4	84.7	85.0	85.3	85.6	86.0	86.3
85+	103.8	105.6	106.5	107.4	108.3	109.2	110.1	111.0	112.0	112.9	113.9
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	9.9	9.8	10.0	10.1	10.3	10.5	10.8	11.0	11.2	11.5	11.7
Lower 95% PI	..	9.2	9.3	9.5	9.7	9.9	10.1	10.3	10.5	10.8	11.0
Upper 95% PI	..	10.5	10.7	10.9	11.1	11.3	11.5	11.8	12.0	12.3	12.6
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	11.0	10.7	10.7	10.7	10.7	10.7	10.7	10.7	10.7	10.8	10.8
Lower 95% PI	..	10.0	10.0	10.0	10.0	10.0	10.0	10.0	10.1	10.1	10.1
Upper 95% PI	..	11.5	11.5	11.5	11.5	11.5	11.5	11.5	11.6	11.5	11.6
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	7.6	7.3	7.3	7.3	7.3	7.3	7.3	7.3	7.4	7.4	7.4
Lower 95% PI	..	6.9	6.9	6.9	6.9	6.9	6.9	6.9	6.9	6.9	6.9
Upper 95% PI	..	7.9	7.9	7.9	7.9	7.9	7.9	7.9	7.9	7.9	8.0

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	0	0	0	0	0	0	0	0	0	0	0
5-9	0	0	0	0	0	0	0	0	0	0	0
10-14	0	0	0	0	0	0	0	0	0	0	0
15-19	0	0	0	0	0	0	0	0	0	0	0
20-24	0	0	0	0	0	0	0	0	1	1	1
25-29	2	1	1	1	1	1	1	1	2	2	2
30-34	2	3	3	3	3	3	3	3	3	4	4
35-39	8	7	7	7	7	7	8	8	8	8	8
40-44	11	15	16	16	16	16	16	16	16	16	17
45-49	35	31	31	32	33	34	35	36	36	36	36
50-54	64	60	61	61	62	63	64	65	67	69	70
55-59	100	92	97	101	105	107	107	108	109	110	111
60-64	98	111	114	119	124	129	138	147	152	157	161
65-69	138	127	130	135	139	143	147	151	157	164	171
70-74	146	150	149	147	146	148	152	157	163	169	174
75-79	167	151	155	159	161	164	164	164	164	165	168
80-84	102	114	122	130	137	143	148	154	160	164	168
85+	85	91	96	102	109	119	129	140	150	161	174
<b>Total</b>	<b>958</b>	<b>954</b>	<b>983</b>	<b>1,013</b>	<b>1,045</b>	<b>1,079</b>	<b>1,114</b>	<b>1,150</b>	<b>1,188</b>	<b>1,226</b>	<b>1,266</b>
Lower 95% PI	..	896	922	951	980	1,012	1,045	1,078	1,113	1,150	1,185
Upper 95% PI	..	1,022	1,054	1,086	1,120	1,156	1,195	1,235	1,275	1,313	1,360







Figure 28: Cancer of the pancreas (ICD-10 C25), Australia, males

**Table 29: Cancers of respiratory and thoracic organs (ICD-10 C33–C38, C45), Australia, females**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2
5–9	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0
10–14	0.2	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0
15–19	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
20–24	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
25–29	0.4	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5
30–34	0.8	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
35–39	2.7	2.8	2.8	2.8	2.7	2.7	2.7	2.7	2.7	2.7	2.6
40–44	8.9	7.2	7.2	7.2	7.2	7.2	7.2	7.2	7.2	7.2	7.2
45–49	17.0	16.7	16.8	16.8	16.9	16.9	16.9	17.0	17.0	17.1	17.1
50–54	28.5	31.5	31.6	31.8	31.9	32.0	32.1	32.2	32.3	32.4	32.5
55–59	57.5	51.3	51.5	51.7	51.9	52.1	52.3	52.4	52.6	52.8	52.9
60–64	77.0	80.3	80.8	81.2	81.6	82.0	82.4	82.7	83.1	83.4	83.7
65–69	113.9	122.1	123.3	124.4	125.5	126.6	127.6	128.5	129.4	130.3	131.1
70–74	155.9	165.0	167.5	169.8	172.0	174.2	176.2	178.1	180.0	181.8	183.5
75–79	181.8	182.1	185.5	188.7	191.7	194.7	197.5	200.1	202.7	205.1	207.4
80–84	173.4	164.3	167.6	170.8	173.8	176.7	179.5	182.1	184.6	187.0	189.3
85+	121.1	133.1	135.8	138.5	141.0	143.4	145.8	148.0	150.1	152.1	154.0
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	30.8	31.8	32.5	33.2	33.9	34.7	35.5	36.3	37.1	38.0	38.9
Lower 95% PI	..	29.8	30.5	31.1	31.8	32.5	33.3	34.1	34.9	35.7	36.5
Upper 95% PI	..	33.8	34.6	35.2	36.0	36.8	37.7	38.5	39.4	40.3	41.3
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	28.9	29.5	29.8	30.2	30.5	30.8	31.1	31.3	31.6	31.8	32.1
Lower 95% PI	..	27.6	28.0	28.3	28.6	28.9	29.2	29.5	29.7	30.0	30.2
Upper 95% PI	..	31.3	31.7	32.0	32.3	32.6	32.9	33.2	33.5	33.7	34.0
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	20.8	21.2	21.4	21.7	21.9	22.1	22.2	22.4	22.6	22.7	22.9
Lower 95% PI	..	19.9	20.1	20.3	20.5	20.7	20.9	21.0	21.2	21.4	21.5
Upper 95% PI	..	22.6	22.8	23.0	23.2	23.4	23.6	23.8	24.0	24.1	24.3

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	0	0	0	1	1	1	1	1	1	1	1
5–9	0	0	0	0	0	0	0	0	0	0	0
10–14	1	0	0	0	0	0	0	0	0	0	0
15–19	0	1	1	1	1	1	1	1	0	0	0
20–24	1	2	2	2	2	2	2	2	2	2	2
25–29	3	3	3	3	3	3	3	3	3	4	4
30–34	6	9	9	9	8	8	8	8	8	8	8
35–39	20	21	20	20	20	21	21	21	21	21	21
40–44	66	55	56	56	56	55	55	54	54	55	56
45–49	116	116	118	121	124	127	130	132	133	133	133
50–54	185	205	208	212	215	219	223	228	234	240	245
55–59	285	275	294	309	323	337	339	345	350	356	362
60–64	314	337	348	365	384	404	439	470	493	516	538
65–69	395	434	451	470	489	506	525	544	571	602	635
70–74	522	549	552	553	562	574	595	620	649	678	702
75–79	531	537	554	569	578	589	595	598	603	613	627
80–84	350	347	371	395	415	429	441	455	469	476	486
85+	222	254	267	283	301	325	348	371	392	416	441
<b>Total</b>	<b>3,017</b>	<b>3,145</b>	<b>3,255</b>	<b>3,369</b>	<b>3,483</b>	<b>3,602</b>	<b>3,727</b>	<b>3,853</b>	<b>3,985</b>	<b>4,121</b>	<b>4,261</b>
Lower 95% PI	..	2,945	3,051	3,160	3,267	3,380	3,498	3,620	3,744	3,872	4,002
Upper 95% PI	..	3,345	3,458	3,577	3,700	3,824	3,955	4,087	4,226	4,369	4,521







Figure 29: Cancers of respiratory and thoracic organs (ICD-10 C33-C38, C45), Australia, females

**Table 30: Cancers of respiratory and thoracic organs (ICD-10 C33–C38, C45), Australia, males**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	0.3	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
5–9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
10–14	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
15–19	0.4	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
20–24	0.2	0.4	0.4	0.4	0.4	0.4	0.5	0.5	0.5	0.5	0.5
25–29	1.3	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9
30–34	0.8	1.7	1.7	1.7	1.7	1.7	1.8	1.8	1.8	1.8	1.8
35–39	3.0	3.5	3.5	3.4	3.4	3.4	3.3	3.3	3.3	3.2	3.2
40–44	8.6	7.7	7.5	7.3	7.1	7.0	6.8	6.6	6.4	6.3	6.1
45–49	16.6	18.3	17.6	17.0	16.3	15.7	15.2	14.6	14.1	13.6	13.1
50–54	42.8	42.2	40.6	39.1	37.6	36.2	34.9	33.6	32.4	31.2	30.0
55–59	93.2	88.2	85.6	83.0	80.5	78.1	75.7	73.5	71.2	69.1	67.0
60–64	167.2	164.5	161.1	157.8	154.6	151.4	148.3	145.2	142.3	139.3	136.5
65–69	272.7	272.3	268.8	265.4	262.0	258.6	255.3	252.0	248.8	245.6	242.5
70–74	398.6	388.9	386.0	383.1	380.3	377.5	374.7	371.9	369.1	366.4	363.6
75–79	468.9	468.6	467.2	465.8	464.5	463.1	461.7	460.3	459.0	457.6	456.3
80–84	524.8	488.1	489.0	490.0	490.9	491.9	492.8	493.8	494.7	495.7	496.7
85+	429.7	471.4	474.9	478.4	481.9	485.5	489.1	492.7	496.3	499.9	503.6
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	61.1	61.4	61.7	62.0	62.4	62.9	63.5	64.1	64.8	65.5	66.3
Lower 95% PI	..	48.8	49.4	49.5	50.2	50.5	51.2	51.6	52.3	53.2	53.7
Upper 95% PI	..	81.6	81.3	81.8	81.3	82.2	82.6	83.4	83.9	84.1	85.3
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	67.1	66.4	65.8	65.1	64.5	63.9	63.4	62.8	62.2	61.7	61.2
Lower 95% PI	..	53.5	53.3	52.8	52.7	52.1	51.8	51.3	51.0	50.8	50.2
Upper 95% PI	..	86.8	85.2	84.6	82.8	82.3	81.2	80.5	79.5	78.3	77.9
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	46.3	45.7	45.2	44.6	44.1	43.6	43.1	42.6	42.2	41.7	41.3
Lower 95% PI	..	35.7	35.5	35.0	34.9	34.5	34.2	33.8	33.5	33.3	32.9
Upper 95% PI	..	62.3	61.0	60.4	58.9	58.5	57.5	56.9	56.1	55.0	54.6

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	2	1	0	0	0	0	0	0	0	0	0
5–9	0	0	0	0	0	0	0	0	0	0	0
10–14	1	1	1	1	1	1	1	1	1	1	1
15–19	3	2	2	2	2	2	2	2	2	2	2
20–24	1	3	3	3	3	3	3	3	3	3	4
25–29	9	6	6	6	6	6	6	7	7	7	7
30–34	6	13	13	13	13	13	13	13	13	13	13
35–39	22	26	25	25	25	26	26	26	26	25	25
40–44	63	58	57	56	55	53	51	49	48	48	48
45–49	112	125	122	121	119	117	115	113	109	105	101
50–54	279	274	266	258	250	245	239	234	230	226	223
55–59	478	485	500	504	505	504	488	476	465	456	449
60–64	692	703	708	722	740	759	798	831	847	857	864
65–69	915	938	956	978	1,004	1,022	1,043	1,062	1,093	1,130	1,169
70–74	1,210	1,184	1,168	1,149	1,140	1,149	1,176	1,210	1,249	1,293	1,325
75–79	1,066	1,094	1,124	1,148	1,164	1,177	1,180	1,174	1,173	1,174	1,194
80–84	673	669	713	760	796	829	857	890	923	947	968
85+	352	407	427	453	487	531	575	619	664	715	770
<b>Total</b>	<b>5,884</b>	<b>5,989</b>	<b>6,092</b>	<b>6,200</b>	<b>6,312</b>	<b>6,436</b>	<b>6,574</b>	<b>6,709</b>	<b>6,854</b>	<b>7,003</b>	<b>7,163</b>
Lower 95% PI	..	4,764	4,875	4,955	5,084	5,173	5,299	5,407	5,537	5,687	5,808
Upper 95% PI	..	7,958	8,023	8,181	8,228	8,412	8,551	8,729	8,879	8,999	9,223







Figure 30: Cancers of respiratory and thoracic organs (ICD-10 C33-C38, C45), Australia, males

**Table 31: Cancers of the trachea, bronchus and lung (ICD-10 C33–C34), Australia, females**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
5–9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
10–14	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
15–19	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
20–24	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
25–29	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3
30–34	0.8	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9
35–39	2.4	2.4	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3
40–44	8.5	6.6	6.5	6.5	6.5	6.5	6.5	6.5	6.5	6.5	6.5
45–49	16.1	15.6	15.7	15.7	15.7	15.7	15.8	15.8	15.8	15.8	15.8
50–54	27.2	29.8	29.9	29.9	30.0	30.1	30.1	30.2	30.2	30.3	30.3
55–59	54.2	48.8	48.9	49.0	49.0	49.1	49.1	49.2	49.2	49.3	49.3
60–64	74.7	76.8	77.1	77.3	77.5	77.7	77.9	78.0	78.2	78.3	78.4
65–69	110.4	117.4	118.3	119.2	120.0	120.7	121.5	122.1	122.8	123.3	123.9
70–74	147.5	159.2	161.3	163.2	165.1	166.9	168.6	170.2	171.7	173.1	174.4
75–79	175.7	175.5	178.4	181.2	183.9	186.4	188.8	191.1	193.2	195.2	197.2
80–84	167.0	157.0	159.9	162.6	165.2	167.7	170.0	172.2	174.3	176.2	178.1
85+	115.6	125.4	127.7	129.9	132.0	134.0	135.8	137.6	139.3	140.9	142.4
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	29.6	30.3	31.0	31.5	32.2	32.8	33.5	34.2	35.0	35.7	36.5
Lower 95% PI	..	28.4	29.1	29.5	30.2	30.8	31.5	32.2	32.9	33.6	34.3
Upper 95% PI	..	32.2	32.9	33.5	34.1	34.8	35.6	36.3	37.0	37.9	38.7
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	27.7	28.1	28.4	28.6	28.9	29.1	29.4	29.6	29.8	30.0	30.1
Lower 95% PI	..	26.4	26.6	26.9	27.1	27.4	27.6	27.8	28.0	28.2	28.4
Upper 95% PI	..	29.8	30.1	30.4	30.7	30.9	31.1	31.3	31.5	31.7	31.9
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	20.0	20.2	20.4	20.5	20.7	20.9	21.0	21.1	21.3	21.4	21.5
Lower 95% PI	..	19.0	19.1	19.2	19.4	19.6	19.7	19.8	20.0	20.1	20.2
Upper 95% PI	..	21.5	21.6	21.8	22.0	22.1	22.3	22.4	22.5	22.7	22.8

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	0	0	0	0	0	0	0	0	0	0	0
5–9	0	0	0	0	0	0	0	0	0	0	0
10–14	1	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0	0
20–24	1	1	1	1	1	1	1	1	1	1	1
25–29	3	2	2	2	2	2	2	2	3	3	3
30–34	6	6	7	7	7	6	6	6	6	6	7
35–39	18	17	17	17	17	18	18	19	19	18	18
40–44	63	50	50	51	51	50	50	49	49	50	51
45–49	110	108	111	113	116	118	121	123	124	124	123
50–54	176	194	196	199	203	206	209	214	219	224	229
55–59	269	261	279	293	305	317	319	323	328	332	337
60–64	305	323	332	347	364	383	415	443	464	485	504
65–69	383	417	433	450	468	483	500	517	541	570	600
70–74	494	530	532	532	539	550	570	593	619	645	667
75–79	513	517	532	547	554	564	569	571	574	583	596
80–84	337	332	354	376	394	407	418	430	443	449	458
85+	212	239	251	265	282	304	325	345	364	386	408
<b>Total</b>	<b>2,891</b>	<b>2,999</b>	<b>3,098</b>	<b>3,201</b>	<b>3,304</b>	<b>3,411</b>	<b>3,523</b>	<b>3,636</b>	<b>3,755</b>	<b>3,876</b>	<b>4,001</b>
Lower 95% PI	..	2,813	2,906	2,999	3,102	3,204	3,309	3,416	3,534	3,642	3,762
Upper 95% PI	..	3,184	3,290	3,402	3,506	3,618	3,737	3,856	3,976	4,110	4,241







Figure 31: Cancers of the trachea, bronchus and lung (ICD-10 C33-C34), Australia, females

**Table 32: Cancers of the trachea, bronchus and lung (ICD-10 C33–C34), Australia, males**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
5–9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
10–14	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
15–19	0.4	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
20–24	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
25–29	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3
30–34	0.8	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1
35–39	2.6	2.7	2.7	2.7	2.6	2.6	2.6	2.6	2.5	2.5	2.5
40–44	7.6	6.6	6.4	6.2	6.1	5.9	5.7	5.5	5.4	5.2	5.1
45–49	15.0	16.3	15.7	15.0	14.4	13.8	13.3	12.7	12.2	11.7	11.2
50–54	39.2	38.3	36.7	35.2	33.8	32.4	31.0	29.7	28.5	27.3	26.2
55–59	84.8	80.3	77.6	74.9	72.4	69.9	67.5	65.1	62.9	60.7	58.6
60–64	152.9	149.8	146.1	142.5	139.0	135.6	132.2	128.9	125.6	122.5	119.4
65–69	248.8	249.0	244.9	240.9	236.9	233.0	229.1	225.2	221.4	217.6	213.9
70–74	368.6	357.9	354.1	350.3	346.5	342.8	339.0	335.3	331.6	327.9	324.3
75–79	432.8	431.4	428.9	426.2	423.6	421.0	418.4	415.7	413.1	410.4	407.8
80–84	478.8	445.2	444.6	444.0	443.3	442.7	442.0	441.3	440.5	439.8	439.0
85+	388.2	422.5	424.0	425.5	426.9	428.4	429.8	431.2	432.6	433.9	435.3
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	55.9	55.9	56.0	56.1	56.2	56.4	56.8	57.1	57.4	57.8	58.3
Lower 95% PI	..	51.0	51.2	51.2	51.3	51.6	51.9	52.3	52.7	53.2	53.6
Upper 95% PI	..	61.7	61.7	61.8	62.0	62.2	62.5	62.7	63.1	63.2	63.8
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	61.4	60.5	59.7	58.9	58.1	57.4	56.6	55.9	55.2	54.5	53.8
Lower 95% PI	..	55.5	54.9	54.1	53.4	52.8	52.1	51.5	50.9	50.4	49.7
Upper 95% PI	..	66.3	65.3	64.5	63.7	62.8	62.0	61.1	60.3	59.3	58.6
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	42.3	41.6	40.9	40.3	39.7	39.1	38.5	37.9	37.3	36.8	36.2
Lower 95% PI	..	37.6	37.1	36.5	36.0	35.5	34.9	34.5	34.0	33.6	33.1
Upper 95% PI	..	46.2	45.5	44.8	44.1	43.4	42.8	42.0	41.4	40.6	40.1

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	1	0	0	0	0	0	0	0	0	0	0
5–9	0	0	0	0	0	0	0	0	0	0	0
10–14	1	0	0	0	0	0	0	0	0	0	0
15–19	3	1	1	1	1	1	1	1	1	1	1
20–24	1	1	1	1	1	1	1	1	1	1	1
25–29	2	2	2	2	2	2	2	2	2	2	2
30–34	6	8	8	8	8	8	8	8	8	8	8
35–39	19	20	20	19	19	20	20	20	20	20	19
40–44	56	50	49	48	47	45	43	42	40	40	39
45–49	101	112	109	107	105	103	101	98	95	91	87
50–54	256	249	240	232	225	218	212	207	203	199	194
55–59	435	442	453	455	454	451	435	422	411	401	392
60–64	633	640	642	652	666	680	712	737	748	753	755
65–69	835	858	871	888	908	920	936	949	973	1,001	1,031
70–74	1,119	1,089	1,071	1,051	1,039	1,043	1,064	1,091	1,122	1,157	1,182
75–79	984	1,008	1,032	1,050	1,062	1,070	1,069	1,060	1,055	1,053	1,068
80–84	614	610	648	689	719	746	769	795	822	840	856
85+	318	364	381	403	432	468	506	542	579	620	665
<b>Total</b>	<b>5,384</b>	<b>5,453</b>	<b>5,529</b>	<b>5,606</b>	<b>5,687</b>	<b>5,776</b>	<b>5,878</b>	<b>5,975</b>	<b>6,080</b>	<b>6,186</b>	<b>6,301</b>
Lower 95% PI	..	4,974	5,052	5,119	5,195	5,280	5,377	5,475	5,572	5,692	5,794
Upper 95% PI	..	6,022	6,094	6,183	6,270	6,366	6,472	6,565	6,678	6,766	6,898







Figure 32: Cancers of the trachea, bronchus and lung (ICD-10 C33-C34), Australia, males

**Table 33: Mesothelioma (ICD-10 C45), Australia, females**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
5-9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
10-14	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
15-19	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
20-24	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
25-29	0.0	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0
30-34	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.0
35-39	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.1	0.1	0.1	0.1
40-44	0.1	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4
45-49	0.6	0.7	0.7	0.7	0.7	0.8	0.8	0.8	0.8	0.8	0.8
50-54	0.9	1.2	1.3	1.3	1.4	1.4	1.5	1.6	1.6	1.7	1.7
55-59	3.0	1.9	2.0	2.1	2.3	2.4	2.5	2.6	2.8	2.9	3.0
60-64	2.0	2.8	3.0	3.2	3.3	3.5	3.7	3.9	4.1	4.3	4.5
65-69	3.2	3.8	4.0	4.3	4.6	4.9	5.2	5.4	5.7	6.0	6.3
70-74	6.9	4.7	5.0	5.4	5.8	6.1	6.5	6.8	7.2	7.5	7.9
75-79	6.2	5.2	5.6	6.0	6.4	6.8	7.2	7.6	8.0	8.4	8.8
80-84	5.9	5.5	6.0	6.4	6.8	7.3	7.7	8.1	8.6	9.0	9.4
85+	3.8	5.6	6.1	6.5	7.0	7.4	7.8	8.3	8.7	9.1	9.6
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	1.1	1.1	1.2	1.3	1.3	1.4	1.5	1.6	1.7	1.8	1.9
Lower 95% PI	..	0.7	0.8	0.9	0.9	1.0	1.1	1.1	1.2	1.2	1.3
Upper 95% PI	..	1.5	1.6	1.6	1.8	1.9	2.0	2.1	2.3	2.4	2.6
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	1.0	1.0	1.1	1.1	1.2	1.3	1.3	1.4	1.4	1.5	1.6
Lower 95% PI	..	0.7	0.7	0.8	0.8	0.9	0.9	1.0	1.0	1.0	1.0
Upper 95% PI	..	1.4	1.4	1.5	1.6	1.7	1.7	1.8	1.9	2.0	2.1
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	0.7	0.7	0.8	0.8	0.9	0.9	0.9	1.0	1.0	1.1	1.1
Lower 95% PI	..	0.5	0.5	0.6	0.6	0.6	0.7	0.7	0.7	0.7	0.7
Upper 95% PI	..	1.0	1.1	1.1	1.2	1.2	1.3	1.3	1.4	1.5	1.5

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	0	0	0	0	0	0	0	0	0	0	0
5-9	0	0	0	0	0	0	0	0	0	0	0
10-14	0	0	0	0	0	0	0	0	0	0	0
15-19	0	0	0	0	0	0	0	0	0	0	0
20-24	0	0	0	0	0	0	0	0	0	0	0
25-29	0	0	0	0	0	0	0	0	0	0	0
30-34	0	1	1	1	1	1	0	0	0	0	0
35-39	2	2	1	1	1	1	1	1	1	1	1
40-44	1	3	3	3	3	3	3	3	3	3	3
45-49	4	5	5	5	6	6	6	6	6	6	7
50-54	6	8	8	9	9	10	10	11	12	12	13
55-59	15	10	11	13	14	15	16	17	18	19	21
60-64	8	12	13	14	16	17	20	22	25	27	29
65-69	11	13	15	16	18	20	21	23	25	28	30
70-74	23	16	17	18	19	20	22	24	26	28	30
75-79	18	15	17	18	19	21	22	23	24	25	27
80-84	12	12	13	15	16	18	19	20	22	23	24
85+	7	11	12	13	15	17	19	21	23	25	27
<b>Total</b>	<b>107</b>	<b>108</b>	<b>117</b>	<b>127</b>	<b>137</b>	<b>148</b>	<b>160</b>	<b>172</b>	<b>185</b>	<b>198</b>	<b>212</b>
Lower 95% PI	..	72	80	89	97	105	113	121	128	135	141
Upper 95% PI	..	144	155	167	180	195	210	226	245	264	286







Figure 33: Mesothelioma (ICD-10 C45), Australia, females

**Table 34: Mesothelioma (ICD-10 C45), Australia, males**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
5-9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
10-14	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
15-19	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
20-24	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
25-29	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
30-34	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
35-39	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
40-44	0.7	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4
45-49	0.7	1.2	1.2	1.2	1.1	1.1	1.1	1.1	1.1	1.1	1.0
50-54	3.5	3.0	3.0	3.0	3.0	3.0	3.0	2.9	2.9	2.9	2.9
55-59	7.4	6.9	6.9	7.0	7.1	7.1	7.2	7.2	7.3	7.3	7.4
60-64	13.8	13.5	13.7	14.0	14.3	14.5	14.8	15.0	15.3	15.5	15.7
65-69	22.6	21.7	22.3	22.9	23.5	24.0	24.6	25.2	25.8	26.3	26.9
70-74	27.7	29.2	30.1	31.0	31.9	32.8	33.8	34.7	35.6	36.5	37.5
75-79	34.3	35.0	36.2	37.5	38.7	39.9	41.2	42.4	43.7	45.0	46.3
80-84	46.0	40.3	41.9	43.4	45.0	46.6	48.3	50.0	51.6	53.4	55.1
85+	39.1	45.9	47.9	49.9	51.9	54.0	56.2	58.4	60.6	62.9	65.2
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	4.8	4.8	5.0	5.3	5.5	5.7	6.0	6.3	6.6	6.9	7.2
Lower 95% PI	..	3.1	3.2	3.3	3.4	3.4	3.6	3.6	3.8	3.9	4.0
Upper 95% PI	..	7.8	8.1	8.7	9.3	10.0	10.4	11.3	12.0	12.6	13.4
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	5.3	5.3	5.4	5.6	5.7	5.8	6.0	6.1	6.3	6.5	6.6
Lower 95% PI	..	3.3	3.4	3.4	3.4	3.4	3.5	3.5	3.5	3.6	3.6
Upper 95% PI	..	8.6	8.9	9.4	9.8	10.4	10.6	11.3	11.7	12.1	12.6
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	3.6	3.6	3.7	3.8	3.9	4.0	4.0	4.1	4.2	4.3	4.4
Lower 95% PI	..	2.3	2.4	2.4	2.4	2.4	2.5	2.4	2.5	2.5	2.5
Upper 95% PI	..	5.7	5.9	6.2	6.4	6.8	6.9	7.3	7.6	7.8	8.1

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	0	0	0	0	0	0	0	0	0	0	0
5-9	0	0	0	0	0	0	0	0	0	0	0
10-14	0	0	0	0	0	0	0	0	0	0	0
15-19	0	0	0	0	0	0	0	0	0	0	0
20-24	0	0	0	0	0	0	0	0	0	0	0
25-29	1	0	0	0	0	0	0	0	0	0	0
30-34	0	1	1	1	1	1	1	1	1	1	1
35-39	2	2	2	1	1	1	1	1	1	1	1
40-44	5	4	4	3	3	3	3	3	3	3	3
45-49	5	8	8	8	8	8	8	8	8	8	8
50-54	23	20	20	20	20	20	20	20	21	21	22
55-59	38	38	41	42	44	46	46	47	47	48	49
60-64	57	58	60	64	68	73	79	86	91	95	100
65-69	76	75	79	84	90	95	101	106	113	121	130
70-74	84	89	91	93	96	100	106	113	121	129	137
75-79	78	82	87	92	97	101	105	108	112	115	121
80-84	59	55	61	67	73	79	84	90	96	102	107
85+	32	40	43	47	53	59	66	73	81	90	100
<b>Total</b>	<b>460</b>	<b>471</b>	<b>497</b>	<b>525</b>	<b>555</b>	<b>587</b>	<b>622</b>	<b>658</b>	<b>696</b>	<b>736</b>	<b>778</b>
Lower 95% PI	..	301	318	327	339	350	371	380	397	417	435
Upper 95% PI	..	757	800	870	938	1,020	1,081	1,185	1,271	1,353	1,454







Figure 34: Mesothelioma (ICD-10 C45), Australia, males

**Table 35: Cancers of bone and connective tissue (ICD-10 C40–C41, C47–C49), Australia, females**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	2.1	2.1	2.2	2.2	2.2	2.3	2.3	2.3	2.4	2.4	2.4
5–9	0.8	0.9	0.9	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8
10–14	2.3	2.1	2.1	2.2	2.2	2.3	2.3	2.4	2.5	2.5	2.6
15–19	2.3	2.5	2.6	2.7	2.7	2.8	2.9	3.0	3.1	3.1	3.2
20–24	1.7	2.3	2.3	2.4	2.4	2.5	2.5	2.6	2.6	2.6	2.7
25–29	1.7	1.9	1.9	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.1
30–34	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.7
35–39	2.3	2.0	2.0	2.0	1.9	1.9	1.9	1.9	1.9	1.9	1.9
40–44	2.7	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5
45–49	3.4	3.5	3.5	3.5	3.5	3.6	3.6	3.6	3.6	3.7	3.7
50–54	6.2	4.9	5.0	5.0	5.1	5.2	5.3	5.3	5.4	5.5	5.6
55–59	7.9	6.7	6.9	7.0	7.2	7.3	7.5	7.6	7.8	7.9	8.1
60–64	7.6	8.9	9.1	9.4	9.6	9.8	10.1	10.3	10.5	10.8	11.0
65–69	10.4	11.1	11.4	11.7	12.0	12.4	12.7	13.0	13.3	13.6	13.9
70–74	11.1	13.2	13.6	13.9	14.3	14.6	15.0	15.4	15.7	16.1	16.5
75–79	14.0	15.1	15.4	15.8	16.2	16.6	17.0	17.4	17.8	18.2	18.6
80–84	15.9	16.8	17.2	17.6	18.0	18.4	18.7	19.1	19.5	19.9	20.3
85+	14.7	18.5	18.9	19.3	19.6	20.0	20.4	20.8	21.2	21.6	21.9
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	4.4	4.6	4.7	4.8	5.0	5.1	5.2	5.4	5.5	5.7	5.8
Lower 95% PI	..	3.8	3.9	4.0	4.1	4.3	4.3	4.4	4.5	4.6	4.7
Upper 95% PI	..	5.3	5.5	5.6	5.8	5.9	6.1	6.3	6.5	6.7	7.0
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	4.2	4.4	4.4	4.5	4.6	4.7	4.8	4.9	4.9	5.0	5.1
Lower 95% PI	..	3.6	3.7	3.8	3.9	3.9	4.0	4.0	4.0	4.1	4.1
Upper 95% PI	..	5.1	5.2	5.3	5.4	5.5	5.6	5.7	5.8	6.0	6.1
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	3.6	3.7	3.7	3.8	3.9	3.9	4.0	4.1	4.1	4.2	4.3
Lower 95% PI	..	3.0	3.1	3.2	3.2	3.3	3.3	3.3	3.4	3.4	3.4
Upper 95% PI	..	4.3	4.4	4.4	4.5	4.6	4.7	4.8	4.9	5.0	5.1

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	13	13	13	13	14	14	14	14	14	14	14
5–9	5	6	6	6	5	5	5	5	5	5	5
10–14	15	14	14	15	15	16	16	16	16	17	17
15–19	15	17	17	18	19	19	20	21	21	22	23
20–24	11	15	15	16	17	17	18	18	19	19	19
25–29	12	13	13	13	14	14	14	15	15	15	16
30–34	13	14	14	14	14	13	13	13	13	13	13
35–39	17	15	15	14	15	15	15	15	15	15	15
40–44	20	19	19	19	19	19	19	19	19	19	19
45–49	23	24	25	25	26	27	27	28	28	29	29
50–54	40	32	33	34	35	36	37	38	39	41	42
55–59	39	36	39	42	45	48	49	50	52	54	55
60–64	31	37	39	42	45	48	54	58	63	67	71
65–69	36	40	42	44	47	49	52	55	59	63	67
70–74	37	44	45	45	47	48	51	54	57	60	63
75–79	41	44	46	48	49	50	51	52	53	54	56
80–84	32	35	38	41	43	45	46	48	50	51	52
85+	27	35	37	39	42	45	49	52	55	59	63
<b>Total</b>	<b>427</b>	<b>453</b>	<b>470</b>	<b>490</b>	<b>509</b>	<b>529</b>	<b>549</b>	<b>571</b>	<b>593</b>	<b>616</b>	<b>639</b>
Lower 95% PI	..	377	392	411	426	442	456	471	487	499	512
Upper 95% PI	..	528	548	569	591	616	643	671	699	732	767







Figure 35: Cancers of bone and connective tissue (ICD-10 C40-C41, C47-C49), Australia, females

**Table 36: Cancers of bone and connective tissue (ICD-10 C40-C41, C47-C49), Australia, males**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	2.0	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1
5-9	1.2	1.0	1.0	0.9	0.9	0.9	0.9	0.9	0.9	0.8	0.8
10-14	0.6	1.9	1.9	1.9	1.9	1.9	1.9	1.9	1.9	1.9	1.9
15-19	2.6	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6
20-24	2.9	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6
25-29	1.9	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5
30-34	1.7	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4
35-39	2.6	2.6	2.6	2.6	2.6	2.5	2.5	2.5	2.5	2.5	2.5
40-44	2.7	3.0	3.0	2.9	2.9	2.9	2.9	2.9	2.8	2.8	2.8
45-49	3.3	3.6	3.6	3.6	3.6	3.5	3.5	3.5	3.5	3.5	3.4
50-54	5.1	4.6	4.6	4.6	4.6	4.5	4.5	4.5	4.5	4.4	4.4
55-59	7.6	6.0	6.0	6.0	6.0	5.9	5.9	5.9	5.9	5.9	5.9
60-64	6.8	7.9	7.9	7.9	7.9	7.9	7.8	7.8	7.8	7.8	7.8
65-69	10.7	10.3	10.3	10.3	10.3	10.3	10.4	10.4	10.4	10.4	10.4
70-74	12.2	13.3	13.4	13.4	13.4	13.5	13.5	13.5	13.6	13.6	13.6
75-79	15.8	17.0	17.1	17.2	17.2	17.3	17.4	17.4	17.5	17.6	17.6
80-84	17.2	21.5	21.6	21.7	21.8	21.9	22.0	22.1	22.3	22.4	22.5
85+	26.9	26.9	27.0	27.2	27.4	27.5	27.7	27.9	28.0	28.2	28.4
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	4.2	4.5	4.5	4.5	4.6	4.6	4.7	4.7	4.8	4.8	4.9
Lower 95% PI	..	3.6	3.6	3.6	3.7	3.7	3.7	3.8	3.8	3.8	3.9
Upper 95% PI	..	5.6	5.7	5.7	5.8	5.9	5.9	5.9	6.0	6.1	6.2
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	4.4	4.7	4.7	4.7	4.7	4.7	4.7	4.7	4.7	4.7	4.7
Lower 95% PI	..	3.7	3.7	3.7	3.7	3.7	3.7	3.7	3.7	3.7	3.7
Upper 95% PI	..	5.9	5.9	5.9	5.9	6.0	5.9	5.9	5.9	5.9	5.9
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	3.6	3.9	3.9	3.9	3.9	3.9	3.9	3.9	3.9	3.9	3.8
Lower 95% PI	..	3.1	3.1	3.1	3.1	3.1	3.1	3.1	3.1	3.1	3.1
Upper 95% PI	..	4.9	4.9	4.9	4.9	4.9	4.9	4.8	4.9	4.9	4.9

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	13	14	14	14	14	14	14	13	13	13	13
5-9	8	7	7	6	6	6	6	6	6	6	6
10-14	4	13	13	13	14	14	14	13	13	13	13
15-19	18	17	17	17	18	18	18	18	19	19	19
20-24	19	17	18	18	18	19	19	19	19	19	20
25-29	13	17	17	17	17	17	18	18	18	19	19
30-34	12	18	18	18	18	18	17	17	17	17	17
35-39	19	19	19	19	19	19	20	20	20	19	19
40-44	20	22	23	23	22	22	22	21	21	21	22
45-49	22	25	25	25	26	26	27	27	27	27	26
50-54	33	30	30	30	30	31	31	31	32	32	33
55-59	39	33	35	36	37	38	38	38	38	39	39
60-64	28	34	35	36	38	39	42	45	47	48	49
65-69	36	36	37	38	40	41	42	44	46	48	50
70-74	37	41	40	40	40	41	42	44	46	48	50
75-79	36	40	41	42	43	44	44	44	45	45	46
80-84	22	29	31	34	35	37	38	40	42	43	44
85+	22	23	24	26	28	30	33	35	38	40	43
<b>Total</b>	<b>401</b>	<b>434</b>	<b>444</b>	<b>453</b>	<b>463</b>	<b>473</b>	<b>484</b>	<b>495</b>	<b>506</b>	<b>517</b>	<b>529</b>
Lower 95% PI	..	348	354	362	370	374	385	396	403	411	420
Upper 95% PI	..	546	559	570	583	602	613	622	638	654	670







Figure 36: Cancers of bone and connective tissue (ICD-10 C40-C41, C47-C49), Australia, males

**Table 37: Breast cancer (ICD-10 C50), Australia, females**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
5-9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
10-14	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
15-19	0.0	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
20-24	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
25-29	6.5	7.0	7.0	7.0	7.0	7.0	7.0	7.0	7.0	7.0	7.0
30-34	23.0	23.4	23.4	23.4	23.4	23.4	23.4	23.4	23.4	23.4	23.4
35-39	59.8	59.2	59.2	59.2	59.2	59.2	59.2	59.2	59.2	59.2	59.2
40-44	123.1	117.1	117.1	117.1	117.1	117.1	117.1	117.1	117.1	117.1	117.1
45-49	178.9	188.5	188.5	188.5	188.5	188.5	188.5	188.5	188.5	188.5	188.5
50-54	254.4	256.8	256.8	256.8	256.8	256.8	256.8	256.8	256.8	256.8	256.8
55-59	310.3	307.5	307.5	307.5	307.5	307.5	307.5	307.5	307.5	307.5	307.5
60-64	352.7	335.2	335.2	335.2	335.2	335.2	335.2	335.2	335.2	335.2	335.2
65-69	338.7	342.5	342.5	342.5	342.5	342.5	342.5	342.5	342.5	342.5	342.5
70-74	332.1	336.0	336.0	336.0	336.0	336.0	336.0	336.0	336.0	336.0	336.0
75-79	305.8	322.1	322.1	322.1	322.1	322.1	322.1	322.1	322.1	322.1	322.1
80-84	302.8	305.7	305.7	305.7	305.7	305.7	305.7	305.7	305.7	305.7	305.7
85+	304.9	289.5	289.5	289.5	289.5	289.5	289.5	289.5	289.5	289.5	289.5
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	120.5	122.2	123.6	124.7	126.1	127.6	129.1	130.7	132.2	133.7	135.2
Lower 95% PI	..	115.8	116.8	117.7	119.1	120.5	121.9	123.2	124.5	125.7	127.2
Upper 95% PI	..	129.5	131.5	132.8	134.2	135.9	137.5	139.3	141.1	142.9	144.5
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	117.2	117.3	117.3	117.3	117.3	117.3	117.3	117.3	117.3	117.3	117.3
Lower 95% PI	..	111.4	111.2	111.1	111.2	111.2	111.3	111.2	111.2	111.1	111.2
Upper 95% PI	..	124.1	124.4	124.5	124.3	124.3	124.2	124.3	124.4	124.5	124.4
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	93.1	93.1	93.1	93.1	93.1	93.1	93.1	93.1	93.1	93.1	93.1
Lower 95% PI	..	88.6	88.4	88.3	88.4	88.4	88.5	88.4	88.4	88.3	88.4
Upper 95% PI	..	98.4	98.7	98.8	98.6	98.6	98.5	98.6	98.7	98.8	98.7

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	0	0	0	0	0	0	0	0	0	0	0
5-9	0	0	0	0	0	0	0	0	0	0	0
10-14	0	0	0	0	0	0	0	0	0	0	0
15-19	0	2	2	2	2	2	2	2	2	2	2
20-24	9	10	10	11	11	11	11	11	11	11	11
25-29	46	48	48	48	48	49	50	51	52	53	53
30-34	170	177	179	181	180	176	172	170	170	171	174
35-39	449	439	435	438	442	455	467	474	475	473	463
40-44	917	891	902	908	907	900	892	885	888	898	923
45-49	1,223	1,307	1,332	1,362	1,389	1,418	1,447	1,467	1,477	1,475	1,464
50-54	1,649	1,670	1,689	1,711	1,734	1,759	1,784	1,818	1,860	1,897	1,936
55-59	1,539	1,647	1,755	1,838	1,916	1,989	1,997	2,021	2,047	2,075	2,105
60-64	1,439	1,407	1,444	1,505	1,576	1,652	1,785	1,903	1,991	2,075	2,154
65-69	1,175	1,217	1,253	1,294	1,335	1,369	1,410	1,449	1,510	1,582	1,659
70-74	1,112	1,118	1,108	1,095	1,097	1,107	1,135	1,170	1,212	1,252	1,286
75-79	893	949	961	972	970	975	971	963	958	962	973
80-84	611	647	677	707	729	742	751	764	776	778	786
85+	559	552	569	591	619	657	692	725	757	793	830
<b>Total</b>	<b>11,791</b>	<b>12,081</b>	<b>12,363</b>	<b>12,661</b>	<b>12,957</b>	<b>13,261</b>	<b>13,566</b>	<b>13,874</b>	<b>14,186</b>	<b>14,499</b>	<b>14,818</b>
Lower 95% PI	..	11,446	11,681	11,946	12,239	12,519	12,806	13,080	13,359	13,633	13,939
Upper 95% PI	..	12,809	13,150	13,488	13,785	14,114	14,439	14,788	15,140	15,498	15,829







Figure 37: Breast cancer (ICD-10 C50), Australia, females

**Table 38: Breast cancer (ICD-10 C50), Australia, males**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
5-9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
10-14	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
15-19	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
20-24	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
25-29	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
30-34	0.0	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
35-39	0.1	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3
40-44	0.4	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5
45-49	0.4	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7
50-54	0.9	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
55-59	1.8	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
60-64	1.4	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2
65-69	3.3	3.1	3.1	3.1	3.1	3.1	3.1	3.1	3.1	3.1	3.1
70-74	6.3	4.3	4.3	4.3	4.3	4.3	4.3	4.3	4.3	4.3	4.3
75-79	3.5	5.7	5.7	5.7	5.7	5.7	5.7	5.7	5.7	5.7	5.7
80-84	13.3	7.6	7.6	7.6	7.6	7.6	7.6	7.6	7.6	7.6	7.6
85+	13.4	10.0	10.0	10.0	10.0	10.0	10.0	10.0	10.0	10.0	10.0
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1
Lower 95% PI	..	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5
Upper 95% PI	..	2.0	2.1	2.1	2.2	2.1	2.2	2.3	2.3	2.4	2.4
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	1.1	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
Lower 95% PI	..	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5
Upper 95% PI	..	2.2	2.2	2.2	2.3	2.2	2.2	2.3	2.2	2.2	2.3
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	0.8	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7
Lower 95% PI	..	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4
Upper 95% PI	..	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	0	0	0	0	0	0	0	0	0	0	0
5-9	0	0	0	0	0	0	0	0	0	0	0
10-14	0	0	0	0	0	0	0	0	0	0	0
15-19	0	0	0	0	0	0	0	0	0	0	0
20-24	1	0	0	0	0	0	0	0	0	0	0
25-29	0	1	1	1	1	1	1	1	1	1	1
30-34	0	1	1	1	1	1	1	1	1	1	1
35-39	1	2	2	2	2	2	2	2	2	2	2
40-44	3	3	3	4	4	3	3	3	3	3	4
45-49	3	5	5	5	5	5	5	5	5	5	5
50-54	6	7	7	7	7	7	7	7	8	8	8
55-59	9	9	9	9	10	10	10	10	10	10	10
60-64	6	10	10	10	11	11	12	13	13	14	14
65-69	11	11	11	11	12	12	13	13	14	14	15
70-74	19	13	13	13	13	13	13	14	14	15	16
75-79	8	13	14	14	14	15	15	15	15	15	15
80-84	17	10	11	12	12	13	13	14	14	15	15
85+	11	9	9	9	10	11	12	13	13	14	15
<b>Total</b>	<b>95</b>	<b>94</b>	<b>97</b>	<b>100</b>	<b>102</b>	<b>106</b>	<b>109</b>	<b>112</b>	<b>115</b>	<b>118</b>	<b>122</b>
Lower 95% PI	..	47	47	50	49	52	53	54	57	58	59
Upper 95% PI	..	195	206	206	219	219	230	241	240	252	261







Figure 38: Breast cancer (ICD-10 C50), Australia, males

**Table 39: Cancers of female genital organs (ICD-10 C51–C58), Australia**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2
5–9	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
10–14	0.5	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7
15–19	1.2	1.6	1.6	1.7	1.7	1.7	1.7	1.8	1.8	1.8	1.8
20–24	3.6	4.0	4.0	4.0	4.1	4.1	4.1	4.1	4.1	4.1	4.2
25–29	11.3	8.6	8.5	8.4	8.3	8.1	8.0	7.9	7.8	7.7	7.6
30–34	14.2	14.8	14.3	13.9	13.5	13.1	12.8	12.5	12.1	11.8	11.5
35–39	20.4	21.5	20.8	20.2	19.6	19.0	18.5	18.0	17.6	17.1	16.7
40–44	26.7	30.0	29.2	28.5	27.8	27.2	26.6	26.1	25.6	25.1	24.7
45–49	44.6	42.3	41.5	40.7	40.1	39.4	38.8	38.3	37.8	37.3	36.9
50–54	62.0	59.2	58.4	57.6	56.9	56.3	55.7	55.2	54.7	54.2	53.8
55–59	88.7	79.4	78.6	77.8	77.2	76.5	76.0	75.4	74.9	74.4	74.0
60–64	104.6	99.8	99.0	98.3	97.7	97.0	96.5	95.9	95.4	95.0	94.5
65–69	108.4	117.1	116.4	115.7	115.1	114.5	113.9	113.3	112.8	112.4	111.9
70–74	117.4	129.4	128.7	128.1	127.4	126.8	126.3	125.7	125.2	124.8	124.3
75–79	141.8	136.8	136.2	135.5	134.9	134.3	133.8	133.3	132.8	132.3	131.9
80–84	142.7	141.0	140.3	139.7	139.1	138.6	138.0	137.5	137.0	136.5	136.1
85+	146.2	143.7	143.1	142.5	141.9	141.4	140.8	140.3	139.8	139.3	138.9
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	39.7	39.9	39.9	39.8	39.9	40.0	40.1	40.3	40.5	40.7	41.0
Lower 95% PI	..	34.8	35.0	35.0	35.2	35.4	35.7	36.0	36.3	36.6	36.9
Upper 95% PI	..	48.5	47.8	47.7	47.6	47.4	47.3	47.2	47.3	47.4	47.4
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	38.1	37.8	37.4	37.0	36.6	36.3	36.0	35.7	35.4	35.1	34.9
Lower 95% PI	..	32.9	32.8	32.5	32.3	32.1	31.9	31.8	31.6	31.4	31.4
Upper 95% PI	..	46.0	45.0	44.5	43.9	43.3	42.8	42.1	41.7	41.3	40.8
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	29.8	29.5	29.2	28.8	28.5	28.2	28.0	27.7	27.5	27.3	27.1
Lower 95% PI	..	25.6	25.5	25.3	25.1	25.0	24.8	24.7	24.5	24.4	24.3
Upper 95% PI	..	36.6	35.7	35.3	34.8	34.3	33.9	33.3	33.1	32.7	32.3

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	1	1	1	1	1	1	1	1	1	1	1
5–9	1	1	1	1	1	1	1	1	1	1	1
10–14	3	4	5	5	5	5	5	5	5	5	5
15–19	8	11	11	11	11	12	12	12	12	13	13
20–24	23	26	27	28	29	29	29	29	29	30	30
25–29	80	59	58	57	57	57	57	58	58	58	57
30–34	105	112	110	107	104	99	94	91	88	86	86
35–39	153	160	153	149	146	146	146	144	141	137	131
40–44	199	228	225	221	216	209	203	197	194	192	194
45–49	305	293	293	294	295	296	298	298	296	292	286
50–54	402	385	384	384	385	386	387	391	396	400	405
55–59	440	425	448	465	481	495	493	496	499	502	507
60–64	427	419	427	441	459	478	514	545	567	588	607
65–69	376	416	426	437	449	458	469	479	498	519	542
70–74	393	431	424	417	416	418	427	438	452	465	476
75–79	414	403	406	409	406	407	403	399	395	395	398
80–84	288	298	311	323	332	336	339	343	348	348	350
85+	268	274	281	291	303	321	337	352	366	382	398
<b>Total</b>	<b>3,886</b>	<b>3,947</b>	<b>3,991</b>	<b>4,043</b>	<b>4,095</b>	<b>4,153</b>	<b>4,214</b>	<b>4,278</b>	<b>4,344</b>	<b>4,414</b>	<b>4,488</b>
Lower 95% PI	..	3,438	3,502	3,557	3,614	3,682	3,748	3,822	3,891	3,964	4,048
Upper 95% PI	..	4,794	4,784	4,843	4,887	4,920	4,974	5,012	5,078	5,141	5,191







Figure 39: Cancers of female genital organs (ICD-10 C51-C58), Australia

**Table 40: Cancer of the cervix (ICD-10 C53), Australia**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
5-9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
10-14	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1
15-19	0.3	0.4	0.4	0.4	0.4	0.4	0.5	0.5	0.5	0.6	0.6
20-24	1.1	1.8	1.8	1.8	1.8	1.9	1.9	1.9	1.9	1.9	2.0
25-29	5.8	4.9	4.7	4.6	4.5	4.3	4.2	4.1	4.0	3.9	3.8
30-34	8.0	8.3	7.9	7.4	7.0	6.6	6.3	6.0	5.6	5.3	5.0
35-39	11.7	10.3	9.6	9.0	8.4	7.8	7.3	6.8	6.3	5.9	5.5
40-44	9.0	10.9	10.1	9.3	8.6	8.0	7.4	6.9	6.4	5.9	5.5
45-49	14.8	10.8	10.0	9.2	8.6	7.9	7.3	6.8	6.3	5.8	5.4
50-54	12.0	10.7	9.9	9.2	8.6	7.9	7.4	6.8	6.3	5.9	5.4
55-59	10.7	10.9	10.1	9.4	8.8	8.1	7.6	7.0	6.6	6.1	5.7
60-64	11.5	11.3	10.6	9.9	9.2	8.6	8.0	7.5	6.9	6.5	6.0
65-69	12.4	12.0	11.2	10.5	9.8	9.1	8.6	8.0	7.5	7.0	6.5
70-74	12.5	12.7	11.9	11.2	10.5	9.8	9.2	8.6	8.1	7.6	7.1
75-79	13.4	13.4	12.6	11.9	11.2	10.5	9.9	9.3	8.8	8.2	7.7
80-84	19.8	14.2	13.4	12.6	11.9	11.2	10.6	10.0	9.4	8.9	8.4
85+	15.3	15.0	14.1	13.4	12.7	12.0	11.3	10.7	10.1	9.6	9.1
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	7.5	7.1	6.7	6.3	5.9	5.6	5.3	5.0	4.7	4.5	4.2
Lower 95% PI	..	4.0	3.9	3.6	3.4	3.2	3.0	2.8	2.7	2.5	2.4
Upper 95% PI	..	12.7	11.7	11.3	10.7	10.0	9.4	8.9	8.4	8.0	7.5
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	7.3	6.9	6.5	6.1	5.7	5.3	5.0	4.7	4.4	4.2	3.9
Lower 95% PI	..	3.9	3.7	3.4	3.2	3.0	2.8	2.7	2.5	2.4	2.2
Upper 95% PI	..	12.4	11.4	10.9	10.2	9.6	8.9	8.4	7.8	7.4	6.9
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	6.2	5.9	5.5	5.2	4.8	4.5	4.3	4.0	3.8	3.6	3.4
Lower 95% PI	..	3.3	3.2	2.9	2.8	2.6	2.4	2.3	2.2	2.0	1.9
Upper 95% PI	..	10.5	9.6	9.2	8.7	8.1	7.6	7.2	6.7	6.4	5.9

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	0	0	0	0	0	0	0	0	0	0	0
5-9	0	0	0	0	0	0	0	0	0	0	0
10-14	0	0	0	0	0	0	0	0	0	0	1
15-19	2	2	3	3	3	3	3	3	4	4	4
20-24	7	12	12	13	13	13	13	13	14	14	14
25-29	41	33	32	31	31	30	30	30	30	29	29
30-34	59	63	60	57	54	50	46	43	41	39	37
35-39	88	77	71	66	62	60	57	54	51	47	43
40-44	67	83	78	72	67	62	57	52	48	45	43
45-49	101	75	71	67	63	60	56	53	49	46	42
50-54	78	70	65	61	58	54	51	48	46	43	41
55-59	53	58	58	56	55	53	49	46	44	41	39
60-64	47	48	46	44	43	42	43	42	41	40	39
65-69	43	43	41	40	38	37	35	34	33	32	32
70-74	42	42	39	36	34	32	31	30	29	28	27
75-79	39	40	38	36	34	32	30	28	26	25	23
80-84	40	30	30	29	28	27	26	25	24	23	22
85+	28	28	28	27	27	27	27	27	26	26	26
<b>Total</b>	<b>735</b>	<b>703</b>	<b>670</b>	<b>640</b>	<b>610</b>	<b>582</b>	<b>556</b>	<b>530</b>	<b>506</b>	<b>483</b>	<b>461</b>
Lower 95% PI	..	397	387	361	345	330	316	301	290	274	264
Upper 95% PI	..	1,259	1,173	1,148	1,094	1,041	991	947	896	866	820







Figure 40: Cancer of the cervix (ICD-10 C53), Australia

**Table 41: Cancer of the uterus (ICD-10 C54–C55), Australia**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
5–9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
10–14	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
15–19	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
20–24	0.0	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
25–29	0.4	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5
30–34	1.6	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
35–39	2.4	3.2	3.2	3.2	3.2	3.2	3.2	3.2	3.2	3.2	3.2
40–44	6.7	7.5	7.5	7.5	7.5	7.5	7.5	7.5	7.5	7.5	7.5
45–49	13.6	15.2	15.2	15.2	15.2	15.2	15.2	15.2	15.2	15.2	15.2
50–54	27.6	26.5	26.5	26.5	26.5	26.5	26.4	26.4	26.4	26.4	26.4
55–59	47.8	39.5	39.5	39.5	39.5	39.5	39.5	39.5	39.5	39.5	39.5
60–64	53.2	51.3	51.3	51.3	51.3	51.3	51.3	51.3	51.3	51.2	51.2
65–69	52.2	58.8	58.8	58.8	58.8	58.8	58.8	58.7	58.7	58.7	58.7
70–74	55.8	60.7	60.7	60.7	60.7	60.7	60.7	60.6	60.6	60.6	60.6
75–79	62.0	57.9	57.8	57.8	57.8	57.8	57.8	57.7	57.7	57.7	57.7
80–84	50.5	52.1	52.1	52.0	52.0	52.0	52.0	51.9	51.9	51.9	51.9
85+	42.0	45.3	45.3	45.3	45.2	45.2	45.2	45.2	45.1	45.1	45.1
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	15.7	16.0	16.2	16.3	16.5	16.7	17.0	17.2	17.5	17.7	18.0
Lower 95% PI	..	14.9	15.1	15.2	15.4	15.6	15.8	16.0	16.3	16.5	16.8
Upper 95% PI	..	17.2	17.4	17.6	17.8	18.0	18.3	18.6	18.8	19.0	19.3
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	15.1	15.1	15.1	15.1	15.1	15.1	15.1	15.1	15.1	15.1	15.1
Lower 95% PI	..	14.1	14.1	14.1	14.1	14.1	14.1	14.1	14.1	14.1	14.1
Upper 95% PI	..	16.3	16.3	16.4	16.4	16.3	16.3	16.4	16.3	16.3	16.3
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	11.7	11.6	11.6	11.6	11.6	11.6	11.6	11.6	11.6	11.6	11.6
Lower 95% PI	..	10.9	10.8	10.8	10.8	10.8	10.8	10.8	10.8	10.8	10.8
Upper 95% PI	..	12.6	12.6	12.6	12.6	12.6	12.6	12.6	12.6	12.6	12.6

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	0	0	0	0	0	0	0	0	0	0	0
5–9	0	0	0	0	0	0	0	0	0	0	0
10–14	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0	0
20–24	0	1	1	1	1	1	1	1	1	1	1
25–29	3	3	3	3	3	3	3	3	3	3	3
30–34	12	9	9	9	9	9	9	9	9	9	9
35–39	18	23	23	23	24	24	25	25	25	25	25
40–44	50	57	57	58	58	57	57	56	57	57	59
45–49	93	105	107	110	112	114	117	118	119	119	118
50–54	179	172	174	176	179	181	184	187	191	195	199
55–59	237	212	226	236	246	256	256	260	263	266	270
60–64	217	215	221	230	241	253	273	291	304	317	329
65–69	181	209	215	222	229	235	242	249	259	271	284
70–74	187	202	200	198	198	200	205	211	219	226	232
75–79	181	171	173	174	174	175	174	173	172	172	174
80–84	102	110	115	120	124	126	128	130	132	132	133
85+	77	86	89	92	97	103	108	113	118	124	129
<b>Total</b>	<b>1,537</b>	<b>1,577</b>	<b>1,615</b>	<b>1,655</b>	<b>1,696</b>	<b>1,738</b>	<b>1,782</b>	<b>1,827</b>	<b>1,873</b>	<b>1,920</b>	<b>1,967</b>
Lower 95% PI	..	1,471	1,506	1,541	1,579	1,621	1,663	1,702	1,749	1,793	1,839
Upper 95% PI	..	1,701	1,743	1,790	1,833	1,875	1,921	1,973	2,016	2,065	2,115







Figure 41: Cancer of the uterus (ICD-10 C54-C55), Australia

**Table 42: Ovarian cancer (ICD-10 C56–C57), Australia**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
5–9	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
10–14	0.5	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6
15–19	0.8	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
20–24	2.5	1.7	1.7	1.7	1.7	1.8	1.8	1.8	1.8	1.8	1.8
25–29	4.4	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8
30–34	3.8	4.2	4.2	4.2	4.2	4.2	4.2	4.2	4.2	4.2	4.2
35–39	5.1	6.4	6.4	6.4	6.4	6.4	6.4	6.4	6.4	6.4	6.4
40–44	7.9	9.5	9.5	9.5	9.5	9.5	9.5	9.5	9.5	9.4	9.4
45–49	14.0	13.6	13.5	13.5	13.5	13.5	13.4	13.4	13.4	13.4	13.4
50–54	18.8	18.6	18.5	18.5	18.5	18.5	18.4	18.4	18.4	18.3	18.3
55–59	26.6	24.7	24.6	24.6	24.6	24.5	24.5	24.5	24.4	24.4	24.4
60–64	34.6	31.6	31.6	31.5	31.5	31.5	31.5	31.5	31.5	31.5	31.4
65–69	35.5	38.8	38.8	38.8	38.8	38.8	38.9	38.9	38.9	38.9	38.9
70–74	38.2	45.4	45.5	45.6	45.6	45.7	45.7	45.8	45.8	45.9	45.9
75–79	52.4	50.8	51.0	51.1	51.2	51.3	51.4	51.5	51.6	51.6	51.7
80–84	53.5	54.6	54.8	54.9	55.1	55.3	55.4	55.5	55.7	55.8	55.9
85+	60.6	56.7	56.9	57.2	57.4	57.6	57.8	58.0	58.1	58.3	58.4
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	13.2	13.5	13.7	13.8	13.9	14.1	14.3	14.5	14.6	14.8	15.0
Lower 95% PI	..	11.9	12.0	12.1	12.3	12.4	12.5	12.7	12.8	13.0	13.2
Upper 95% PI	..	15.6	15.8	15.9	16.0	16.2	16.4	16.6	16.8	17.0	17.2
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	12.6	12.7	12.7	12.7	12.7	12.7	12.7	12.7	12.7	12.8	12.8
Lower 95% PI	..	11.2	11.2	11.2	11.3	11.2	11.2	11.3	11.2	11.2	11.2
Upper 95% PI	..	14.6	14.6	14.6	14.5	14.6	14.6	14.5	14.6	14.6	14.6
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	9.8	9.8	9.8	9.8	9.8	9.8	9.8	9.8	9.8	9.8	9.8
Lower 95% PI	..	8.7	8.7	8.7	8.7	8.7	8.7	8.7	8.7	8.7	8.7
Upper 95% PI	..	11.3	11.3	11.3	11.2	11.2	11.2	11.2	11.2	11.2	11.2

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	0	0	0	0	0	0	0	0	0	0	0
5–9	1	1	1	1	1	1	1	1	1	1	1
10–14	3	4	4	4	4	4	4	4	4	4	4
15–19	5	7	7	7	7	7	7	8	8	8	8
20–24	16	11	12	12	12	12	13	13	13	13	13
25–29	31	18	18	18	19	19	20	20	20	21	21
30–34	28	32	32	32	32	32	31	31	31	31	31
35–39	38	48	47	47	48	49	51	51	52	51	50
40–44	59	72	73	74	74	73	72	72	72	72	74
45–49	96	94	96	98	99	101	103	104	105	105	104
50–54	122	121	122	123	125	126	128	130	133	136	138
55–59	132	132	141	147	153	159	159	161	163	165	167
60–64	141	133	136	142	148	155	168	179	187	195	202
65–69	123	138	142	147	151	155	160	164	171	180	188
70–74	128	151	150	148	149	151	155	160	165	171	176
75–79	153	150	152	154	154	155	155	154	153	154	156
80–84	108	115	121	127	131	134	136	139	141	142	144
85+	111	108	112	117	123	131	138	145	152	160	168
<b>Total</b>	<b>1,295</b>	<b>1,335</b>	<b>1,366</b>	<b>1,399</b>	<b>1,431</b>	<b>1,465</b>	<b>1,500</b>	<b>1,535</b>	<b>1,571</b>	<b>1,607</b>	<b>1,645</b>
Lower 95% PI	..	1,173	1,198	1,229	1,260	1,285	1,315	1,350	1,378	1,411	1,444
Upper 95% PI	..	1,541	1,577	1,611	1,642	1,688	1,727	1,760	1,806	1,846	1,889







Figure 42: Ovarian cancer (ICD-10 C56-C57), Australia

**Table 43: Cancers of the vulva, vagina and placenta (ICD-10 C58, C51–C52), Australia**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
5–9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
10–14	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
15–19	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
20–24	0.0	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3
25–29	0.7	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6
30–34	0.8	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.0	1.0	1.0
35–39	1.2	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
40–44	3.1	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3
45–49	2.2	2.8	2.8	2.8	2.8	2.8	2.8	2.9	2.9	2.9	2.9
50–54	3.5	3.4	3.4	3.4	3.4	3.5	3.5	3.5	3.5	3.6	3.6
55–59	3.6	4.3	4.3	4.3	4.3	4.4	4.4	4.4	4.4	4.4	4.5
60–64	5.4	5.6	5.6	5.6	5.7	5.7	5.7	5.7	5.8	5.8	5.8
65–69	8.4	7.6	7.6	7.7	7.7	7.7	7.7	7.7	7.8	7.8	7.8
70–74	10.8	10.6	10.6	10.6	10.6	10.6	10.7	10.7	10.7	10.7	10.7
75–79	14.0	14.7	14.7	14.7	14.7	14.7	14.7	14.7	14.7	14.7	14.7
80–84	18.8	20.1	20.1	20.1	20.1	20.1	20.0	20.0	20.0	20.0	20.0
85+	28.4	26.8	26.7	26.7	26.6	26.6	26.5	26.5	26.4	26.4	26.3
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	3.3	3.4	3.4	3.4	3.5	3.5	3.6	3.6	3.7	3.7	3.8
Lower 95% PI	..	3.1	3.1	3.1	3.2	3.2	3.3	3.3	3.4	3.4	3.5
Upper 95% PI	..	4.3	4.4	4.4	4.5	4.5	4.6	4.7	4.8	4.8	4.9
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	3.0	3.1	3.1	3.1	3.1	3.1	3.1	3.1	3.1	3.1	3.1
Lower 95% PI	..	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8
Upper 95% PI	..	4.0	4.0	4.1	4.1	4.1	4.2	4.2	4.3	4.3	4.4
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3
Lower 95% PI	..	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.1	2.1
Upper 95% PI	..	3.4	3.4	3.4	3.5	3.5	3.6	3.6	3.8	3.7	3.8

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	1	1	1	1	1	1	1	1	1	1	1
5–9	0	0	0	0	0	0	0	0	0	0	0
10–14	0	0	0	0	0	0	0	0	0	0	0
15–19	1	1	1	1	1	1	1	1	1	1	1
20–24	0	2	2	2	2	2	2	2	2	2	2
25–29	5	4	4	4	4	4	4	4	4	4	4
30–34	6	8	8	8	8	8	8	8	8	8	8
35–39	9	12	12	12	12	13	13	13	13	13	13
40–44	23	17	17	17	17	17	17	17	17	17	18
45–49	15	19	20	20	21	21	22	22	22	23	23
50–54	23	22	22	23	23	24	24	25	26	26	27
55–59	18	23	24	26	27	28	28	29	29	30	31
60–64	22	23	24	25	27	28	30	33	34	36	37
65–69	29	27	28	29	30	31	32	33	34	36	38
70–74	36	35	35	35	35	35	36	37	39	40	41
75–79	41	43	44	44	44	45	44	44	44	44	45
80–84	38	43	45	46	48	49	49	50	51	51	51
85+	52	51	53	54	57	60	63	66	69	72	75
<b>Total</b>	<b>319</b>	<b>332</b>	<b>340</b>	<b>349</b>	<b>357</b>	<b>367</b>	<b>376</b>	<b>385</b>	<b>394</b>	<b>404</b>	<b>414</b>
Lower 95% PI	..	304	312	319	327	336	344	353	361	370	379
Upper 95% PI	..	426	436	448	461	467	488	496	517	525	542







Figure 43: Cancers of the vulva, vagina and placenta (ICD-10 C58, C51-C52), Australia

**Table 44: Cancers of male genital organs (ICD-10 C60–C63), Australia**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	0.8	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6
5–9	0.1	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
10–14	0.0	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4
15–19	4.2	4.6	4.6	4.6	4.6	4.6	4.6	4.6	4.7	4.7	4.7
20–24	12.1	9.8	9.8	9.8	9.8	9.9	9.9	9.9	9.9	9.9	9.9
25–29	13.7	13.7	13.7	13.8	13.8	13.8	13.8	13.9	13.9	13.9	13.9
30–34	15.1	14.1	14.1	14.1	14.2	14.2	14.2	14.2	14.3	14.3	14.3
35–39	13.4	12.3	12.3	12.3	12.3	12.4	12.4	12.4	12.4	12.4	12.4
40–44	14.6	12.1	12.1	12.1	12.1	12.1	12.1	12.1	12.1	12.1	12.1
45–49	23.3	23.5	23.6	23.6	23.6	23.6	23.6	23.6	23.6	23.6	23.6
50–54	75.9	72.2	72.2	72.2	72.2	72.2	72.2	72.2	72.2	72.2	72.2
55–59	200.8	187.0	187.0	187.0	187.0	187.0	187.0	187.0	187.0	187.0	187.0
60–64	355.1	362.4	362.4	362.4	362.4	362.4	362.4	362.5	362.5	362.5	362.5
65–69	580.5	554.8	554.8	554.8	554.9	554.9	554.9	554.9	554.9	554.9	554.9
70–74	719.1	725.3	725.3	725.3	725.3	725.3	725.3	725.3	725.4	725.4	725.4
75–79	873.5	864.5	864.5	864.5	864.5	864.5	864.5	864.5	864.5	864.5	864.6
80–84	951.3	983.8	983.8	983.8	983.8	983.8	983.8	983.8	983.8	983.8	983.9
85+	1,069.3	1,099.1	1,099.1	1,099.1	1,099.1	1,099.1	1,099.1	1,099.1	1,099.1	1,099.1	1,099.1
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	123.5	124.4	126.5	128.6	130.8	133.3	136.2	138.9	141.7	144.7	147.8
Lower 95% PI	..	118.0	119.7	121.6	123.7	126.0	128.6	131.2	133.7	136.4	139.5
Upper 95% PI	..	132.8	135.4	137.6	140.1	142.9	146.1	148.9	152.5	155.6	158.5
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	135.8	134.8	134.8	134.8	134.9	134.9	134.9	134.9	134.9	134.9	134.9
Lower 95% PI	..	127.8	127.6	127.6	127.5	127.5	127.4	127.4	127.2	127.1	127.3
Upper 95% PI	..	143.7	144.1	144.2	144.3	144.4	144.7	144.7	145.3	145.4	145.1
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	95.1	93.9	93.9	94.0	94.0	94.0	94.0	94.0	94.0	94.0	94.0
Lower 95% PI	..	88.7	88.5	88.5	88.4	88.4	88.3	88.2	88.1	88.1	88.1
Upper 95% PI	..	101.2	101.7	101.7	101.8	102.0	102.3	102.3	102.9	103.0	102.6

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	5	4	4	4	4	4	4	4	4	4	4
5–9	1	1	1	1	1	1	2	2	2	2	2
10–14	0	9	9	10	10	10	10	10	10	10	10
15–19	29	32	32	33	33	33	34	34	34	35	35
20–24	80	66	68	70	71	72	72	72	72	73	74
25–29	96	94	94	94	95	97	100	102	104	105	106
30–34	110	105	106	107	107	105	103	103	103	104	106
35–39	99	90	89	90	91	94	96	97	98	97	96
40–44	107	91	92	93	93	92	91	91	91	92	95
45–49	157	161	164	168	171	175	179	182	183	183	182
50–54	495	470	472	475	480	487	493	502	514	525	536
55–59	1,030	1,029	1,092	1,136	1,174	1,207	1,205	1,212	1,222	1,235	1,253
60–64	1,470	1,549	1,593	1,659	1,735	1,817	1,951	2,073	2,157	2,230	2,294
65–69	1,948	1,912	1,974	2,045	2,127	2,192	2,268	2,337	2,438	2,553	2,676
70–74	2,183	2,207	2,195	2,176	2,175	2,208	2,276	2,360	2,455	2,560	2,643
75–79	1,986	2,019	2,080	2,131	2,166	2,197	2,209	2,205	2,209	2,218	2,263
80–84	1,220	1,349	1,434	1,526	1,596	1,658	1,712	1,774	1,835	1,879	1,918
85+	876	948	989	1,040	1,111	1,202	1,293	1,382	1,471	1,571	1,680
<b>Total</b>	<b>11,892</b>	<b>12,137</b>	<b>12,490</b>	<b>12,857</b>	<b>13,242</b>	<b>13,652</b>	<b>14,097</b>	<b>14,540</b>	<b>15,001</b>	<b>15,475</b>	<b>15,972</b>
Lower 95% PI	..	11,505	11,820	12,163	12,520	12,902	13,314	13,733	14,148	14,595	15,082
Upper 95% PI	..	12,950	13,366	13,763	14,179	14,626	15,122	15,590	16,136	16,642	17,128







Figure 44: Cancers of male genital organs (ICD-10 C60-C63), Australia

**Table 45: Prostate cancer (ICD-10 C61), Australia**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
5-9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
10-14	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
15-19	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
20-24	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
25-29	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
30-34	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
35-39	0.5	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3
40-44	2.9	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7
45-49	16.3	16.1	16.1	16.1	16.1	16.1	16.1	16.1	16.1	16.1	16.1
50-54	69.1	66.0	66.0	66.0	66.0	66.0	66.0	66.0	66.0	66.0	66.0
55-59	197.5	181.5	181.5	181.5	181.5	181.5	181.5	181.5	181.5	181.5	181.5
60-64	350.7	357.1	357.1	357.1	357.1	357.1	357.1	357.1	357.1	357.1	357.1
65-69	573.6	549.4	549.4	549.4	549.4	549.4	549.4	549.4	549.4	549.4	549.4
70-74	711.6	719.4	719.4	719.4	719.4	719.4	719.4	719.4	719.4	719.4	719.4
75-79	868.7	858.0	858.0	858.0	858.0	858.0	858.0	858.0	858.0	858.0	858.0
80-84	941.1	976.5	976.5	976.5	976.5	976.5	976.5	976.5	976.5	976.5	976.5
85+	1,065.6	1,090.8	1,090.8	1,090.8	1,090.8	1,090.8	1,090.8	1,090.8	1,090.8	1,090.8	1,090.8
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	116.2	117.4	119.5	121.5	123.8	126.3	129.1	131.8	134.6	137.6	140.6
Lower 95% PI	..	112.5	114.3	116.3	118.5	120.8	123.5	126.1	128.6	131.4	134.5
Upper 95% PI	..	123.6	126.0	128.0	130.3	133.0	136.1	138.8	142.2	145.1	148.0
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	128.5	127.8	127.8	127.8	127.8	127.8	127.8	127.8	127.8	127.8	127.8
Lower 95% PI	..	122.3	122.2	122.3	122.3	122.3	122.2	122.3	122.1	122.2	122.3
Upper 95% PI	..	134.4	134.7	134.6	134.4	134.5	134.6	134.5	135.0	134.9	134.5
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	88.1	87.2	87.2	87.2	87.2	87.2	87.2	87.2	87.2	87.2	87.2
Lower 95% PI	..	83.4	83.4	83.4	83.4	83.4	83.4	83.4	83.3	83.3	83.4
Upper 95% PI	..	92.3	92.5	92.4	92.3	92.4	92.5	92.3	92.8	92.7	92.4

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	0	0	0	0	0	0	0	0	0	0	0
5-9	0	0	0	0	0	0	0	0	0	0	0
10-14	0	0	0	0	0	0	0	0	0	0	0
15-19	0	0	0	0	0	0	0	0	0	0	0
20-24	0	0	0	0	0	0	0	0	0	0	0
25-29	0	0	0	0	0	0	0	0	0	0	0
30-34	0	0	0	0	0	0	0	0	0	0	0
35-39	4	2	2	2	2	3	3	3	3	3	3
40-44	21	20	20	20	20	20	20	20	20	20	21
45-49	110	110	112	115	117	120	122	124	125	125	124
50-54	451	430	432	435	439	445	451	459	470	480	490
55-59	1,013	999	1,060	1,102	1,139	1,172	1,169	1,176	1,186	1,198	1,215
60-64	1,452	1,526	1,570	1,634	1,710	1,790	1,922	2,042	2,125	2,197	2,260
65-69	1,925	1,893	1,954	2,024	2,106	2,170	2,245	2,314	2,414	2,528	2,649
70-74	2,160	2,190	2,177	2,158	2,157	2,190	2,258	2,340	2,435	2,539	2,622
75-79	1,975	2,004	2,065	2,114	2,150	2,180	2,192	2,189	2,192	2,201	2,246
80-84	1,207	1,339	1,423	1,515	1,584	1,646	1,699	1,760	1,821	1,865	1,904
85+	873	941	981	1,033	1,103	1,193	1,283	1,371	1,460	1,559	1,668
<b>Total</b>	<b>11,191</b>	<b>11,454</b>	<b>11,797</b>	<b>12,154</b>	<b>12,529</b>	<b>12,929</b>	<b>13,365</b>	<b>13,799</b>	<b>14,250</b>	<b>14,714</b>	<b>15,202</b>
Lower 95% PI	..	10,973	11,290	11,633	11,994	12,370	12,782	13,201	13,614	14,061	14,542
Upper 95% PI	..	12,053	12,441	12,805	13,185	13,619	14,087	14,527	15,050	15,526	15,999







Figure 45: Prostate cancer (ICD-10 C61), Australia

**Table 46: Cancers of other male genital organs (ICD-10 C62–C63, C60), Australia**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	0.8	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6
5–9	0.1	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
10–14	0.0	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4
15–19	4.2	4.6	4.6	4.6	4.6	4.6	4.6	4.6	4.7	4.7	4.7
20–24	12.1	9.8	9.8	9.8	9.8	9.8	9.9	9.9	9.9	9.9	9.9
25–29	13.7	13.7	13.7	13.8	13.8	13.8	13.8	13.8	13.9	13.9	13.9
30–34	15.1	14.0	14.1	14.1	14.1	14.2	14.2	14.2	14.2	14.2	14.3
35–39	12.8	11.9	12.0	12.0	12.0	12.0	12.0	12.0	12.1	12.1	12.1
40–44	11.7	9.4	9.4	9.4	9.4	9.4	9.4	9.5	9.5	9.5	9.5
45–49	7.0	7.4	7.4	7.4	7.4	7.4	7.4	7.4	7.5	7.5	7.5
50–54	6.7	6.2	6.2	6.2	6.2	6.2	6.2	6.2	6.2	6.2	6.2
55–59	3.3	5.5	5.5	5.5	5.5	5.5	5.5	5.6	5.6	5.6	5.6
60–64	4.3	5.3	5.3	5.3	5.3	5.3	5.4	5.4	5.4	5.4	5.4
65–69	6.9	5.4	5.5	5.5	5.5	5.5	5.5	5.5	5.5	5.5	5.5
70–74	7.6	5.9	5.9	5.9	5.9	5.9	5.9	5.9	5.9	5.9	6.0
75–79	4.8	6.5	6.5	6.5	6.5	6.6	6.6	6.6	6.6	6.6	6.6
80–84	10.1	7.3	7.4	7.4	7.4	7.4	7.4	7.4	7.4	7.4	7.4
85+	3.7	8.3	8.3	8.3	8.3	8.3	8.3	8.3	8.3	8.3	8.3
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	7.3	7.0	7.0	7.0	7.0	7.1	7.1	7.1	7.1	7.1	7.1
Lower 95% PI	..	5.5	5.4	5.3	5.2	5.2	5.1	5.1	5.0	5.0	5.0
Upper 95% PI	..	9.2	9.4	9.6	9.8	9.8	10.0	10.2	10.3	10.4	10.4
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	7.3	7.0	7.1	7.1	7.1	7.1	7.1	7.1	7.1	7.1	7.1
Lower 95% PI	..	5.5	5.4	5.3	5.2	5.2	5.2	5.1	5.1	5.0	5.0
Upper 95% PI	..	9.3	9.4	9.7	9.9	9.9	10.1	10.2	10.4	10.5	10.5
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	7.0	6.7	6.8	6.8	6.8	6.8	6.8	6.8	6.8	6.8	6.8
Lower 95% PI	..	5.2	5.2	5.1	5.0	5.0	4.9	4.8	4.8	4.7	4.7
Upper 95% PI	..	8.9	9.1	9.3	9.6	9.6	9.8	9.9	10.0	10.2	10.2

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	5	4	4	4	4	4	4	4	4	4	4
5–9	1	1	1	1	1	1	2	2	2	2	2
10–14	0	9	9	10	10	10	10	10	10	10	10
15–19	29	32	32	33	33	33	34	34	34	35	35
20–24	80	66	68	70	71	72	72	72	72	73	74
25–29	96	94	94	94	95	97	99	102	104	105	106
30–34	110	104	106	107	106	105	103	102	103	104	105
35–39	95	88	87	87	89	91	93	95	95	95	93
40–44	86	71	72	72	72	72	71	71	71	72	74
45–49	47	51	52	53	54	55	56	57	58	58	57
50–54	44	40	40	41	41	42	42	43	44	45	46
55–59	17	30	32	34	35	36	36	36	36	37	37
60–64	18	23	23	24	26	27	29	31	32	33	34
65–69	23	19	19	20	21	22	22	23	24	25	27
70–74	23	18	18	18	18	18	19	19	20	21	22
75–79	11	15	16	16	16	17	17	17	17	17	17
80–84	13	10	11	11	12	12	13	13	14	14	14
85+	3	7	7	8	8	9	10	10	11	12	13
<b>Total</b>	<b>701</b>	<b>683</b>	<b>693</b>	<b>703</b>	<b>713</b>	<b>722</b>	<b>732</b>	<b>741</b>	<b>751</b>	<b>761</b>	<b>770</b>
Lower 95% PI	..	532	531	530	526	532	532	532	534	534	540
Upper 95% PI	..	897	926	958	994	1,006	1,035	1,063	1,086	1,115	1,129







Figure 46: Cancers of other male genital organs (ICD-10 C62-C63, C60), Australia

**Table 47: Cancers of the urinary tract (ICD-10 C64–C68), Australia, females**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	2.4	2.5	2.5	2.6	2.6	2.7	2.7	2.7	2.8	2.8	2.9
5–9	0.6	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4
10–14	0.2	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3
15–19	0.2	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.4	0.4	0.4
20–24	0.0	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.6	0.6
25–29	1.3	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1
30–34	1.9	1.9	2.0	2.0	2.0	2.0	2.1	2.1	2.1	2.2	2.2
35–39	2.8	3.5	3.5	3.5	3.6	3.6	3.7	3.7	3.7	3.8	3.8
40–44	5.5	5.7	5.7	5.7	5.8	5.8	5.8	5.9	5.9	5.9	5.9
45–49	10.2	9.0	9.0	9.0	9.0	9.0	9.0	9.0	9.0	9.1	9.1
50–54	15.4	14.5	14.4	14.4	14.4	14.4	14.3	14.3	14.3	14.3	14.3
55–59	22.0	23.5	23.5	23.4	23.4	23.4	23.3	23.3	23.2	23.2	23.2
60–64	32.8	37.3	37.2	37.2	37.2	37.2	37.2	37.2	37.2	37.1	37.1
65–69	53.0	55.0	55.1	55.2	55.2	55.3	55.4	55.5	55.5	55.6	55.7
70–74	78.2	73.7	73.9	74.1	74.3	74.5	74.7	74.9	75.1	75.3	75.5
75–79	91.8	89.7	90.0	90.3	90.6	90.9	91.2	91.5	91.8	92.1	92.4
80–84	109.5	101.9	102.2	102.5	102.9	103.2	103.5	103.9	104.2	104.5	104.9
85+	101.5	111.9	112.2	112.6	112.9	113.2	113.6	113.9	114.2	114.5	114.9
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	16.8	17.1	17.3	17.5	17.7	18.0	18.3	18.6	18.9	19.2	19.5
Lower 95% PI	..	14.7	14.8	14.9	15.1	15.3	15.4	15.6	15.8	16.1	16.3
Upper 95% PI	..	20.0	20.4	20.7	21.0	21.4	21.9	22.3	22.7	23.1	23.6
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	15.5	15.6	15.6	15.7	15.7	15.7	15.8	15.8	15.8	15.9	15.9
Lower 95% PI	..	13.4	13.4	13.4	13.4	13.4	13.3	13.3	13.3	13.2	13.2
Upper 95% PI	..	18.2	18.4	18.5	18.6	18.7	18.9	19.0	19.1	19.2	19.3
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	11.1	11.2	11.2	11.3	11.3	11.3	11.3	11.4	11.4	11.4	11.5
Lower 95% PI	..	9.7	9.6	9.6	9.6	9.6	9.6	9.6	9.6	9.5	9.5
Upper 95% PI	..	13.1	13.3	13.3	13.4	13.5	13.6	13.7	13.8	13.8	13.9

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	15	15	16	16	16	16	16	16	17	17	17
5–9	4	3	3	3	3	2	2	2	2	2	2
10–14	1	2	2	2	2	2	2	2	2	2	2
15–19	1	2	2	2	2	2	2	2	2	3	3
20–24	0	3	3	4	4	4	4	4	4	4	4
25–29	9	7	7	7	7	7	7	8	8	8	8
30–34	14	15	15	15	15	15	15	15	16	16	16
35–39	21	26	26	26	27	28	29	30	30	30	30
40–44	41	43	44	44	45	44	44	44	45	45	47
45–49	70	62	64	65	66	68	69	70	71	71	70
50–54	100	94	95	96	97	98	100	101	104	106	108
55–59	109	126	134	140	146	151	151	153	155	156	158
60–64	134	156	160	167	175	183	198	211	221	230	239
65–69	184	196	202	208	215	221	228	235	245	257	270
70–74	262	245	244	241	243	245	252	261	271	281	289
75–79	268	264	269	272	273	275	275	274	273	275	279
80–84	221	215	226	237	245	250	254	259	265	266	270
85+	186	213	221	230	241	257	271	285	299	314	329
<b>Total</b>	<b>1,640</b>	<b>1,688</b>	<b>1,730</b>	<b>1,776</b>	<b>1,822</b>	<b>1,871</b>	<b>1,922</b>	<b>1,974</b>	<b>2,027</b>	<b>2,083</b>	<b>2,141</b>
Lower 95% PI	..	1,453	1,481	1,514	1,551	1,588	1,620	1,659	1,701	1,743	1,785
Upper 95% PI	..	1,974	2,036	2,097	2,156	2,219	2,297	2,366	2,434	2,507	2,587







Figure 47: Cancers of the urinary tract (ICD-10 C64-C68), Australia, females

**Table 48: Cancers of the urinary tract (ICD-10 C64–C68), Australia, males**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7
5–9	0.1	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3
10–14	0.0	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3
15–19	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4
20–24	0.6	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7
25–29	0.7	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
30–34	3.0	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6
35–39	4.2	5.1	5.1	5.1	5.1	5.1	5.1	5.1	5.1	5.1	5.1
40–44	8.4	9.9	9.9	9.9	9.9	9.9	9.9	9.9	9.9	9.9	9.9
45–49	20.1	18.8	18.8	18.8	18.8	18.8	18.8	18.8	18.8	18.8	18.8
50–54	36.9	35.0	35.0	35.0	35.0	35.0	35.0	35.0	35.0	35.0	35.0
55–59	58.3	62.2	62.2	62.2	62.2	62.2	62.2	62.2	62.2	62.2	62.2
60–64	83.1	103.2	103.2	103.2	103.2	103.2	103.2	103.2	103.2	103.2	103.2
65–69	152.3	156.8	156.8	156.8	156.8	156.8	156.8	156.8	156.8	156.8	156.8
70–74	227.3	217.2	217.2	217.2	217.2	217.2	217.2	217.2	217.2	217.2	217.2
75–79	286.3	278.1	278.1	278.1	278.1	278.1	278.1	278.1	278.1	278.1	278.1
80–84	345.4	337.4	337.4	337.4	337.4	337.4	337.4	337.4	337.4	337.4	337.4
85+	388.2	398.7	398.7	398.7	398.7	398.7	398.7	398.7	398.7	398.7	398.7
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	39.2	40.6	41.3	41.9	42.7	43.5	44.4	45.2	46.1	47.0	48.0
Lower 95% PI	..	38.7	39.4	40.0	40.8	41.5	42.4	43.1	44.0	44.9	45.8
Upper 95% PI	..	42.7	43.4	44.1	44.8	45.7	46.6	47.5	48.4	49.3	50.4
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	43.5	44.2	44.2	44.2	44.2	44.2	44.2	44.2	44.2	44.2	44.2
Lower 95% PI	..	42.2	42.2	42.2	42.2	42.2	42.2	42.2	42.2	42.2	42.2
Upper 95% PI	..	46.5	46.5	46.4	46.4	46.4	46.4	46.5	46.4	46.4	46.4
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	29.8	30.5	30.5	30.5	30.5	30.5	30.5	30.5	30.5	30.5	30.5
Lower 95% PI	..	29.1	29.1	29.1	29.1	29.1	29.1	29.1	29.1	29.1	29.1
Upper 95% PI	..	32.3	32.2	32.2	32.2	32.2	32.2	32.3	32.2	32.2	32.2

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	11	11	11	11	11	11	11	11	11	11	11
5–9	1	2	2	2	2	2	2	2	2	2	2
10–14	0	2	2	2	2	2	2	2	2	2	2
15–19	3	3	3	3	3	3	3	3	3	3	3
20–24	4	5	5	5	5	5	5	5	5	5	5
25–29	5	9	9	9	9	9	9	9	10	10	10
30–34	22	19	19	19	19	19	19	18	18	19	19
35–39	31	37	37	37	37	39	39	40	40	40	39
40–44	62	74	75	76	76	75	75	74	74	75	77
45–49	136	129	131	134	137	140	143	145	146	146	145
50–54	241	228	229	230	233	236	239	243	249	254	260
55–59	299	342	363	378	390	401	401	403	406	411	417
60–64	344	441	454	472	494	517	556	590	614	635	653
65–69	511	540	558	578	601	619	641	660	689	721	756
70–74	690	661	657	652	651	661	682	707	735	766	791
75–79	651	649	669	685	697	707	711	709	710	713	728
80–84	443	463	492	524	547	569	587	608	629	644	658
85+	318	344	359	377	403	436	469	501	534	570	610
<b>Total</b>	<b>3,772</b>	<b>3,960</b>	<b>4,075</b>	<b>4,195</b>	<b>4,319</b>	<b>4,452</b>	<b>4,593</b>	<b>4,733</b>	<b>4,879</b>	<b>5,028</b>	<b>5,186</b>
Lower 95% PI	..	3,779	3,889	4,005	4,125	4,251	4,386	4,516	4,659	4,806	4,953
Upper 95% PI	..	4,164	4,284	4,406	4,535	4,675	4,821	4,974	5,122	5,274	5,444







Figure 48: Cancers of the urinary tract (ICD-10 C64-C68), Australia, males

**Table 49: Cancer of the eye (ICD-10 C69), Australia, females**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	1.1	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
5-9	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
10-14	0.3	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
15-19	0.0	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
20-24	0.5	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3
25-29	0.3	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4
30-34	0.7	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5
35-39	0.5	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6
40-44	0.9	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8
45-49	0.1	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
50-54	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
55-59	0.8	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
60-64	2.2	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.0
65-69	2.9	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4
70-74	2.4	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0
75-79	3.1	3.6	3.6	3.6	3.6	3.6	3.6	3.6	3.6	3.6	3.6
80-84	5.5	4.3	4.3	4.3	4.3	4.3	4.3	4.3	4.3	4.3	4.3
85+	2.7	5.1	5.1	5.1	5.1	5.1	5.1	5.1	5.1	5.1	5.1
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	1.0	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2
Lower 95% PI	..	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8
Upper 95% PI	..	1.6	1.7	1.7	1.7	1.7	1.7	1.7	1.8	1.8	1.8
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	0.9	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
Lower 95% PI	..	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7
Upper 95% PI	..	1.5	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	0.8	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9
Lower 95% PI	..	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6
Upper 95% PI	..	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	7	8	8	8	8	8	8	8	8	7	7
5-9	1	0	0	0	0	0	0	0	0	0	0
10-14	2	1	1	1	1	1	1	1	1	1	1
15-19	0	1	1	1	1	1	1	1	1	1	1
20-24	3	2	2	2	2	2	2	2	2	2	2
25-29	2	3	3	3	3	3	3	3	3	3	3
30-34	5	4	4	4	4	4	4	4	4	4	4
35-39	4	5	5	5	5	5	5	5	5	5	5
40-44	7	6	6	6	6	6	6	6	6	6	6
45-49	1	7	7	7	8	8	8	8	8	8	8
50-54	8	8	8	9	9	9	9	9	9	10	10
55-59	4	9	9	10	10	10	10	11	11	11	11
60-64	9	8	9	9	9	10	11	11	12	12	13
65-69	10	9	9	9	10	10	10	10	11	11	12
70-74	8	10	10	10	10	10	10	10	11	11	11
75-79	9	11	11	11	11	11	11	11	11	11	11
80-84	11	9	10	10	10	10	11	11	11	11	11
85+	5	10	10	10	11	12	12	13	13	14	15
<b>Total</b>	<b>96</b>	<b>110</b>	<b>112</b>	<b>114</b>	<b>116</b>	<b>119</b>	<b>121</b>	<b>123</b>	<b>126</b>	<b>128</b>	<b>131</b>
Lower 95% PI	..	75	76	78	79	80	82	83	85	86	89
Upper 95% PI	..	162	166	169	172	178	180	185	188	193	195







Figure 49: Cancer of the eye (ICD-10 C69), Australia, females

Table 50: Cancer of the eye (ICD-10 C69), Australia, males

Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
5-9	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
10-14	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
15-19	0.0	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
20-24	0.5	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3
25-29	0.3	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4
30-34	0.3	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6
35-39	0.5	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9
40-44	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
45-49	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
50-54	1.5	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.0
55-59	1.8	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6
60-64	1.9	3.4	3.4	3.4	3.4	3.4	3.4	3.4	3.4	3.4	3.4
65-69	8.6	4.4	4.4	4.4	4.4	4.4	4.4	4.4	4.4	4.4	4.4
70-74	4.3	5.5	5.5	5.5	5.5	5.5	5.5	5.5	5.5	5.5	5.5
75-79	4.8	6.7	6.7	6.7	6.7	6.7	6.7	6.7	6.7	6.7	6.7
80-84	6.2	8.0	8.0	8.0	8.0	8.0	8.0	8.0	8.0	8.0	8.0
85+	11.0	9.4	9.4	9.4	9.4	9.4	9.4	9.4	9.4	9.4	9.4
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	1.4	1.6	1.6	1.6	1.6	1.7	1.7	1.7	1.7	1.7	1.8
Lower 95% PI	..	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
Upper 95% PI	..	2.1	2.2	2.2	2.3	2.3	2.4	2.4	2.5	2.5	2.6
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7
Lower 95% PI	..	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.1	1.1
Upper 95% PI	..	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.5	2.5
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
Lower 95% PI	..	1.0	1.0	1.0	1.0	1.0	0.9	0.9	0.9	0.9	0.9
Upper 95% PI	..	1.8	1.8	1.8	1.8	1.9	1.9	1.9	1.9	1.9	1.9

Number of new cases 2001 and expected number of new cases 2002 to 2011

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	9	9	9	9	9	9	9	9	9	9	9
5-9	1	0	0	0	0	0	0	0	0	0	0
10-14	0	1	1	1	1	1	1	1	1	1	1
15-19	0	1	1	1	1	1	1	1	1	1	1
20-24	3	2	2	2	2	2	2	2	2	2	2
25-29	2	3	3	3	3	3	3	3	3	3	3
30-34	2	4	4	5	4	4	4	4	4	4	4
35-39	4	6	6	6	6	6	7	7	7	7	7
40-44	9	9	9	9	9	9	9	9	9	9	9
45-49	10	10	11	11	11	11	12	12	12	12	12
50-54	10	13	13	13	13	13	14	14	14	15	15
55-59	9	14	15	16	16	17	17	17	17	17	17
60-64	8	15	15	16	16	17	18	19	20	21	22
65-69	29	15	16	16	17	17	18	18	19	20	21
70-74	13	17	17	17	17	17	17	18	19	19	20
75-79	11	16	16	17	17	17	17	17	17	17	18
80-84	8	11	12	12	13	13	14	14	15	15	16
85+	9	8	8	9	9	10	11	12	13	13	14
<b>Total</b>	<b>137</b>	<b>154</b>	<b>158</b>	<b>161</b>	<b>165</b>	<b>169</b>	<b>173</b>	<b>177</b>	<b>182</b>	<b>186</b>	<b>190</b>
Lower 95% PI	..	117	118	120	122	122	124	126	128	130	133
Upper 95% PI	..	207	215	222	229	239	246	256	262	272	279







Figure 50: Cancer of the eye (ICD-10 C69), Australia, males

**Table 51: Cancers of the brain and central nervous system (ICD-10 C70–C72), Australia, females**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	4.3	4.2	4.2	4.2	4.2	4.2	4.2	4.2	4.2	4.2	4.2
5–9	2.0	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1
10–14	1.2	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.8
15–19	1.4	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
20–24	1.1	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7
25–29	2.7	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1
30–34	2.4	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7
35–39	2.4	3.3	3.3	3.3	3.3	3.3	3.3	3.3	3.3	3.3	3.3
40–44	5.4	4.1	4.2	4.2	4.2	4.2	4.2	4.2	4.2	4.2	4.2
45–49	4.8	5.4	5.4	5.4	5.4	5.4	5.5	5.5	5.5	5.5	5.5
50–54	8.5	7.4	7.4	7.4	7.4	7.4	7.4	7.4	7.4	7.4	7.4
55–59	7.9	10.3	10.3	10.3	10.3	10.3	10.3	10.3	10.3	10.3	10.3
60–64	14.0	13.8	13.8	13.8	13.8	13.8	13.8	13.8	13.8	13.8	13.8
65–69	16.7	17.2	17.2	17.2	17.2	17.2	17.2	17.2	17.2	17.2	17.2
70–74	20.3	19.5	19.5	19.5	19.5	19.5	19.5	19.5	19.5	19.5	19.5
75–79	22.6	20.3	20.3	20.4	20.4	20.4	20.4	20.4	20.4	20.4	20.5
80–84	19.3	20.0	20.0	20.0	20.1	20.1	20.1	20.2	20.2	20.2	20.2
85+	13.6	19.2	19.2	19.3	19.3	19.3	19.4	19.4	19.4	19.5	19.5
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	6.1	6.3	6.4	6.4	6.5	6.5	6.6	6.7	6.7	6.8	6.9
Lower 95% PI	..	5.2	5.2	5.2	5.2	5.2	5.3	5.3	5.3	5.4	5.4
Upper 95% PI	..	7.8	8.0	8.1	8.2	8.4	8.5	8.7	8.8	9.0	9.1
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	5.9	6.1	6.1	6.1	6.1	6.1	6.1	6.1	6.1	6.1	6.1
Lower 95% PI	..	5.0	5.0	5.0	4.9	4.9	4.9	4.9	4.8	4.8	4.8
Upper 95% PI	..	7.5	7.5	7.6	7.7	7.7	7.8	7.9	7.9	8.0	8.1
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	5.0	5.1	5.1	5.1	5.1	5.1	5.1	5.1	5.1	5.1	5.1
Lower 95% PI	..	4.2	4.2	4.2	4.2	4.2	4.1	4.1	4.1	4.1	4.0
Upper 95% PI	..	6.3	6.3	6.4	6.4	6.5	6.5	6.6	6.6	6.7	6.7

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	27	26	26	26	26	25	25	25	25	25	25
5–9	13	13	13	13	13	13	13	13	13	13	13
10–14	8	12	12	12	12	12	12	12	12	12	12
15–19	9	11	11	11	11	11	11	11	11	11	11
20–24	7	11	12	12	12	12	12	12	12	12	13
25–29	19	15	14	14	15	15	15	15	16	16	16
30–34	18	20	20	20	20	20	20	19	19	19	20
35–39	18	24	24	24	25	25	26	27	27	27	26
40–44	40	32	32	32	32	32	32	32	32	32	33
45–49	33	38	38	39	40	41	42	42	43	43	42
50–54	55	48	49	49	50	51	52	53	54	55	56
55–59	39	55	59	61	64	66	67	68	68	69	70
60–64	57	58	59	62	65	68	73	78	82	85	88
65–69	58	61	63	65	67	69	71	73	76	79	83
70–74	68	65	64	64	64	64	66	68	70	73	75
75–79	66	60	61	61	61	62	61	61	61	61	62
80–84	39	42	44	46	48	49	49	50	51	51	52
85+	25	37	38	39	41	44	46	49	51	53	56
<b>Total</b>	<b>599</b>	<b>628</b>	<b>640</b>	<b>653</b>	<b>666</b>	<b>680</b>	<b>694</b>	<b>708</b>	<b>723</b>	<b>738</b>	<b>754</b>
Lower 95% PI	..	516	522	530	537	545	553	561	572	581	589
Upper 95% PI	..	775	797	822	845	869	896	923	944	972	1,002







Figure 51: Cancers of the brain and central nervous system (ICD-10 C70-C72), Australia, females

**Table 52: Cancers of the brain and central nervous system (ICD-10 C70–C72), Australia, males**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	3.8	3.8	3.8	3.8	3.8	3.8	3.8	3.8	3.8	3.8	3.8
5–9	4.0	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5
10–14	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2
15–19	2.0	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5
20–24	2.9	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0
25–29	3.6	3.5	3.5	3.5	3.5	3.5	3.5	3.5	3.5	3.5	3.5
30–34	4.8	4.1	4.1	4.1	4.1	4.1	4.1	4.1	4.1	4.1	4.1
35–39	4.2	5.0	5.0	5.0	5.0	5.0	5.0	5.0	5.0	5.0	5.0
40–44	4.5	6.4	6.4	6.4	6.4	6.4	6.4	6.4	6.4	6.4	6.4
45–49	7.9	8.6	8.6	8.6	8.6	8.6	8.6	8.6	8.6	8.6	8.6
50–54	12.4	11.6	11.6	11.6	11.6	11.6	11.6	11.6	11.6	11.6	11.6
55–59	15.0	15.2	15.2	15.2	15.2	15.2	15.2	15.2	15.2	15.2	15.2
60–64	21.0	19.2	19.1	19.1	19.1	19.1	19.1	19.1	19.1	19.1	19.1
65–69	27.7	23.0	23.0	23.0	23.1	23.1	23.1	23.1	23.1	23.1	23.1
70–74	25.7	26.6	26.7	26.7	26.7	26.7	26.8	26.8	26.8	26.8	26.8
75–79	27.7	29.9	30.0	30.1	30.1	30.2	30.2	30.2	30.3	30.3	30.3
80–84	30.4	33.0	33.2	33.3	33.4	33.5	33.6	33.6	33.7	33.8	33.8
85+	31.7	36.1	36.4	36.6	36.7	36.9	37.0	37.1	37.2	37.3	37.4
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	8.5	8.6	8.7	8.8	8.9	9.0	9.1	9.2	9.3	9.4	9.5
Lower 95% PI	..	7.4	7.5	7.6	7.6	7.7	7.8	7.9	8.0	8.1	8.2
Upper 95% PI	..	10.1	10.2	10.3	10.4	10.5	10.6	10.8	10.9	11.0	11.2
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	8.9	8.9	8.9	8.9	8.9	8.9	8.9	8.9	8.9	8.9	8.9
Lower 95% PI	..	7.6	7.6	7.6	7.6	7.6	7.6	7.6	7.6	7.7	7.6
Upper 95% PI	..	10.5	10.5	10.5	10.5	10.5	10.5	10.5	10.5	10.5	10.5
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	7.4	7.4	7.4	7.4	7.4	7.4	7.4	7.4	7.4	7.4	7.4
Lower 95% PI	..	6.3	6.3	6.3	6.3	6.3	6.4	6.3	6.3	6.3	6.3
Upper 95% PI	..	8.6	8.6	8.6	8.6	8.6	8.6	8.6	8.7	8.6	8.7

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	25	25	25	25	24	24	24	24	24	24	24
5–9	28	17	17	17	17	17	17	17	17	17	17
10–14	15	15	15	16	16	16	16	16	15	15	15
15–19	14	17	17	17	18	18	18	18	18	18	18
20–24	19	20	21	21	22	22	22	22	22	22	22
25–29	25	24	24	24	24	25	25	26	26	26	27
30–34	35	30	31	31	31	30	30	29	29	30	30
35–39	31	36	36	36	37	38	39	39	39	39	38
40–44	33	48	49	49	49	49	48	48	48	49	50
45–49	53	59	60	61	62	64	65	66	67	67	66
50–54	81	75	76	76	77	78	79	80	82	84	86
55–59	77	84	89	92	95	98	98	98	99	100	102
60–64	87	82	84	88	92	96	103	109	114	118	121
65–69	93	79	82	85	88	91	94	97	101	106	111
70–74	78	81	81	80	80	81	84	87	91	95	98
75–79	63	70	72	74	75	77	77	77	77	78	79
80–84	39	45	48	52	54	56	58	61	63	64	66
85+	26	31	33	35	37	40	44	47	50	53	57
<b>Total</b>	<b>822</b>	<b>840</b>	<b>859</b>	<b>879</b>	<b>898</b>	<b>919</b>	<b>940</b>	<b>962</b>	<b>983</b>	<b>1,005</b>	<b>1,027</b>
Lower 95% PI	..	724	741	758	773	791	810	827	844	864	883
Upper 95% PI	..	982	1,003	1,026	1,052	1,076	1,100	1,127	1,154	1,178	1,206







Figure 52: Cancers of the brain and central nervous system (ICD-10 C70-C72), Australia, males

**Table 53: Cancers of thyroid and other endocrine glands (ICD-10 C73–C75), Australia, females**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	1.1	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9
5–9	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3
10–14	0.6	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2
15–19	2.3	2.7	2.8	2.9	2.9	3.0	3.0	3.1	3.2	3.2	3.3
20–24	6.5	5.5	5.6	5.8	6.0	6.1	6.3	6.4	6.6	6.7	6.9
25–29	7.4	9.0	9.3	9.6	9.9	10.2	10.5	10.8	11.1	11.4	11.7
30–34	12.3	12.2	12.7	13.2	13.6	14.1	14.6	15.1	15.5	16.0	16.5
35–39	13.3	14.4	15.0	15.6	16.3	16.9	17.5	18.1	18.7	19.3	19.9
40–44	14.9	15.5	16.2	16.9	17.6	18.2	18.9	19.6	20.3	21.0	21.6
45–49	14.6	15.8	16.5	17.2	17.9	18.5	19.2	19.9	20.6	21.3	22.0
50–54	17.4	15.4	16.1	16.8	17.4	18.1	18.7	19.4	20.1	20.7	21.4
55–59	11.9	14.8	15.4	16.0	16.6	17.2	17.8	18.4	19.0	19.6	20.2
60–64	14.9	13.9	14.4	14.9	15.5	16.0	16.6	17.1	17.6	18.2	18.7
65–69	10.7	12.8	13.3	13.8	14.2	14.7	15.1	15.6	16.0	16.5	17.0
70–74	11.6	11.8	12.2	12.5	12.9	13.3	13.6	14.0	14.4	14.7	15.1
75–79	14.0	10.8	11.0	11.3	11.6	11.8	12.1	12.4	12.6	12.9	13.2
80–84	11.9	9.8	9.9	10.1	10.3	10.4	10.6	10.8	10.9	11.1	11.3
85+	9.8	8.9	8.9	9.0	9.1	9.1	9.2	9.2	9.3	9.4	9.4
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	9.4	9.6	10.0	10.4	10.8	11.2	11.6	12.0	12.4	12.8	13.2
Lower 95% PI	..	8.5	8.7	8.9	9.0	9.2	9.2	9.3	9.3	9.3	9.3
Upper 95% PI	..	10.7	11.3	11.9	12.6	13.2	14.0	14.8	15.5	16.4	17.2
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	9.3	9.5	9.8	10.2	10.6	10.9	11.3	11.6	12.0	12.3	12.7
Lower 95% PI	..	8.4	8.6	8.7	8.8	8.9	9.0	9.0	9.0	9.0	8.9
Upper 95% PI	..	10.6	11.1	11.7	12.3	12.9	13.6	14.3	15.0	15.7	16.5
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	8.2	8.5	8.8	9.1	9.5	9.8	10.1	10.4	10.7	11.1	11.4
Lower 95% PI	..	7.6	7.7	7.8	7.9	8.0	8.1	8.1	8.1	8.0	8.0
Upper 95% PI	..	9.4	9.9	10.4	11.0	11.5	12.1	12.8	13.4	14.1	14.8

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	7	6	6	6	6	5	5	5	5	5	5
5–9	2	2	2	2	2	2	2	2	2	2	2
10–14	4	7	7	8	8	8	8	8	8	8	8
15–19	15	18	19	19	20	20	21	22	22	23	23
20–24	42	36	38	40	42	43	45	46	47	48	50
25–29	52	62	63	65	68	71	75	79	83	86	89
30–34	91	92	97	101	105	106	107	110	113	117	123
35–39	100	107	111	116	121	130	138	145	150	154	156
40–44	111	118	125	131	136	140	144	148	154	161	170
45–49	100	109	116	124	132	139	148	155	161	167	171
50–54	113	100	106	112	118	124	130	137	145	153	161
55–59	59	79	88	95	103	111	116	121	126	132	138
60–64	61	58	62	67	73	79	88	97	105	112	120
65–69	37	46	49	52	55	59	62	66	71	76	82
70–74	39	39	40	41	42	44	46	49	52	55	58
75–79	41	32	33	34	35	36	36	37	38	38	40
80–84	24	21	22	23	25	25	26	27	28	28	29
85+	18	17	18	18	19	21	22	23	24	26	27
<b>Total</b>	<b>916</b>	<b>950</b>	<b>1,000</b>	<b>1,055</b>	<b>1,109</b>	<b>1,164</b>	<b>1,219</b>	<b>1,276</b>	<b>1,333</b>	<b>1,392</b>	<b>1,451</b>
Lower 95% PI	..	840	869	901	924	951	971	985	999	1,010	1,017
Upper 95% PI	..	1,059	1,132	1,209	1,294	1,376	1,468	1,567	1,668	1,774	1,886







Figure 53: Cancers of thyroid and other endocrine glands (ICD-10 C73-C75), Australia, females

**Table 54: Cancers of thyroid and other endocrine glands (ICD-10 C73–C75), Australia, males**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	1.5	1.3	1.3	1.3	1.3	1.3	1.3	1.2	1.2	1.2	1.2
5–9	0.4	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5
10–14	0.0	0.8	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9
15–19	1.4	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.5	1.5
20–24	1.7	1.8	1.8	1.8	1.9	1.9	2.0	2.0	2.0	2.1	2.1
25–29	3.0	2.3	2.4	2.4	2.5	2.5	2.6	2.6	2.7	2.7	2.8
30–34	3.3	2.9	3.0	3.1	3.1	3.2	3.3	3.4	3.4	3.5	3.6
35–39	4.2	3.6	3.7	3.7	3.8	3.9	4.0	4.1	4.2	4.2	4.3
40–44	2.7	4.2	4.3	4.4	4.5	4.6	4.7	4.8	4.9	5.0	5.1
45–49	5.0	4.8	4.9	5.0	5.2	5.3	5.4	5.5	5.6	5.7	5.8
50–54	5.8	5.4	5.5	5.7	5.8	5.9	6.1	6.2	6.3	6.4	6.6
55–59	5.5	6.0	6.2	6.3	6.4	6.6	6.7	6.9	7.0	7.1	7.3
60–64	8.0	6.6	6.8	6.9	7.1	7.2	7.4	7.5	7.7	7.8	8.0
65–69	6.9	7.2	7.4	7.5	7.7	7.9	8.0	8.2	8.3	8.5	8.6
70–74	7.9	7.9	8.0	8.2	8.3	8.5	8.7	8.8	9.0	9.2	9.3
75–79	9.7	8.5	8.7	8.8	9.0	9.2	9.3	9.5	9.7	9.8	10.0
80–84	6.2	9.1	9.3	9.5	9.7	9.8	10.0	10.2	10.3	10.5	10.7
85+	12.2	9.8	10.0	10.2	10.3	10.5	10.7	10.8	11.0	11.2	11.4
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	3.6	3.6	3.7	3.8	3.9	4.0	4.2	4.3	4.4	4.5	4.6
Lower 95% PI	..	2.9	2.9	3.0	3.1	3.2	3.3	3.4	3.5	3.6	3.7
Upper 95% PI	..	4.4	4.5	4.6	4.7	4.8	5.0	5.1	5.2	5.3	5.5
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	3.7	3.7	3.8	3.8	3.9	4.0	4.1	4.2	4.2	4.3	4.4
Lower 95% PI	..	2.9	3.0	3.1	3.1	3.2	3.3	3.3	3.4	3.5	3.6
Upper 95% PI	..	4.5	4.6	4.6	4.7	4.8	4.9	5.0	5.1	5.2	5.2
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	3.2	3.2	3.3	3.3	3.4	3.4	3.5	3.6	3.6	3.7	3.8
Lower 95% PI	..	2.5	2.5	2.6	2.7	2.7	2.8	2.8	2.9	3.0	3.0
Upper 95% PI	..	3.9	4.0	4.0	4.1	4.2	4.2	4.3	4.4	4.5	4.5

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	10	8	8	8	8	8	8	8	8	8	8
5–9	3	3	3	3	3	3	3	3	3	3	3
10–14	0	6	6	6	6	6	6	6	7	7	7
15–19	10	9	9	9	10	10	10	10	11	11	11
20–24	11	12	13	13	14	14	14	15	15	15	16
25–29	21	16	16	17	17	18	19	19	20	21	21
30–34	24	22	23	23	24	24	24	24	25	25	26
35–39	31	26	27	27	28	30	31	32	33	33	33
40–44	20	31	33	34	35	35	35	36	37	38	40
45–49	34	33	34	36	37	39	41	42	44	44	45
50–54	38	35	36	37	39	40	41	43	45	47	49
55–59	28	33	36	38	40	42	43	44	46	47	49
60–64	33	28	30	32	34	36	40	43	46	48	50
65–69	23	25	26	28	30	31	33	34	37	39	42
70–74	24	24	24	25	25	26	27	29	30	32	34
75–79	22	20	21	22	23	23	24	24	25	25	26
80–84	8	13	14	15	16	17	17	18	19	20	21
85+	10	8	9	10	10	11	13	14	15	16	17
<b>Total</b>	<b>350</b>	<b>353</b>	<b>368</b>	<b>383</b>	<b>398</b>	<b>414</b>	<b>430</b>	<b>446</b>	<b>463</b>	<b>480</b>	<b>498</b>
Lower 95% PI	..	279	290	304	316	332	345	358	373	389	405
Upper 95% PI	..	427	445	461	479	495	514	534	553	571	591







Figure 54: Cancers of thyroid and other endocrine glands (ICD-10 C73-C75), Australia, males

**Table 55: Cancers of unknown primary site (ICD-10 C76–C80, C26, C39), Australia, females**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	0.3	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
5–9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
10–14	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
15–19	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
20–24	0.0	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3
25–29	0.3	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7
30–34	0.8	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
35–39	2.1	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4
40–44	4.7	4.0	4.0	4.0	4.0	4.0	4.0	4.0	4.0	4.0	3.9
45–49	7.2	6.5	6.5	6.5	6.5	6.5	6.5	6.5	6.5	6.4	6.4
50–54	10.0	10.6	10.5	10.5	10.5	10.4	10.4	10.4	10.4	10.3	10.3
55–59	16.9	16.8	16.7	16.7	16.6	16.6	16.5	16.4	16.4	16.3	16.3
60–64	28.4	26.3	26.2	26.1	26.0	25.9	25.8	25.7	25.6	25.5	25.4
65–69	37.5	40.4	40.2	40.1	40.0	39.8	39.7	39.6	39.4	39.3	39.2
70–74	62.7	60.8	60.7	60.6	60.4	60.3	60.2	60.0	59.9	59.7	59.6
75–79	82.5	90.1	90.0	90.0	89.9	89.8	89.7	89.7	89.6	89.5	89.5
80–84	121.4	131.3	131.4	131.5	131.6	131.8	131.9	132.0	132.1	132.3	132.4
85+	199.1	188.5	189.1	189.6	190.1	190.6	191.1	191.6	192.2	192.7	193.2
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	16.0	16.5	16.7	16.9	17.1	17.4	17.6	17.9	18.2	18.4	18.7
Lower 95% PI	..	15.2	15.4	15.5	15.7	16.0	16.1	16.3	16.5	16.7	16.9
Upper 95% PI	..	18.2	18.4	18.5	18.9	19.1	19.5	19.8	20.2	20.6	21.0
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	14.3	14.5	14.5	14.4	14.4	14.4	14.4	14.4	14.4	14.4	14.3
Lower 95% PI	..	13.3	13.3	13.3	13.2	13.2	13.2	13.1	13.1	13.0	12.9
Upper 95% PI	..	16.1	16.0	16.0	16.0	16.0	16.0	16.0	16.1	16.2	16.2
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	9.5	9.6	9.6	9.6	9.6	9.6	9.6	9.5	9.5	9.5	9.5
Lower 95% PI	..	8.8	8.8	8.8	8.7	8.7	8.7	8.7	8.6	8.5	8.5
Upper 95% PI	..	11.0	10.9	10.8	10.9	10.8	10.8	10.8	10.9	11.0	11.0

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	2	0	0	0	0	0	0	0	0	0	0
5–9	0	0	0	0	0	0	0	0	0	0	0
10–14	1	0	0	0	0	0	0	0	0	0	0
15–19	1	1	1	1	1	1	1	1	1	1	1
20–24	0	2	2	2	2	2	2	2	2	2	2
25–29	2	5	5	5	5	5	5	5	5	5	5
30–34	6	10	10	10	10	10	10	10	10	10	10
35–39	16	18	17	17	18	18	19	19	19	19	18
40–44	35	30	31	31	31	30	30	30	30	30	31
45–49	49	45	46	47	48	49	50	50	51	50	50
50–54	65	69	69	70	71	72	72	74	75	76	78
55–59	84	90	96	100	104	107	107	108	109	110	111
60–64	116	110	113	117	122	128	137	146	152	158	163
65–69	130	143	147	151	156	159	163	167	174	182	190
70–74	210	203	200	197	197	199	203	209	216	223	228
75–79	241	266	269	271	271	272	271	268	266	267	270
80–84	245	278	291	304	314	320	324	330	336	337	340
85+	365	359	371	387	406	432	457	480	502	528	554
<b>Total</b>	<b>1,568</b>	<b>1,630</b>	<b>1,669</b>	<b>1,713</b>	<b>1,756</b>	<b>1,804</b>	<b>1,852</b>	<b>1,900</b>	<b>1,948</b>	<b>1,998</b>	<b>2,052</b>
Lower 95% PI	..	1,499	1,538	1,578	1,613	1,657	1,696	1,736	1,772	1,807	1,849
Upper 95% PI	..	1,802	1,839	1,884	1,938	1,988	2,047	2,102	2,167	2,238	2,306







Figure 55: Cancers of unknown primary site (ICD-10 C76-C80, C26, C39), Australia, females

**Table 56: Cancers of unknown primary site (ICD-10 C76–C80, C26, C39), Australia, males**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.1	0.1	0.1	0.1
5–9	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
10–14	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
15–19	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
20–24	0.5	0.4	0.4	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3
25–29	0.9	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.6	0.6	0.6
30–34	1.1	1.3	1.2	1.2	1.2	1.2	1.2	1.2	1.1	1.1	1.1
35–39	3.1	2.3	2.2	2.2	2.2	2.1	2.1	2.1	2.0	2.0	2.0
40–44	4.4	4.1	4.0	3.9	3.9	3.8	3.7	3.7	3.6	3.5	3.5
45–49	8.9	7.4	7.3	7.2	7.0	6.9	6.8	6.7	6.5	6.4	6.3
50–54	10.9	13.4	13.2	13.0	12.8	12.6	12.3	12.1	11.9	11.7	11.5
55–59	22.8	23.6	23.3	23.0	22.6	22.3	22.0	21.7	21.3	21.0	20.7
60–64	41.1	39.7	39.2	38.8	38.3	37.9	37.4	37.0	36.5	36.1	35.7
65–69	61.4	62.8	62.3	61.7	61.2	60.6	60.1	59.6	59.1	58.5	58.0
70–74	95.2	93.9	93.3	92.8	92.2	91.6	91.1	90.5	90.0	89.4	88.9
75–79	142.1	133.7	133.2	132.7	132.2	131.8	131.3	130.8	130.3	129.9	129.4
80–84	173.1	183.9	183.7	183.4	183.2	182.9	182.7	182.4	182.1	181.9	181.6
85+	245.4	248.0	248.1	248.3	248.4	248.6	248.8	248.9	249.1	249.3	249.4
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	18.0	18.3	18.5	18.7	18.9	19.2	19.5	19.8	20.1	20.4	20.7
Lower 95% PI	..	16.2	16.4	16.6	16.8	17.1	17.3	17.6	17.8	18.1	18.4
Upper 95% PI	..	21.0	21.1	21.3	21.6	21.9	22.2	22.5	22.8	23.2	23.5
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	20.5	20.4	20.3	20.2	20.0	19.9	19.8	19.7	19.6	19.4	19.3
Lower 95% PI	..	18.2	18.1	18.0	17.9	17.8	17.7	17.6	17.5	17.4	17.3
Upper 95% PI	..	23.1	22.9	22.7	22.6	22.5	22.4	22.2	22.1	22.0	21.8
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	13.6	13.6	13.5	13.4	13.3	13.2	13.1	13.0	12.9	12.8	12.7
Lower 95% PI	..	11.9	11.8	11.7	11.6	11.6	11.5	11.4	11.3	11.2	11.2
Upper 95% PI	..	15.7	15.6	15.4	15.4	15.2	15.1	15.0	14.9	14.8	14.7

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	1	1	1	1	1	1	1	1	1	1	1
5–9	1	0	0	0	0	0	0	0	0	0	0
10–14	1	1	1	1	1	1	1	1	1	1	1
15–19	2	1	1	1	1	1	1	1	1	1	1
20–24	3	3	3	3	3	3	3	3	3	3	3
25–29	6	5	5	5	5	5	5	5	5	5	5
30–34	8	9	9	9	9	9	9	8	8	8	8
35–39	23	17	16	16	16	16	16	16	16	16	15
40–44	32	31	31	30	30	29	28	27	27	27	27
45–49	60	51	51	51	51	51	51	51	51	50	49
50–54	71	87	86	86	85	85	84	84	85	85	86
55–59	117	130	136	139	142	144	142	140	139	139	139
60–64	170	170	172	177	183	190	201	211	217	222	226
65–69	206	217	222	227	235	240	246	251	259	269	280
70–74	289	286	282	278	276	279	286	294	305	316	324
75–79	323	312	321	327	331	335	335	334	333	333	339
80–84	222	252	268	285	297	308	318	329	340	347	354
85+	201	214	223	235	251	272	293	313	333	356	381
<b>Total</b>	<b>1,736</b>	<b>1,786</b>	<b>1,828</b>	<b>1,872</b>	<b>1,918</b>	<b>1,968</b>	<b>2,020</b>	<b>2,071</b>	<b>2,125</b>	<b>2,179</b>	<b>2,238</b>
Lower 95% PI	..	1,577	1,618	1,661	1,699	1,747	1,792	1,841	1,888	1,937	1,992
Upper 95% PI	..	2,044	2,085	2,131	2,187	2,239	2,300	2,353	2,415	2,477	2,539







Figure 56: Cancers of unknown primary site (ICD-10 C76-C80, C26, C39), Australia, males

**Table 57: Cancers of lymphoid and haematopoietic tissue (ICD-10 C81–C96), Australia, females**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	8.0	8.0	8.0	8.0	8.0	8.0	8.0	8.1	8.1	8.1	8.1
5–9	5.8	5.7	5.7	5.7	5.8	5.8	5.8	5.8	5.8	5.8	5.8
10–14	5.6	5.1	5.2	5.2	5.2	5.2	5.3	5.3	5.3	5.3	5.4
15–19	5.4	7.1	7.1	7.2	7.2	7.3	7.3	7.4	7.4	7.4	7.5
20–24	8.9	8.3	8.3	8.4	8.4	8.5	8.5	8.6	8.6	8.6	8.7
25–29	8.8	8.2	8.3	8.3	8.4	8.4	8.5	8.5	8.6	8.6	8.6
30–34	7.3	8.9	9.0	9.0	9.1	9.1	9.2	9.2	9.2	9.3	9.3
35–39	10.8	11.3	11.4	11.4	11.5	11.6	11.6	11.7	11.7	11.8	11.8
40–44	13.8	16.0	16.1	16.2	16.3	16.3	16.4	16.5	16.5	16.6	16.7
45–49	23.6	23.2	23.3	23.5	23.6	23.7	23.8	23.9	24.0	24.1	24.2
50–54	36.7	33.5	33.7	33.9	34.0	34.2	34.3	34.5	34.6	34.7	34.8
55–59	49.8	48.0	48.3	48.5	48.7	48.9	49.1	49.3	49.4	49.6	49.7
60–64	62.2	68.3	68.5	68.8	69.1	69.3	69.6	69.8	70.0	70.2	70.4
65–69	94.0	94.9	95.3	95.7	96.1	96.4	96.7	97.0	97.3	97.5	97.7
70–74	118.9	126.5	127.1	127.7	128.3	128.8	129.3	129.7	130.1	130.5	130.9
75–79	149.7	159.7	160.7	161.6	162.5	163.4	164.2	164.9	165.6	166.3	166.9
80–84	177.9	192.5	194.1	195.6	197.0	198.4	199.6	200.8	201.9	202.9	203.9
85+	206.2	226.5	228.9	231.1	233.2	235.1	237.0	238.7	240.3	241.8	243.2
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	33.9	35.8	36.4	36.9	37.5	38.1	38.8	39.4	40.1	40.7	41.4
Lower 95% PI	..	32.8	33.3	33.8	34.3	34.9	35.5	36.2	36.7	37.3	37.9
Upper 95% PI	..	38.8	39.5	40.1	40.7	41.4	42.0	42.7	43.4	44.1	44.9
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	31.8	33.1	33.3	33.5	33.6	33.8	34.0	34.1	34.3	34.4	34.5
Lower 95% PI	..	30.3	30.5	30.6	30.8	31.0	31.2	31.3	31.4	31.6	31.7
Upper 95% PI	..	35.8	36.1	36.3	36.5	36.6	36.8	36.9	37.1	37.2	37.3
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	24.4	25.3	25.4	25.5	25.7	25.8	25.9	26.0	26.1	26.2	26.3
Lower 95% PI	..	23.1	23.3	23.4	23.5	23.6	23.7	23.9	24.0	24.0	24.1
Upper 95% PI	..	27.4	27.5	27.7	27.8	27.9	28.0	28.1	28.2	28.3	28.4

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	50	50	49	49	49	49	48	48	48	48	48
5–9	38	37	37	37	37	37	37	37	37	37	37
10–14	37	34	35	35	35	36	36	36	36	36	36
15–19	36	47	48	49	49	50	51	51	52	52	52
20–24	57	54	56	58	60	60	61	61	61	62	63
25–29	62	57	56	57	58	59	61	62	64	65	66
30–34	54	67	69	69	70	68	67	67	67	68	69
35–39	81	84	84	85	86	89	92	93	94	94	92
40–44	103	122	124	125	126	125	125	125	125	127	131
45–49	161	161	165	170	174	178	183	186	188	189	188
50–54	238	218	222	226	230	234	239	244	251	257	263
55–59	247	257	275	290	303	316	319	324	329	334	340
60–64	254	287	295	309	325	342	370	396	416	434	452
65–69	326	337	349	362	374	385	398	410	429	450	473
70–74	398	421	419	416	419	424	437	452	469	486	501
75–79	437	471	480	488	490	495	495	493	492	497	504
80–84	359	407	430	452	470	481	491	502	513	517	524
85+	378	432	450	472	498	533	566	598	628	662	697
<b>Total</b>	<b>3,316</b>	<b>3,542</b>	<b>3,641</b>	<b>3,748</b>	<b>3,853</b>	<b>3,963</b>	<b>4,074</b>	<b>4,185</b>	<b>4,299</b>	<b>4,415</b>	<b>4,536</b>
Lower 95% PI	..	3,245	3,331	3,427	3,528	3,628	3,731	3,839	3,941	4,046	4,156
Upper 95% PI	..	3,839	3,951	4,070	4,177	4,297	4,416	4,532	4,658	4,784	4,916







Figure 57: Cancers of lymphoid and haematopoietic tissue (ICD-10 C81-C96), Australia, females

**Table 58: Cancers of lymphoid and haematopoietic tissue (ICD-10 C81–C96), Australia, males**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	11.0	10.7	10.7	10.7	10.7	10.7	10.7	10.7	10.6	10.6	10.6
5–9	6.6	6.1	6.1	6.1	6.1	6.1	6.2	6.2	6.2	6.2	6.2
10–14	7.2	7.7	7.8	7.8	7.9	7.9	7.9	7.9	8.0	8.0	8.0
15–19	9.0	8.9	8.9	9.0	9.0	9.0	9.0	9.0	9.1	9.1	9.1
20–24	9.5	9.5	9.5	9.5	9.6	9.6	9.6	9.6	9.6	9.6	9.7
25–29	11.1	10.3	10.4	10.4	10.5	10.5	10.5	10.5	10.6	10.6	10.6
30–34	10.5	12.3	12.4	12.5	12.5	12.6	12.6	12.7	12.7	12.7	12.8
35–39	15.0	16.2	16.3	16.4	16.4	16.5	16.5	16.6	16.6	16.7	16.7
40–44	22.9	22.5	22.6	22.7	22.8	22.9	23.0	23.0	23.1	23.1	23.2
45–49	33.5	32.5	32.6	32.7	32.8	32.9	33.0	33.1	33.1	33.2	33.3
50–54	44.9	47.7	47.9	48.0	48.2	48.3	48.4	48.5	48.6	48.7	48.7
55–59	69.6	70.5	70.7	70.9	71.1	71.3	71.4	71.6	71.7	71.8	71.9
60–64	104.8	102.8	103.1	103.4	103.7	103.9	104.1	104.3	104.5	104.7	104.8
65–69	135.9	144.7	145.1	145.6	145.9	146.3	146.6	146.8	147.1	147.3	147.5
70–74	193.0	193.7	194.3	194.9	195.4	195.9	196.3	196.7	197.1	197.4	197.6
75–79	243.2	246.2	247.1	247.9	248.7	249.4	250.0	250.5	251.0	251.4	251.8
80–84	315.0	300.6	301.9	303.1	304.2	305.1	306.0	306.8	307.5	308.1	308.7
85+	319.8	359.0	360.8	362.5	364.0	365.4	366.6	367.7	368.7	369.6	370.4
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	44.6	46.0	46.8	47.6	48.4	49.2	50.1	51.0	51.9	52.8	53.8
Lower 95% PI	..	43.4	44.1	44.9	45.6	46.4	47.2	48.0	48.9	49.6	50.5
Upper 95% PI	..	48.8	49.7	50.4	51.3	52.3	53.3	54.3	55.2	56.3	57.3
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	48.2	49.1	49.3	49.5	49.6	49.8	49.9	50.0	50.1	50.2	50.3
Lower 95% PI	..	46.3	46.5	46.6	46.7	46.8	46.9	47.0	47.1	47.0	47.1
Upper 95% PI	..	52.1	52.3	52.5	52.7	52.9	53.1	53.2	53.3	53.6	53.6
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	36.3	36.9	37.1	37.2	37.3	37.4	37.5	37.6	37.6	37.7	37.8
Lower 95% PI	..	34.7	34.8	35.0	35.0	35.1	35.1	35.2	35.3	35.2	35.3
Upper 95% PI	..	39.3	39.5	39.6	39.7	39.9	40.1	40.1	40.2	40.4	40.5

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	72	70	69	69	69	68	68	68	67	67	67
5–9	46	42	42	42	42	42	42	41	41	41	41
10–14	50	54	55	56	56	57	57	57	57	56	56
15–19	62	62	62	63	64	65	65	66	67	68	68
20–24	63	64	66	68	69	70	70	70	71	71	72
25–29	78	71	71	71	72	74	76	77	79	80	81
30–34	76	92	94	94	94	93	92	91	91	93	94
35–39	111	119	118	119	121	125	128	130	131	131	129
40–44	168	169	173	175	175	174	174	173	174	176	181
45–49	226	222	227	233	238	244	250	255	257	258	256
50–54	293	310	313	316	320	326	331	337	346	354	362
55–59	357	388	413	431	446	460	460	464	469	474	482
60–64	434	439	453	473	496	521	561	597	622	644	663
65–69	456	499	516	536	560	578	599	619	646	678	711
70–74	586	589	588	585	586	596	616	640	667	697	720
75–79	553	575	595	611	623	634	639	639	641	645	659
80–84	404	412	440	470	493	514	532	553	574	588	602
85+	262	310	325	343	368	400	431	462	493	528	566
<b>Total</b>	<b>4,297</b>	<b>4,488</b>	<b>4,621</b>	<b>4,756</b>	<b>4,895</b>	<b>5,040</b>	<b>5,190</b>	<b>5,339</b>	<b>5,493</b>	<b>5,648</b>	<b>5,811</b>
Lower 95% PI	..	4,234	4,358	4,488	4,616	4,746	4,884	5,024	5,171	5,303	5,459
Upper 95% PI	..	4,761	4,903	5,045	5,195	5,356	5,521	5,680	5,841	6,023	6,192







Figure 58: Cancers of lymphoid and haematopoietic tissue (ICD-10 C81-C96), Australia, males

**Table 59: Non-Hodgkin lymphoma (ICD-10 C82-C85, C96), Australia, females**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	0.5	0.3	0.3	0.2	0.2	0.1	0.1	0.1	0.0	0.0	0.0
5-9	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
10-14	0.6	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9
15-19	1.2	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.6	1.6	1.6
20-24	2.3	2.1	2.1	2.1	2.2	2.2	2.2	2.2	2.3	2.3	2.3
25-29	1.7	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.4	2.4	2.4
30-34	2.4	2.6	2.6	2.7	2.7	2.7	2.8	2.8	2.8	2.9	2.9
35-39	4.1	4.3	4.4	4.4	4.5	4.5	4.5	4.6	4.6	4.7	4.7
40-44	7.0	8.1	8.1	8.2	8.3	8.3	8.4	8.4	8.5	8.6	8.6
45-49	13.9	13.6	13.7	13.8	13.9	14.0	14.1	14.2	14.3	14.4	14.5
50-54	21.1	20.3	20.5	20.7	20.8	20.9	21.1	21.2	21.3	21.4	21.5
55-59	27.2	28.2	28.4	28.6	28.9	29.1	29.2	29.4	29.6	29.8	29.9
60-64	35.0	38.2	38.5	38.8	39.1	39.4	39.7	40.0	40.2	40.5	40.7
65-69	50.4	51.2	51.7	52.2	52.6	53.1	53.5	53.9	54.3	54.7	55.1
70-74	60.9	66.6	67.3	68.0	68.7	69.4	70.0	70.6	71.2	71.8	72.4
75-79	72.9	81.2	82.3	83.4	84.4	85.4	86.3	87.3	88.2	89.0	89.9
80-84	86.7	92.5	94.1	95.6	97.1	98.5	99.8	101.1	102.4	103.6	104.8
85+	81.3	101.1	103.2	105.2	107.1	109.0	110.8	112.5	114.2	115.8	117.4
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	16.1	17.5	18.0	18.3	18.7	19.2	19.6	20.1	20.5	21.0	21.4
Lower 95% PI	..	16.5	16.9	17.3	17.7	18.2	18.6	19.0	19.4	19.9	20.3
Upper 95% PI	..	18.6	19.0	19.4	19.8	20.2	20.7	21.1	21.6	22.0	22.5
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	15.1	16.2	16.4	16.6	16.7	16.9	17.1	17.2	17.4	17.5	17.7
Lower 95% PI	..	15.3	15.5	15.7	15.9	16.0	16.2	16.3	16.5	16.7	16.8
Upper 95% PI	..	17.1	17.3	17.5	17.6	17.8	18.0	18.1	18.3	18.4	18.5
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	11.3	12.0	12.1	12.3	12.4	12.5	12.6	12.7	12.8	12.9	13.0
Lower 95% PI	..	11.4	11.5	11.6	11.8	11.9	12.0	12.1	12.2	12.3	12.4
Upper 95% PI	..	12.7	12.8	12.9	13.0	13.1	13.2	13.3	13.4	13.5	13.6

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	3	2	2	1	1	1	1	0	0	0	0
5-9	7	7	7	7	8	8	8	8	8	8	8
10-14	4	5	5	5	5	6	6	6	6	6	6
15-19	8	9	10	10	10	10	11	11	11	11	11
20-24	15	13	14	15	15	16	16	16	16	16	17
25-29	12	15	15	15	16	16	17	17	18	18	18
30-34	18	20	20	21	21	21	20	20	21	21	21
35-39	31	32	32	33	33	35	36	37	37	37	37
40-44	52	61	63	64	64	64	64	64	64	66	68
45-49	95	94	97	100	103	106	109	111	112	113	112
50-54	137	132	135	138	140	143	146	150	154	158	162
55-59	135	151	162	171	180	188	190	193	197	201	205
60-64	143	160	166	174	184	194	211	227	239	251	262
65-69	175	182	189	197	205	212	220	228	239	253	267
70-74	204	222	222	222	224	229	237	246	257	268	277
75-79	213	239	246	251	254	259	260	261	262	266	272
80-84	175	196	208	221	232	239	245	253	260	264	269
85+	149	193	203	215	229	247	265	282	299	317	336
<b>Total</b>	<b>1,576</b>	<b>1,735</b>	<b>1,796</b>	<b>1,860</b>	<b>1,924</b>	<b>1,992</b>	<b>2,060</b>	<b>2,129</b>	<b>2,200</b>	<b>2,272</b>	<b>2,348</b>
Lower 95% PI	..	1,635	1,693	1,755	1,820	1,886	1,949	2,015	2,084	2,155	2,229
Upper 95% PI	..	1,835	1,898	1,966	2,029	2,097	2,171	2,243	2,317	2,390	2,468







Figure 59: Non-Hodgkin lymphoma (ICD-10 C82-C85, C96), Australia, females

**Table 60: Non-Hodgkin lymphoma (ICD-10 C82–C85, C96), Australia, males**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
5–9	1.6	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
10–14	1.4	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.8
15–19	2.5	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5
20–24	3.0	3.1	3.2	3.2	3.2	3.2	3.2	3.2	3.2	3.2	3.2
25–29	4.4	4.1	4.1	4.1	4.2	4.2	4.2	4.1	4.1	4.1	4.1
30–34	5.5	5.7	5.8	5.8	5.8	5.8	5.8	5.8	5.8	5.8	5.8
35–39	6.7	8.4	8.4	8.4	8.4	8.5	8.5	8.5	8.5	8.5	8.5
40–44	13.2	12.3	12.3	12.3	12.4	12.4	12.4	12.4	12.4	12.4	12.4
45–49	18.7	17.8	17.9	17.9	18.0	18.0	18.0	18.0	18.0	18.0	18.0
50–54	25.4	25.5	25.6	25.7	25.7	25.8	25.8	25.8	25.8	25.8	25.8
55–59	33.1	36.0	36.1	36.2	36.2	36.3	36.3	36.3	36.3	36.3	36.3
60–64	51.2	49.6	49.7	49.8	49.8	49.8	49.9	49.8	49.8	49.8	49.7
65–69	65.9	65.9	66.0	66.0	66.1	66.0	66.0	65.9	65.8	65.7	65.6
70–74	83.3	83.9	83.9	83.9	83.9	83.8	83.7	83.5	83.4	83.1	82.9
75–79	97.2	102.4	102.4	102.4	102.3	102.2	102.0	101.8	101.5	101.2	100.9
80–84	133.3	121.0	121.1	121.2	121.1	121.0	120.8	120.5	120.2	119.8	119.4
85+	120.8	140.5	140.7	140.8	140.8	140.7	140.6	140.3	139.9	139.5	139.1
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	20.0	20.5	20.8	21.1	21.4	21.7	22.1	22.4	22.7	23.0	23.3
Lower 95% PI	..	18.2	18.5	18.8	19.1	19.4	19.7	19.9	20.2	20.5	20.8
Upper 95% PI	..	23.1	23.4	23.8	24.1	24.5	24.8	25.2	25.5	25.9	26.3
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	21.4	21.7	21.7	21.8	21.8	21.8	21.8	21.8	21.7	21.7	21.6
Lower 95% PI	..	19.3	19.3	19.3	19.3	19.4	19.4	19.3	19.3	19.3	19.2
Upper 95% PI	..	24.5	24.5	24.6	24.6	24.6	24.5	24.5	24.5	24.5	24.4
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	16.1	16.3	16.3	16.3	16.3	16.3	16.3	16.3	16.3	16.3	16.3
Lower 95% PI	..	14.4	14.5	14.5	14.5	14.5	14.5	14.5	14.5	14.5	14.4
Upper 95% PI	..	18.5	18.5	18.5	18.5	18.5	18.5	18.5	18.5	18.4	18.4

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	8	8	8	8	8	8	8	8	7	7	7
5–9	11	9	8	8	8	8	8	8	8	8	8
10–14	10	13	13	13	13	13	13	13	13	13	13
15–19	17	17	17	17	17	18	18	18	18	18	18
20–24	20	21	22	23	23	23	23	23	23	23	24
25–29	31	28	28	28	29	29	30	30	31	31	32
30–34	40	43	43	44	44	43	42	42	42	42	43
35–39	50	61	61	61	62	64	66	67	67	67	65
40–44	97	92	94	95	95	94	94	93	93	95	97
45–49	126	122	124	128	130	133	137	139	140	140	139
50–54	166	166	167	169	171	174	176	179	184	188	192
55–59	170	198	211	220	227	234	234	235	237	240	243
60–64	212	212	218	228	239	250	268	285	296	306	315
65–69	221	227	235	243	253	261	270	278	289	302	316
70–74	253	255	254	252	252	255	263	272	282	293	302
75–79	221	239	246	252	256	260	261	260	259	260	264
80–84	171	166	177	188	196	204	210	217	224	229	233
85+	99	121	127	133	142	154	165	176	187	199	213
<b>Total</b>	<b>1,923</b>	<b>1,999</b>	<b>2,055</b>	<b>2,110</b>	<b>2,167</b>	<b>2,225</b>	<b>2,285</b>	<b>2,343</b>	<b>2,403</b>	<b>2,462</b>	<b>2,523</b>
Lower 95% PI	..	1,779	1,830	1,878	1,928	1,983	2,037	2,088	2,143	2,196	2,248
Upper 95% PI	..	2,254	2,315	2,380	2,443	2,505	2,570	2,638	2,702	2,768	2,839







Figure 60: Non-Hodgkin lymphoma (ICD-10 C82-C85, C96), Australia, males

**Table 61: Leukaemia (ICD-10 C91–C95), Australia, females**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	7.5	7.7	7.8	7.8	7.9	7.9	7.9	8.0	8.0	8.1	8.1
5–9	4.6	4.3	4.3	4.3	4.3	4.3	4.3	4.3	4.3	4.3	4.3
10–14	3.9	3.1	3.1	3.1	3.1	3.1	3.1	3.1	3.1	3.1	3.1
15–19	1.1	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6
20–24	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3
25–29	3.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5
30–34	2.7	3.2	3.2	3.2	3.2	3.2	3.2	3.2	3.1	3.1	3.1
35–39	3.9	4.1	4.1	4.1	4.1	4.1	4.1	4.1	4.1	4.1	4.1
40–44	3.8	5.0	5.0	5.0	5.0	5.0	5.0	5.0	5.0	5.0	5.0
45–49	7.0	6.2	6.2	6.2	6.2	6.2	6.2	6.2	6.2	6.2	6.2
50–54	10.2	8.3	8.3	8.3	8.3	8.3	8.4	8.4	8.4	8.4	8.4
55–59	14.3	12.0	12.0	12.0	12.0	12.0	12.0	12.0	12.0	12.0	12.0
60–64	15.4	17.5	17.5	17.4	17.4	17.4	17.4	17.4	17.3	17.3	17.3
65–69	24.8	24.8	24.7	24.6	24.6	24.5	24.4	24.3	24.2	24.2	24.1
70–74	31.4	33.9	33.8	33.6	33.5	33.3	33.2	33.0	32.8	32.6	32.4
75–79	44.9	45.3	45.1	44.8	44.6	44.3	44.0	43.7	43.4	43.1	42.8
80–84	52.5	59.7	59.3	59.0	58.6	58.2	57.7	57.3	56.9	56.4	55.9
85+	80.7	77.8	77.3	76.8	76.3	75.7	75.2	74.6	74.0	73.4	72.8
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	10.7	10.9	11.0	11.1	11.1	11.2	11.3	11.4	11.4	11.5	11.6
Lower 95% PI	..	9.4	9.4	9.4	9.3	9.3	9.3	9.2	9.3	9.2	9.2
Upper 95% PI	..	12.5	12.6	12.8	13.0	13.1	13.3	13.5	13.6	13.8	14.0
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	10.0	10.1	10.1	10.1	10.0	10.0	10.0	10.0	9.9	9.9	9.9
Lower 95% PI	..	8.8	8.7	8.6	8.5	8.4	8.4	8.2	8.2	8.1	8.0
Upper 95% PI	..	11.5	11.5	11.5	11.6	11.6	11.6	11.7	11.7	11.7	11.7
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	8.0	8.0	8.0	8.0	8.0	8.0	8.0	7.9	7.9	7.9	7.9
Lower 95% PI	..	7.0	7.0	6.9	6.9	6.8	6.8	6.7	6.7	6.6	6.6
Upper 95% PI	..	9.0	9.0	9.1	9.1	9.1	9.1	9.2	9.1	9.2	9.2

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	47	48	48	48	48	48	48	48	48	48	48
5–9	30	28	28	28	28	28	28	28	27	27	27
10–14	26	21	21	21	21	21	21	21	21	21	21
15–19	7	17	17	17	18	18	18	18	18	18	18
20–24	15	15	16	16	17	17	17	17	17	17	17
25–29	25	17	17	17	17	18	18	18	19	19	19
30–34	20	24	24	24	24	24	23	23	23	23	23
35–39	29	30	30	30	31	31	32	33	33	33	32
40–44	28	38	39	39	39	39	38	38	38	39	40
45–49	48	43	44	45	46	47	48	48	49	49	48
50–54	66	54	55	55	56	57	58	59	61	62	63
55–59	71	64	68	72	75	78	78	79	80	81	82
60–64	63	73	75	78	82	86	93	99	103	107	111
65–69	86	88	90	93	96	98	101	103	107	112	117
70–74	105	113	111	110	109	110	112	115	118	122	124
75–79	131	134	135	135	134	134	133	131	129	129	129
80–84	106	126	131	136	140	141	142	143	144	144	144
85+	148	148	152	157	163	172	180	187	193	201	209
<b>Total</b>	<b>1,051</b>	<b>1,082</b>	<b>1,101</b>	<b>1,123</b>	<b>1,143</b>	<b>1,165</b>	<b>1,186</b>	<b>1,207</b>	<b>1,228</b>	<b>1,249</b>	<b>1,271</b>
Lower 95% PI	..	933	940	951	955	967	979	980	995	1,001	1,009
Upper 95% PI	..	1,231	1,262	1,295	1,331	1,362	1,393	1,434	1,461	1,497	1,533







Figure 61: Leukaemia (ICD-10 C91-C95), Australia, females

**Table 62: Leukaemia (ICD-10 C91–C95), Australia, males**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	9.6	9.5	9.5	9.5	9.5	9.5	9.5	9.5	9.4	9.4	9.4
5–9	4.8	4.2	4.2	4.2	4.2	4.2	4.2	4.2	4.2	4.2	4.2
10–14	3.8	3.8	3.8	3.8	3.9	3.9	3.9	3.9	3.9	3.9	3.9
15–19	3.3	3.4	3.4	3.4	3.4	3.4	3.4	3.4	3.4	3.5	3.5
20–24	2.7	3.0	3.1	3.1	3.1	3.1	3.1	3.1	3.1	3.2	3.2
25–29	2.9	3.1	3.1	3.1	3.1	3.2	3.2	3.2	3.2	3.2	3.2
30–34	3.4	3.6	3.6	3.6	3.7	3.7	3.7	3.7	3.8	3.8	3.8
35–39	4.6	4.6	4.6	4.7	4.7	4.7	4.8	4.8	4.8	4.9	4.9
40–44	5.9	6.2	6.2	6.3	6.3	6.4	6.4	6.5	6.5	6.5	6.6
45–49	8.1	8.7	8.8	8.8	8.9	8.9	8.9	9.0	9.0	9.0	9.1
50–54	11.5	12.9	13.0	13.0	13.1	13.1	13.1	13.2	13.2	13.2	13.2
55–59	20.9	20.1	20.1	20.2	20.2	20.2	20.2	20.2	20.2	20.2	20.2
60–64	31.4	31.7	31.7	31.6	31.6	31.6	31.6	31.6	31.5	31.5	31.5
65–69	41.7	48.2	48.2	48.1	48.0	48.0	47.9	47.8	47.7	47.6	47.5
70–74	71.5	68.6	68.5	68.4	68.3	68.2	68.1	67.9	67.7	67.5	67.4
75–79	91.9	90.4	90.3	90.3	90.2	90.0	89.9	89.7	89.5	89.2	89.0
80–84	116.2	112.2	112.2	112.2	112.2	112.1	112.0	111.8	111.6	111.4	111.1
85+	119.6	134.7	134.9	135.1	135.2	135.2	135.2	135.1	135.0	134.8	134.6
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	15.2	15.7	16.0	16.2	16.4	16.6	16.9	17.2	17.4	17.7	17.9
Lower 95% PI	..	14.3	14.5	14.7	14.9	15.2	15.4	15.6	15.8	16.1	16.3
Upper 95% PI	..	18.4	18.7	19.0	19.2	19.4	19.7	20.0	20.3	20.6	20.9
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	16.5	16.9	16.9	17.0	17.0	17.0	17.0	17.0	17.0	17.0	16.9
Lower 95% PI	..	15.4	15.4	15.4	15.5	15.5	15.5	15.5	15.4	15.4	15.4
Upper 95% PI	..	19.8	19.8	19.9	19.9	19.8	19.8	19.8	19.8	19.8	19.8
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	12.5	12.8	12.8	12.9	12.9	12.9	12.9	12.9	12.9	12.9	12.9
Lower 95% PI	..	11.6	11.6	11.6	11.6	11.7	11.6	11.7	11.6	11.6	11.6
Upper 95% PI	..	15.1	15.1	15.2	15.2	15.1	15.1	15.1	15.1	15.1	15.1

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0–4	63	62	62	61	61	60	60	60	60	60	59
5–9	33	29	29	29	29	29	28	28	28	28	28
10–14	26	27	27	27	28	28	28	28	28	27	27
15–19	23	23	24	24	24	25	25	25	25	26	26
20–24	18	21	21	22	22	23	23	23	23	23	24
25–29	20	21	21	21	22	22	23	23	24	24	25
30–34	25	27	27	28	28	27	27	27	27	28	28
35–39	34	34	34	34	35	36	37	38	38	38	38
40–44	43	46	48	48	49	49	48	48	49	50	51
45–49	55	60	61	63	64	66	68	69	70	70	70
50–54	75	84	85	86	87	88	90	91	94	96	98
55–59	107	111	118	122	127	130	130	131	132	134	136
60–64	130	135	139	145	151	159	170	181	188	194	199
65–69	140	166	171	177	184	190	196	201	210	219	229
70–74	217	209	207	205	205	208	214	221	229	238	245
75–79	209	211	217	222	226	229	230	229	229	229	233
80–84	149	154	164	174	182	189	195	202	208	213	217
85+	98	116	121	128	137	148	159	170	181	193	206
<b>Total</b>	<b>1,465</b>	<b>1,535</b>	<b>1,576</b>	<b>1,617</b>	<b>1,659</b>	<b>1,704</b>	<b>1,750</b>	<b>1,796</b>	<b>1,842</b>	<b>1,889</b>	<b>1,939</b>
Lower 95% PI	..	1,399	1,432	1,470	1,510	1,553	1,592	1,635	1,677	1,717	1,764
Upper 95% PI	..	1,796	1,848	1,900	1,945	1,988	2,044	2,096	2,152	2,204	2,264







Figure 62: Leukaemia (ICD-10 C91-C95), Australia, males

**Table 63: Cancers attributed to alcohol consumption, Australia, females**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
5-9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
10-14	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
15-19	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
20-24	0.5	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3
25-29	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
30-34	3.4	3.3	3.3	3.3	3.3	3.3	3.3	3.3	3.3	3.3	3.3
35-39	7.5	7.5	7.5	7.5	7.5	7.5	7.5	7.5	7.5	7.5	7.5
40-44	15.0	14.3	14.3	14.3	14.3	14.3	14.3	14.3	14.3	14.3	14.3
45-49	21.3	22.9	22.9	22.9	22.9	22.9	22.9	22.9	22.9	22.9	22.9
50-54	33.8	34.1	34.1	34.1	34.1	34.1	34.1	34.1	34.1	34.1	34.1
55-59	41.8	40.7	40.7	40.7	40.7	40.7	40.7	40.7	40.8	40.8	40.8
60-64	48.1	45.6	45.6	45.6	45.6	45.7	45.7	45.7	45.8	45.8	45.8
65-69	50.5	50.8	50.8	50.9	51.0	51.0	51.1	51.1	51.2	51.2	51.3
70-74	46.9	46.3	46.3	46.4	46.5	46.6	46.7	46.7	46.8	46.9	46.9
75-79	37.2	40.3	40.4	40.4	40.5	40.6	40.7	40.8	40.8	40.9	41.0
80-84	50.0	50.8	50.9	51.0	51.1	51.2	51.3	51.4	51.5	51.6	51.7
85+	57.0	54.2	54.3	54.4	54.5	54.6	54.7	54.8	54.8	54.9	55.0
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	16.5	16.7	16.9	17.1	17.3	17.6	17.8	18.1	18.3	18.5	18.8
Lower 95% PI	..	15.9	16.1	16.2	16.4	16.6	16.8	17.0	17.2	17.4	17.6
Upper 95% PI	..	17.6	17.9	18.1	18.4	18.6	18.9	19.2	19.5	19.8	20.1
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	16.0	15.9	16.0	16.0	16.0	16.0	16.0	16.0	16.0	16.0	16.0
Lower 95% PI	..	15.1	15.1	15.1	15.1	15.1	15.1	15.1	15.1	15.0	15.0
Upper 95% PI	..	16.8	16.9	16.9	16.9	16.9	17.0	17.0	17.1	17.1	17.2
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	12.6	12.6	12.6	12.6	12.6	12.6	12.6	12.6	12.6	12.6	12.6
Lower 95% PI	..	11.9	11.9	11.9	11.9	11.9	11.9	11.8	11.8	11.8	11.8
Upper 95% PI	..	13.3	13.3	13.3	13.3	13.4	13.4	13.4	13.4	13.5	13.5

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	0	0	0	0	0	0	0	0	0	0	0
5-9	0	0	0	0	0	0	0	0	0	0	0
10-14	0	0	0	0	0	0	0	0	0	0	0
15-19	0	1	1	1	1	1	1	1	1	1	1
20-24	3	2	2	2	2	2	2	2	2	2	2
25-29	7	8	8	8	8	8	8	8	8	8	8
30-34	25	25	26	26	26	25	25	24	24	24	25
35-39	56	56	55	55	56	58	59	60	60	60	59
40-44	112	109	110	111	111	110	109	108	108	110	113
45-49	145	159	162	165	169	172	176	178	179	179	178
50-54	219	222	224	227	230	234	237	242	247	252	257
55-59	207	218	232	243	254	263	264	268	271	275	279
60-64	196	191	196	205	215	225	243	260	272	283	294
65-69	175	180	186	192	199	204	210	216	226	237	248
70-74	157	154	153	151	152	153	158	163	169	175	180
75-79	109	119	120	122	122	123	123	122	121	122	124
80-84	101	107	113	118	122	124	126	128	131	131	133
85+	105	103	107	111	116	124	131	137	143	150	158
<b>Total</b>	<b>1,618</b>	<b>1,654</b>	<b>1,695</b>	<b>1,738</b>	<b>1,782</b>	<b>1,826</b>	<b>1,872</b>	<b>1,917</b>	<b>1,964</b>	<b>2,011</b>	<b>2,058</b>
Lower 95% PI	..	1,568	1,606	1,643	1,684	1,726	1,768	1,806	1,847	1,887	1,925
Upper 95% PI	..	1,745	1,789	1,840	1,887	1,933	1,982	2,037	2,090	2,144	2,202







Figure 63: Cancers attributed to alcohol consumption, Australia, females

**Table 64: Cancers attributed to alcohol consumption, Australia, males**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
5-9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
10-14	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
15-19	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
20-24	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.4
25-29	0.6	0.5	0.5	0.5	0.5	0.6	0.6	0.6	0.6	0.6	0.6
30-34	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.2	1.2
35-39	1.6	1.9	1.9	1.9	2.0	2.0	2.0	2.1	2.1	2.1	2.1
40-44	4.4	4.5	4.5	4.5	4.5	4.5	4.5	4.5	4.5	4.6	4.6
45-49	10.2	9.1	9.0	9.0	8.9	8.9	8.8	8.8	8.8	8.7	8.7
50-54	16.7	16.5	16.4	16.2	16.1	16.0	15.9	15.7	15.6	15.5	15.4
55-59	23.8	24.7	24.6	24.4	24.3	24.1	24.0	23.8	23.7	23.5	23.4
60-64	45.1	40.7	40.6	40.5	40.4	40.3	40.2	40.1	40.0	39.9	39.8
65-69	49.1	49.0	49.1	49.2	49.3	49.4	49.5	49.6	49.6	49.7	49.8
70-74	59.5	60.3	60.6	61.0	61.3	61.7	62.0	62.3	62.6	62.9	63.2
75-79	66.8	64.3	64.8	65.4	65.9	66.4	66.9	67.4	67.9	68.4	68.9
80-84	66.6	61.3	61.9	62.5	63.1	63.7	64.3	64.8	65.4	66.0	66.5
85+	55.6	61.7	62.4	63.0	63.6	64.2	64.8	65.4	65.9	66.5	67.1
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	12.2	12.1	12.3	12.5	12.7	12.9	13.2	13.5	13.7	14.0	14.3
Lower 95% PI	..	10.1	10.2	10.4	10.6	10.8	10.9	11.2	11.3	11.5	11.8
Upper 95% PI	..	14.6	15.0	15.2	15.5	15.8	16.2	16.5	16.9	17.2	17.5
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	12.9	12.7	12.7	12.7	12.8	12.8	12.8	12.9	12.9	12.9	12.9
Lower 95% PI	..	10.6	10.5	10.6	10.6	10.6	10.6	10.6	10.6	10.6	10.6
Upper 95% PI	..	15.4	15.5	15.6	15.6	15.7	15.8	15.9	15.9	16.0	16.0
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	9.6	9.3	9.4	9.4	9.4	9.4	9.4	9.4	9.4	9.5	9.5
Lower 95% PI	..	7.8	7.8	7.8	7.8	7.8	7.8	7.8	7.8	7.8	7.8
Upper 95% PI	..	11.3	11.4	11.4	11.5	11.5	11.6	11.6	11.6	11.7	11.7

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	0	0	0	0	0	0	0	0	0	0	0
5-9	0	0	0	0	0	0	0	0	0	0	0
10-14	0	0	0	0	0	0	0	0	0	0	0
15-19	0	1	1	1	1	1	1	1	1	1	1
20-24	2	2	2	2	2	2	2	2	2	3	3
25-29	4	3	3	4	4	4	4	4	5	5	5
30-34	8	7	7	8	8	8	8	8	8	8	9
35-39	12	14	14	14	15	15	16	16	16	17	16
40-44	32	34	34	34	35	34	34	34	34	35	36
45-49	69	62	63	64	65	66	67	68	68	68	67
50-54	109	107	107	107	107	108	108	109	111	113	114
55-59	122	136	144	148	152	156	154	154	155	155	157
60-64	187	174	178	185	193	202	216	229	238	245	252
65-69	165	169	175	181	189	195	202	209	218	229	240
70-74	181	183	183	183	184	188	195	203	212	222	230
75-79	152	150	156	161	165	169	171	172	174	176	180
80-84	85	84	90	97	102	107	112	117	122	126	130
85+	46	53	56	60	64	70	76	82	88	95	103
<b>Total</b>	<b>1,173</b>	<b>1,179</b>	<b>1,214</b>	<b>1,249</b>	<b>1,286</b>	<b>1,324</b>	<b>1,367</b>	<b>1,409</b>	<b>1,452</b>	<b>1,496</b>	<b>1,542</b>
Lower 95% PI	..	988	1,011	1,040	1,069	1,102	1,132	1,167	1,201	1,235	1,276
Upper 95% PI	..	1,426	1,477	1,521	1,568	1,616	1,676	1,727	1,785	1,844	1,895







Figure 64: Cancers attributed to alcohol consumption, Australia, males

**Table 65: Cancers attributed to smoking, Australia, females**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
5-9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
10-14	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
15-19	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
20-24	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
25-29	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
30-34	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
35-39	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
40-44	4.3	3.6	3.6	3.6	3.6	3.6	3.6	3.6	3.5	3.5	3.5
45-49	11.3	11.4	11.4	11.4	11.4	11.4	11.4	11.4	11.4	11.4	11.4
50-54	25.6	27.6	27.6	27.6	27.6	27.7	27.7	27.7	27.7	27.7	27.7
55-59	54.2	49.8	49.8	49.8	49.8	49.8	49.8	49.8	49.8	49.8	49.8
60-64	77.9	79.5	79.6	79.7	79.8	79.9	80.0	80.0	80.1	80.1	80.2
65-69	119.2	124.4	125.0	125.6	126.2	126.8	127.3	127.7	128.2	128.6	129.0
70-74	171.5	179.2	180.8	182.3	183.7	185.0	186.3	187.5	188.6	189.6	190.6
75-79	187.5	189.9	192.0	194.0	195.9	197.8	199.5	201.1	202.6	204.1	205.4
80-84	176.3	169.7	171.5	173.1	174.7	176.2	177.6	178.9	180.1	181.3	182.4
85+	157.8	165.2	166.6	167.8	169.0	170.1	171.1	172.1	173.0	173.9	174.7
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	31.1	31.9	32.5	33.0	33.5	34.1	34.8	35.5	36.2	36.9	37.7
Lower 95% PI	..	27.4	27.8	28.3	28.8	29.2	29.9	30.4	31.1	31.7	32.4
Upper 95% PI	..	37.4	38.2	38.6	39.3	40.1	40.8	41.6	42.3	43.2	44.0
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	28.9	29.4	29.5	29.7	29.9	30.0	30.2	30.3	30.5	30.6	30.7
Lower 95% PI	..	25.3	25.4	25.6	25.7	25.7	25.9	26.0	26.1	26.2	26.4
Upper 95% PI	..	34.2	34.6	34.7	35.0	35.3	35.4	35.6	35.7	35.9	35.9
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	20.5	20.7	20.8	21.0	21.1	21.2	21.3	21.3	21.4	21.5	21.6
Lower 95% PI	..	18.1	18.1	18.3	18.3	18.4	18.5	18.5	18.6	18.7	18.8
Upper 95% PI	..	23.9	24.1	24.2	24.4	24.5	24.6	24.7	24.8	24.9	24.9

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	0	0	0	0	0	0	0	0	0	0	0
5-9	0	0	0	0	0	0	0	0	0	0	0
10-14	0	0	0	0	0	0	0	0	0	0	0
15-19	0	0	0	0	0	0	0	0	0	0	0
20-24	0	0	0	0	0	0	0	0	0	0	0
25-29	0	0	0	0	0	0	0	0	0	0	0
30-34	0	0	0	0	0	0	0	0	0	0	0
35-39	0	0	0	0	0	0	0	0	0	0	0
40-44	32	27	27	28	28	27	27	27	27	27	28
45-49	77	79	80	82	84	86	88	89	89	89	89
50-54	166	179	181	184	187	189	192	196	201	205	209
55-59	269	267	284	298	310	322	323	327	332	336	341
60-64	318	334	343	358	375	394	426	454	476	496	515
65-69	413	442	457	475	492	507	524	540	565	594	625
70-74	574	597	596	594	600	610	629	653	680	707	729
75-79	547	560	573	585	590	599	601	601	602	610	621
80-84	356	359	380	400	417	428	436	447	457	462	469
85+	289	315	327	343	361	386	409	431	452	476	501
<b>Total</b>	<b>3,042</b>	<b>3,157</b>	<b>3,249</b>	<b>3,346</b>	<b>3,444</b>	<b>3,547</b>	<b>3,656</b>	<b>3,766</b>	<b>3,882</b>	<b>4,002</b>	<b>4,126</b>
Lower 95% PI	..	2,710	2,782	2,874	2,955	3,038	3,137	3,230	3,336	3,435	3,550
Upper 95% PI	..	3,696	3,816	3,916	4,035	4,164	4,284	4,415	4,541	4,685	4,819







Figure 65: Cancers attributed to smoking, Australia, females

**Table 66: Cancers attributed to smoking, Australia, males**

**Age-specific and age-standardised incidence rates (per 100,000), observed 2001 and projected 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
5-9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
10-14	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
15-19	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
20-24	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
25-29	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
30-34	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
35-39	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
40-44	7.4	7.1	7.0	6.9	6.8	6.7	6.6	6.6	6.5	6.4	6.3
45-49	27.2	26.9	26.4	25.8	25.3	24.8	24.3	23.8	23.3	22.8	22.4
50-54	57.7	57.1	55.6	54.1	52.7	51.3	50.0	48.8	47.5	46.3	45.2
55-59	121.8	119.3	116.5	113.9	111.3	108.7	106.3	103.9	101.5	99.3	97.1
60-64	225.2	223.4	219.6	215.9	212.3	208.8	205.3	201.8	198.5	195.2	191.9
65-69	357.5	356.2	352.1	348.1	344.1	340.1	336.2	332.3	328.5	324.7	320.9
70-74	505.2	494.6	490.9	487.3	483.6	479.9	476.3	472.7	469.1	465.5	461.9
75-79	580.8	576.6	574.3	571.9	569.4	567.0	564.6	562.1	559.6	557.2	554.7
80-84	660.4	623.6	623.1	622.6	622.1	621.5	621.0	620.4	619.7	619.1	618.4
85+	583.4	637.2	638.8	640.2	641.7	643.1	644.5	645.9	647.2	648.6	649.9
<b>Rates per 100,000 for all ages combined with 95% prediction intervals (95% PI)</b>											
Crude	78.4	79.0	79.5	80.0	80.6	81.3	82.2	83.1	84.0	85.0	86.1
Lower 95% PI	..	71.4	71.7	72.3	72.8	73.6	74.4	75.1	76.1	77.0	78.0
Upper 95% PI	..	88.1	88.8	89.2	89.9	90.6	91.7	92.7	93.6	94.6	95.6
<b>Age-standardised rates (ASR), standardised to the Australian Standard Population 2001 (A2001)</b>											
ASR (A2001)	86.1	85.4	84.7	83.9	83.2	82.4	81.7	81.0	80.3	79.6	78.9
Lower 95% PI	..	77.8	77.0	76.4	75.7	75.1	74.5	73.7	73.2	72.7	72.1
Upper 95% PI	..	94.5	93.8	92.8	92.0	91.1	90.3	89.7	88.7	87.9	87.1
<b>Age-standardised rates (ASR), standardised to the WHO World Standard Population 2000 (W2000)</b>											
ASR (W2000)	59.4	58.8	58.2	57.6	57.0	56.4	55.8	55.2	54.7	54.1	53.6
Lower 95% PI	..	52.7	52.0	51.6	51.1	50.6	50.0	49.5	49.1	48.6	48.2
Upper 95% PI	..	66.1	65.6	64.8	64.1	63.3	62.7	62.2	61.4	60.8	60.1

**Number of new cases 2001 and expected number of new cases 2002 to 2011**

Age group	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
0-4	0	0	0	0	0	0	0	0	0	0	0
5-9	0	0	0	0	0	0	0	0	0	0	0
10-14	0	0	0	0	0	0	0	0	0	0	0
15-19	0	0	0	0	0	0	0	0	0	0	0
20-24	0	0	0	0	0	0	0	0	0	0	0
25-29	0	0	0	0	0	0	0	0	0	0	0
30-34	0	0	0	0	0	0	0	0	0	0	0
35-39	0	0	0	0	0	0	0	0	0	0	0
40-44	55	54	54	53	53	51	50	49	49	48	49
45-49	183	184	184	184	184	184	184	183	181	177	172
50-54	376	372	363	356	351	346	342	339	338	337	335
55-59	625	656	681	692	698	702	685	673	663	655	650
60-64	932	955	965	988	1,017	1,047	1,105	1,154	1,181	1,201	1,215
65-69	1,200	1,227	1,253	1,283	1,319	1,344	1,374	1,400	1,443	1,494	1,547
70-74	1,534	1,505	1,486	1,462	1,450	1,461	1,495	1,538	1,588	1,643	1,683
75-79	1,320	1,347	1,382	1,409	1,427	1,441	1,443	1,434	1,430	1,429	1,452
80-84	847	855	908	966	1,009	1,047	1,080	1,118	1,156	1,182	1,206
85+	478	550	575	606	649	703	758	812	866	927	993
<b>Total</b>	<b>7,550</b>	<b>7,705</b>	<b>7,850</b>	<b>7,999</b>	<b>8,156</b>	<b>8,326</b>	<b>8,515</b>	<b>8,700</b>	<b>8,895</b>	<b>9,094</b>	<b>9,304</b>
Lower 95% PI	..	6,961	7,080	7,227	7,369	7,531	7,699	7,857	8,049	8,235	8,436
Upper 95% PI	..	8,592	8,771	8,921	9,097	9,275	9,491	9,710	9,904	10,117	10,338







Figure 66: Cancers attributed to smoking, Australia, males

# Appendix A: Data sources and issues

## National Cancer Statistics Clearing House (NCSCH)

Numbers of new cases of cancer from 1982 to 2001 used in the projections in this report are sourced from the National Cancer Statistics Clearing House (NCSCH), a national database maintained by the AIHW.

Cancer is a notifiable disease in all Australian states and territories. The data are collected by cancer registries and include clinical and demographic information about people with newly diagnosed cancer. This information is obtained from hospitals, pathologists, radiation oncologists, cancer treatment centres and nursing homes.

The state and territory cancer registries are members of the Australasian Association of Cancer Registries (AACR) and provide data annually to the AIHW, which is responsible for the national collection of cancer incidence statistics through the NCSCH. National statistics are currently available for all years from 1982 to 2001 and are published annually, the most recent publication being *Cancer in Australia 2001* (AIHW & AACR 2004).

## Cancers not included in the projections

The NCSCH does not include non-melanoma skin cancers (NMSC), as they are not required to be reported to the cancer registries. These are the most common cancers diagnosed in Australia, but only rarely result in mortality (AIHW & AACR 2004). The most common forms of NMSC are basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). In 2001, there were an estimated 112,000 females and 144,000 males treated for BCC and 47,000 females and 71,000 males treated for SCC (NCCI 2003).

These cancers are usually diagnosed and treated outside hospitals by general practitioners and dermatologists and in skin cancer clinics (NCCI 2003), but they are not legally notifiable and are not routinely registered by all state and cancer registries. The ICD-10 code (WHO 1992) for NMSC is C44 and these cancers have been excluded from the projections, owing to the lack of complete data.

A number of chronic myeloproliferative and myelodysplastic syndromes with ICD-10 codes in the range D45–D47, formerly considered to be disorders of uncertain behaviour, have recently become recognised as cancers. The NCSCH does not yet have complete coverage of these cancers, for reasons outlined in the following section, so they have also been excluded from the projections.

## Impact of coding and reporting changes

Cancers are registered and coded using the International Classification of Diseases for Oncology (ICD-O); either the second edition, ICD-O-2 (WHO 1990) or the third edition, ICD-O-3 (WHO 2000). In both editions of ICD-O, neoplasms (tumours) are coded by both morphology (tumour type and behaviour) and topography (site).

The AACR has agreed that all state and territory cancer registries will eventually code in ICD-O-3. By the time of reporting 2001 cancer data, only four states and territories

(Australian Capital Territory, New South Wales, Tasmania and Western Australia) had made the transition to ICD-O-3 and a complete recode of all historical cancers is still being completed for some states and territories.

In this report, cancers are tabulated and reported using the ICD-10 codes (WHO 1992) shown in Table 2 for females and in Table 4 for males. ICD-O morphology and topography codes are summarised using a single code in ICD-10.

In ICD-O-2, all malignant neoplasms (cancers) corresponded to an ICD-10 code in the range C00–C97, and benign and in situ neoplasms and other neoplasms of unknown or uncertain behaviour corresponded to an ICD-10 code in the range D00–D48.

In ICD-O-3, some neoplasms previously considered to be of uncertain behaviour are now coded as malignant (for a list, refer to Threlfall & Thompson 2004, p. 61). In ICD-10, these neoplasms correspond to a code in the range D45–D47, which also includes some non-malignant neoplasms. ICD-10 codes in the range D45–D47 include polycythaemia vera (D45), myelodysplastic syndromes (D46) and other neoplasms of uncertain or unknown behaviour of lymphoid, haematopoietic and related tissue (D47).

Only cancers (malignant neoplasms) are included in the projections, and because the coverage of cancers in the range D45–D47 is not yet complete in the NCSCH, these conditions have not been included in the projections.

The four states that reported 2001 cancer data in ICD-O-3 represent a total of 47.7% of the 2001 Australian population. These states reported a total of 218 cancers with ICD-10 codes in the range D45–D47 in 2001.

For the states and territories that already code in ICD-O-3, rules for multiple primaries (which apply to persons with more than one neoplasm present) have resulted in some cancers that were formerly reported as leukaemia in ICD-10 (codes C91–C95) being no longer reported, because of prior incidence of one of the above conditions in the range D45–D47.

A study of cases registered in 2002 by the WA Cancer Registry (Threlfall & Thompson 2004, p. 61) found that in addition to the 221 cases of leukaemia reported, there were 12 further cases not reported because of prior incidence of one of the above conditions. So out of a total of 233 that would formerly have been reported in the range C91–C95 in ICD-10, 12 (5%) will no longer be reported. The transition to ICD-O-3 may lead to similar declines in the number of cancers reported in the range C91–C95 in other states and territories.

Conversely, a number of neoplasms, particularly ovarian neoplasms, considered to be malignant in ICD-O-2 are now considered to be of uncertain behaviour in ICD-O-3 (for a list, refer to Appendix 6 of ICD-O-3, WHO 2000, p. 240). In addition, some previously recorded papillary transitional cell neoplasms of the bladder may be reclassified as non-malignant in the transition to ICD-O-3 (Thursfield et al. 2004), although such neoplasms may later progress to become malignant.

As a result, the number of cases of some cancers, particularly ovarian cancer and bladder cancer (included in cancers of the urinary tract) may be currently overstated in the NCSCH and hence the projections for these cancers will also be overstated. Work has not yet been completed to quantify the effect (if any) of these changes.

## ABS population estimates and projections

Data on estimated resident population (ERP) from 1982 to 2003 used in this report were sourced from the Australian Bureau of Statistics (ABS 2003b). The AIHW preferred series (series 8) of the ABS population projections (ABS 2003c) was used to provide estimates of ERP from 2004 to 2011.

The AIHW has examined the most recent ABS population projections and has determined that series 8 is the most appropriate to use. This series assumes a continuation of past trends of rapidly declining rates of mortality. The alternative ABS mortality scenario assumes a slow-down in the rate of decline in mortality; there is no evidence of this occurring. Different ABS scenarios for fertility and migration will have little impact on the older age groups in which cancer incidence predominates.

Full details of the ABS population estimates and projections used are shown in the internet-only tables that accompany this report on the AIHW website <[www.aihw.gov.au](http://www.aihw.gov.au)>.

The standard populations used to produce age-standardised rates (see Appendix B) are shown in Table A1.

**Table A1: Standard populations: Australia 2001 and WHO 2000**

Age group	Australian Standard Population 2001 (A2001)		WHO World Standard Population 2000 (W2000)	
	Number	% of total	Number	% of total
0-4	1,282,357	6.6	8.86	8.9
5-9	1,351,664	7.0	8.69	8.7
10-14	1,353,177	7.0	8.60	8.6
15-19	1,352,745	7.0	8.47	8.5
20-24	1,302,412	6.7	8.22	8.2
25-29	1,407,081	7.2	7.93	7.9
30-34	1,466,615	7.6	7.61	7.6
35-39	1,492,204	7.7	7.15	7.1
40-44	1,479,257	7.6	6.59	6.6
45-49	1,358,594	7.0	6.04	6.0
50-54	1,300,777	6.7	5.37	5.4
55-59	1,008,799	5.2	4.55	4.5
60-64	822,024	4.2	3.72	3.7
65-69	682,513	3.5	2.96	3.0
70-74	638,380	3.3	2.21	2.2
75-79	519,356	2.7	1.52	1.5
80-84	330,050	1.7	0.91	0.9
85+	265,235	1.4	0.63	0.6
<b>Total</b>	<b>19,413,240</b>	<b>100.0</b>	<b>100.03</b>	<b>100.0</b>

Source: A2001—ABS 2003a; W2000—Ahmad et al. 2000.

# Appendix B: Statistical methods

## Cancer incidence rates and summary measures

For examples of how to calculate the following rates, see Appendix B of *Cancer in Australia 2001* (AIHW & AACR 2004). All rates are expressed as annual rates per 100,000 population.

### Age-specific rates

An age-specific rate is defined as the number of events for a specified age group over a specified period (for example, a year) divided by the total population at risk of the event in that age group. The age-specific cancer incidence rates for females and males in this report were calculated by dividing the number of new cases of cancer in a year by the corresponding estimated resident population (ERP) in the same age group at 30 June of that year.

### Crude rates

A crude rate is a summary rate across all age groups that is defined as the number of events divided by the total population at risk of the event over a specified period (for example, a year). For example, the crude cancer incidence rate for Australian males in 2001 is defined as the total number of new cases of cancer occurring among males in 2001 across all age groups divided by the total Australian male ERP at 30 June 2001.

### Age-standardised rates (ASR)

Age-standardised rates are summary rates across all age groups that enable comparisons to be made between populations which have different age structures. This report uses direct standardisation, in which the age-specific rates are multiplied by a constant population, which effectively removes the influence of the age structure on the summary rate.

In this report, rates are age-standardised to two standards, the 2001 Australian total ERP (ABS 2003a) as advocated by the National Health Data Committee (NHDC) for use in Australian health statistics and the new world standard population advocated by the World Health Organization (WHO) for use in international comparisons (Ahmad et al. 2000). These two standards are shown in Table A1 in Appendix A.

The method used for all the calculations of age-standardised rates consists of three steps:

- Step 1* Calculate the age-specific rate (as above) for each age group.
- Step 2* Calculate the expected number of cases in each 5-year age group by multiplying the age-specific rates by the corresponding standard population and dividing by 100,000, giving the expected number of cases.
- Step 3* To give the age-standardised rate, sum the expected number of cases across all age groups. Divide this sum by the total of the standard population used in the calculation and multiply by 100,000.

## Projection of the age-standardised rates

### Methods for projecting cancer incidence rates

Previous AIHW projections of cancer incidence (AIHW & AACR 1998; AIHW & AACR: Jelfs et al. 1996) relied on projecting the age-specific rates using separate models for each age group. Although this works well for the most common cancers, there can be problems with rarer cancers where the trends in the age-specific rates may be highly volatile, especially at younger ages where there are very few cases for most cancers. Extrapolating conflicting trends for different ages can also lead to a projected age distribution that is completely different from the historical age distribution for that cancer.

More recent unpublished projections undertaken by the AIHW tried to resolve these problems using methods adapted by Dr Chris Stevenson from the age-period interaction methods used by Coory and Armstrong (1998) for the projection of cancer incidence for New South Wales Area and Rural Health Services. These in turn had been derived from international projection methodology using linear and non-linear Poisson regression models developed by Dyba and Hakulinen (Hakulinen & Dyba 1994). Dyba and Hakulinen have since made some refinements to their approach (Dyba et al. 1997; Dyba 2000).

Other projections have been done using more complex age-period-cohort models (Taylor & McNeil 1997) or even multiple models with a model averaging approach (NZMOH 2002). Recent projections by the South Australian Cancer Registry (2005) have tried to improve on the original AIHW approach by incorporating tests for first-order autocorrelation and using robust variance estimators. A forthcoming paper by Clements et al. (2005) fits generalized additive models with a two-dimensional spline for age and period, to project lung cancer incidence for a number of countries.

### Functional data analysis

For the current projections, a functional data analysis (FDA) approach (Ramsey & Silverman 1997, 2001) has been used. In this approach the age distribution of the cancer is treated as a function and it is this function that is modelled and projected, rather than each of the age-specific rates. This approach is less susceptible to problems with low numbers of cases in the younger age groups than separate models for each age group.

A number of the projection methods outlined above were tried, and they produced similar results for the more common cancers, where there are large numbers of historical cases. For this project, projections by age group for a range of cancers were required, including some rarer cancers with only a small number of historical cases. As with the age-period models, the FDA approach uses as data the age-specific rates, rather than summary measures such as the age-standardised rates, and as a result produces projections for each age group as well as prediction intervals (see below) for each projected age-specific rate.

The FDA approach was chosen as it produces projections for rare cancers such as female mesothelioma that are stable in the sense that they are not highly susceptible to minor changes in either the data or the model parameters.

The FDA approach was applied by adapting computer routines written for the statistical software package R <[www.r-project.org](http://www.r-project.org)>, by Professor Rob Hyndman of Monash University (Hyndman & Ullah 2005). Using these routines, the historical age distribution function of cancer incidence is firstly smoothed, using regression splines, which can be shown to produce similar results to the earlier age-period methods (Heuer 1997).

The smoothed age distribution functions are then modelled using robust weighted principal components analysis to find a set of optimal (orthonormal) basis functions. Time series forecasting methods are then used to project the coefficients associated with these basis functions. The projected coefficients are then combined with the basis functions to produce projected age distributions of cancer incidence. Using the FDA approach, the projected age distribution can change gradually over time, which is why this approach can be considered to generalise the related Lee–Carter approach (Lee 2000; Lee & Carter 1992).

Most of the modelling for these projections was done on the log scale, with the exception of cancers with a strongly increasing trend, where the model on the log scale appeared to unreasonably exacerbate the trend. The projections for melanoma and the skin and lip group of cancers are examples of where the model was fitted on a linear rather than a log scale. Note that when the modelling is done on a log scale and the results transformed back to the original scale, prediction intervals will not necessarily be symmetrical about the projected value (the lower 95% prediction bound will usually be closer to the projection than the upper 95% prediction bound).

## **Prediction intervals**

The computer routines produce prediction intervals for the projected age-specific rates, and these prediction intervals have been combined to produce prediction intervals for the crude and age-standardised rates for all ages.

Prediction intervals are confidence intervals for predictions and can be used to assess the relative expected accuracy of the different projections. For example, in the projection for all cancers for males, the expected number of cases for 2011 is 63,087 with a 95% prediction interval that ranges from 58,122 to 68,752. The width of this prediction interval is 10,630 cases which is 16% of the expected number of cases.

Compare this with the same calculations for female eye cancer where the expected number of cases for 2011 is 131 with a 95% prediction interval from 89 to 195. The width of this interval is 106 cases which is 81% of the expected number of cases. The projection for all cancers for males is based on a total of 735,308 historical cases from 1982 to 2001, whereas the projection for female eye cancer is based on a total of 1,647 cases from 1982 to 2001, so it is not surprising that the projection for all cancers for males is expected to be relatively more accurate.

The prediction intervals reflect two components of variability in the smoothed age-specific rates: (1) one that reflects the volatility in the age-specific rates and (2) one that reflects increased uncertainty the further in time we try to project. This second component we would expect to be small early in the projection period, but to increase later in the projection period. For some of the projections, this second component appears to be negligible compared with the first component, and the prediction interval appears to be much the same width through the entire projection period from 2002 to 2011.

Dr Mark Clements of NCEPH, who reviewed the methodology, has suggested further work on the prediction intervals, outside the scope of the current project. Initial simulations suggest that in most instances the current prediction intervals are conservative; in particular, they are too wide in the early part of the projection period, but appear suitable towards the end of the projection period.

95% prediction intervals have been calculated as this is the AIHW standard for confidence intervals. However, Professor Hyndman suggests the use of much narrower 80% intervals when dealing with predictions and this is set as the default in his computer package.

# References

- ABS (Australian Bureau of Statistics) 2003a. Australian demographic statistics. ABS cat. no. 3101.0, September quarter 2002, 2001 census edition – final. Canberra: ABS.
- ABS 2003b. Population by age and sex, Australian states and territories. ABS cat. no. 3201.0. Canberra: ABS.
- ABS 2003c. Population projections, Australia 2002 to 2101. ABS cat. no. 3222.0. Canberra: ABS.
- Ahmad OB, Boschi-Pinto C, Lopez AD, Murray CJ, Lozano R & Inoue M 2000. Age standardization of rates: a new WHO standard. EIP/GPE/EBD discussion paper series no. 31 <[www3.who.int/whosis/discussion\\_papers/discussion\\_papers.cfm](http://www3.who.int/whosis/discussion_papers/discussion_papers.cfm)>. Geneva: World Health Organization.
- AIHW (Australian Institute of Health and Welfare) 1998. Breast and cervical cancer screening in Australia 1996–1997. AIHW cat. no. CAN 3. Canberra: AIHW (Cancer Series no. 8).
- AIHW 2004. Cervical screening in Australia 2001–2002. AIHW cat. no. CAN 22. Canberra: AIHW (Cancer Series no. 27).
- AIHW 2005a. 2004 National Drug Strategy Household Survey: first results. AIHW cat. no. PHE 57. Canberra: AIHW (Drug Statistics Series no. 13).
- AIHW 2005b. BreastScreen Australia monitoring report 2001–2002. AIHW cat. no. CAN 24. Canberra: AIHW (Cancer Series no. 29).
- AIHW: Ridolfo B & Stevenson C 2001. The quantification of drug-caused mortality and morbidity in Australia, 1998. AIHW cat. no. PHE 29. Canberra: AIHW (Drug Statistics Series no. 7).
- AIHW & AACR (Australasian Association of Cancer Registries) 1998. Cancer in Australia 1991–1994 (with projections to 1999). AIHW cat. no. CAN 2. Canberra: AIHW (Cancer Series no. 7).
- AIHW & AACR 2003. Cancer in Australia 2000. AIHW cat. no. CAN 18. Canberra: AIHW (Cancer Series no. 23).
- AIHW & AACR 2004. Cancer in Australia 2001. AIHW cat. no. CAN 23. Canberra: AIHW (Cancer Series no. 28).
- AIHW & AACR: Jelfs P, Coates M, Giles G, Shugg D, Threlfall T, Roder D et al. 1996. Cancer in Australia 1989–1990 (with projections to 1995). Canberra: AIHW (Cancer Series no. 5).
- Booth H, Maindonald J & Smith L 2001. Age–time interactions in mortality projection: applying Lee–Carter to Australia. Working Papers in Demography 85 <[demography.anu.edu.au/Publications/workingpapers.php](http://demography.anu.edu.au/Publications/workingpapers.php)>. Canberra: Australian National University.
- Booth H, Maindonald J & Smith L 2002. Applying Lee–Carter under conditions of variable mortality decline. *Population Studies* 56:325–36.
- Clements MS, Armstrong BK & Moolgavkar SH 2005. Lung cancer rate predictions using generalized additive models. *Biostatistics* (in press).
- Coory M & Armstrong BK 1998. Cancer incidence projections for area and rural health services in New South Wales. Sydney: NSW Cancer Council.
- Coory M, Baade P, Aitken J, Smithers M, McLeod GRC & Ring I 2005. Trends for in-situ and invasive melanoma in Queensland, Australia, 1982 to 2002. *Cancer Causes Control* (in press).

- DoHA (Department of Health and Ageing) 2005. Investing in Australia's health: strengthening cancer care. Budget 2005–2006 Health Fact Sheet no. 1 <[www.health.gov.au/budget2005](http://www.health.gov.au/budget2005)>. Canberra: DoHA.
- Dyba T 2000. Precision of cancer incidence projections based on Poisson distributed observations. Helsinki: Finnish Statistical Society.
- Dyba T, Hakulinen T & Paivarinta L 1997. A simple non-linear model in incidence projection. *Statistics in Medicine* 16:2297–309.
- Erbas B, Hyndman RJ & Gertig DM 2005. Forecasting age-specific breast cancer mortality using functional data models. *Statistics in Medicine* (in press).
- Frazer I 2004. Preventing cervical cancer: the immunologist's role. Paper presented at the 18th World Conference on Health Promotion and Health Education. Melbourne, 26–30 April 2004.
- Giles GG, Armstrong BK, Burton RC, Staples MP & Thursfield VJ 1996. Has mortality from melanoma stopped rising in Australia? Analysis of trends between 1931 and 1994. *BMJ (British Medical Journal)* 312(7039):1121–5.
- Hakulinen T & Dyba T 1994. Precision of incidence predictions based on Poisson distributed observations. *Statistics in Medicine* 13:1513–23.
- Heuer C 1997. Modeling of time trends and interactions in vital rates using restricted regression splines. *Biometrics* 53(1):161–77.
- Hill DJ, White VM & Gray NJ 1988. Measures of tobacco smoking in Australia 1974–1986 by means of a standard method. *Medical Journal of Australia* 149:10–2.
- Hyndman RJ & Ullah MS 2005. Robust forecasting of mortality and fertility rates: a functional data approach. Invited paper presented at the 55th session of the International Statistical Institute <[www-personal.buseco.monash.edu.au/~hyndman](http://www-personal.buseco.monash.edu.au/~hyndman)>. Sydney, April 2005.
- Lee RD 2000. The Lee–Carter method for forecasting mortality, with various extensions and applications. *North American Actuarial Journal* 4(1):80–91.
- Lee RD & Carter LR 1992. Modeling and forecasting US mortality. *Journal of the American Statistical Association* 87(419):659–71.
- Lee R & Miller T 2001. Evaluating the performance of the Lee–Carter method for forecasting mortality. *Demography* 38(4):537–49.
- Leigh J & Driscoll T 2003. Malignant mesothelioma in Australia, 1945–2002. *International Journal of Occupational and Environmental Health* 9:206–17.
- NCCI (National Cancer Control Initiative) 2003. The 2002 national non-melanoma skin cancer survey: a report by the NCCI Non-melanoma Skin Cancer Working Group. Ed. Staples MP. Melbourne: NCCI.
- NOHSC (National Occupational Health and Safety Commission) 2004. The incidence of mesothelioma in Australia 1999 to 2001, Australian Mesothelioma Register report 2004. <[www.nohsc.gov.au/PDF/Statistics/Meso2004.pdf](http://www.nohsc.gov.au/PDF/Statistics/Meso2004.pdf)>. Canberra: NOHSC.
- NZMOH (New Zealand Ministry of Health) 2002. Cancer in New Zealand – trends and projections. *Public Health Intelligence Occasional Bulletin* no. 15. Wellington: NZMOH.
- Ramsey JO & Silverman BW 1997. *Functional data analysis*. New York: Springer-Verlag.
- Ramsey JO & Silverman BW 2001. *Functional data analysis*. In: Smelser J & Bates PB (eds). *International encyclopedia of the social & behavioural sciences*. Oxford: Pergamon. <[www.stats.ox.ac.uk/~silverma/pdf/iesbs.pdf](http://www.stats.ox.ac.uk/~silverma/pdf/iesbs.pdf)>:5822–8.
- SACR (South Australian Cancer Registry) 2005. Cancer in South Australia 2002 – with projections to 2005. Adelaide: South Australian Department of Health.

Taylor R & McNeil D 1997. Predictions of incidence of major cancers in NSW to 2001. Sydney: NSW Cancer Council.

Threlfall TJ 1997. Cancer incidence and mortality projections for Western Australia, 1996–2001. Statistical Series no. 50. Perth: Department of Health, Western Australia.

Threlfall TJ & Thompson JR 2004. Cancer incidence and mortality in Western Australia, 2002. Statistical Series no. 71. Perth: Department of Health, Western Australia.

Thursfield V, Farrugia H, Billett D & Giles G 2004. Cancer in Victoria 2003. Canstat no. 41. Melbourne: Cancer Council Victoria.

Tracey E, Roder D, Bishop J, Chen S & Chen W 2005. Cancer in New South Wales: incidence and mortality 2003. Sydney: Cancer Institute NSW.

Tracey EA & Supramaniam R 2002. Cancer in New South Wales: incidence and mortality 2000 featuring projections to 2010 for selected sites. Sydney: Cancer Council NSW.

White V, Hill D, Siahpush M & Bobevski I 2003. How has the prevalence of cigarette smoking changed among Australian adults? Trends in smoking prevalence between 1980 and 2001. *Tobacco Control* 12(supplement ii):67–74.

WHO (World Health Organization) 1990. International classification of diseases for oncology, 2nd edn. Eds: Percy C, Van Holten V & Muir C. Geneva: WHO.

WHO 1992. International statistical classification of diseases and related health problems, 10th revision. <[www3.who.int/icd/vol1htm2003/fr-icd.htm](http://www3.who.int/icd/vol1htm2003/fr-icd.htm)>. Geneva: WHO.

WHO 2000. International classification of diseases for oncology, 3rd edn. Eds: Fritz A, Percy C, Jack A, Shanmugaratnum K, Sobin L, Parkin DM & Whelan S. Geneva: WHO.

Woodward SD 1981. Trends in cigarette consumption in Australia. *Australia and New Zealand Journal of Medicine* 14:405–7.